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Abstract 
Cancer of the gastrointestinal tract remains a significant cause of morbidity and mortality. Although 
surgical resection of the primary tumour remains the cornerstone of curative treatment, 
chemotherapy forms an increasingly important component of the management armamentarium. 
Response to therapy, however, is by no means uniform and thus the development of new agents is 
highly desirable.  
There is a significant body of evidence implicating iron in the malignant progression of 
gastrointestinal cancer.  Tumours acquire an excess of iron which in turn propagates their malignant 
phenotype. This project aimed to demonstrate that a strategy to deplete tumour cells of iron using 
the licensed iron chelator Deferasirox was effective in the treatment of oesophageal and colorectal 
cancer.     
Deferasirox significantly impedes cellular viability and proliferation both in-vitro and in-vivo in 
oesophageal and colorectal cancer models. The drug can overcome established chemotherapy 
resistance and may also act as a chemosensitiser. The disturbance of normal intracellular iron 
homeostasis and increased dependence of gastrointestinal tumour cells on iron means chelation 
may offer targeted therapy. Certain iron regulatory proteins may also serve as biomarkers for 
treatment efficacy.  Deferasirox therefore represents an effective and well tolerated adjunct to 
existing therapies that should be considered for future clinical trials.  
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Chapter 1. Introduction 
 
1.1 Gastrointestinal Cancer 
 
Cancer is a disease characterised by uncontrolled growth and spread of structurally and biologically 
abnormally differentiated cells that can originate from any tissues within the body. 1  
 
On a worldwide basis, there are over 12.5 million new cases of cancer each year and the disease is 
responsible for over 7.5 million deaths. 2 In the United Kingdom (UK), cancer is a major cause of 
morbidity and mortality with over 300,000 people per year diagnosed. 3 The disease is responsible 
for more than 1 in 4 deaths in the UK; a figure significantly greater than those caused by ischaemic 
heart disease or stroke. 4 
 
The gastrointestinal tract runs from the mouth to the anus and includes organs such as the 
oesophagus, stomach, small intestine, colon and rectum. 5 Cancer of the gastrointestinal tract 
encompasses a range of heterogeneous malignancies arising from different organs which, when 
grouped together, accounts for approximately 20% of all new cancer diagnoses each year. 6 
 
Within this thesis two specific forms of gastrointestinal malignancy have been focused upon; the 
first being cancer of the oesophagus (a disease whose incidence has increased dramatically over 
recent decades) and the second, cancer of the colon and rectum (the second largest cause of cancer 
related death in the UK). 7, 8 
 
 
 
 
2 
 
1.2 Cancer of the Oesophagus 
 
1.2.1 Structure and Function of the Oesophagus 
 
The oesophagus is a muscular tubular structure, approximately 25 cm in length, joining the pharynx 
to the stomach. 5 Its primary function is the conduction of food from the mouth to the stomach 
through the action of peristalsis. 5 It is lined predominantly by squamous epithelium and (apart from 
some striated muscle in the upper cricopharyngeal sphincter) is comprised of smooth muscle under 
autonomic control. 9 The distal oesophagus is protected against the regurgitation of acidic gastric 
contents by a ‘functional’ lower oesophageal sphincter assisted by the constricting muscle bands of 
the diaphragm and an acute angle of entry into the stomach. 9 The final 1.5-2 cm of the oesophagus 
is situated below the diaphragm and is lined my columnar epithelium. 9 The transition point from 
squamous to columnar epithelium occurs at around 40 cm (from the incisor teeth) and is clearly 
visible on endoscopy. 9 
 
1.2.2 Oesophageal Cancer 
 
Owing to the different types of epithelium found within the oesophagus there are two main forms of 
oesophageal carcinoma – squamous cell carcinoma (SCC, which tends to arise in the upper two 
thirds of the oesophagus) and adenocarcinoma (OAC, which typically arises in the lower third). 9 
Other less common subtypes include melanoma, leiomyosarcoma and small-cell carcinoma. 10 
 
Cancer of the oesophagus is a global health problem and was the 6th most common cancer on a 
worldwide basis in 2002. 11 It is characterised by a worldwide geographical variation in incidence, 
being the 4th most common tumour in developing countries but only the 15th in developed countries. 
12  
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Over the past 30 years the relative incidence of oesophageal carcinoma has risen dramatically, 
largely driven by an unprecedented increase in cases of the OAC subtype. 13 In the UK, oesophageal 
carcinoma is now the 9th most common cancer (by incidence) with over 8,000 new cases per year. 14 
There is a strong male to female preponderance with an incidence ratio of 2:1 in favour of males. 14 
Overall 5 year survival rates remain poor (13%). 14 This compares with rates of 20% in China and 
15.4% in the United States. 15 The disease is uncommon below the age of 50. 16 
 
1.2.2.1 Squamous Cell Carcinoma 
 
Squamous cell carcinoma (SCC) of the oesophagus remains the predominant histological type of 
oesophageal carcinoma worldwide. 17 It typically arises in the upper two thirds of the oesophagus 
and risk factors for its development are well documented (Table 1.1). Heavy alcohol intake is 
associated with at least a 20 fold greater risk and smokers have at least 5 times the risk of non-
smokers. 16 
 
Rates of SCC are highest in the so called Asian belt encompassing Turkey, north eastern Iran, 
Kazakhstan and northern and central China. 17 Incidence rates in these areas are greater than 100 
cases per 100 000 population annually. 17 SCC rates are also high in certain parts of southern and 
eastern Africa. 17 
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1.2.2.2 Oesophageal Adenocarcinoma 
 
OAC typically arises in the lower third of the oesophagus. 9  
 
The main risk factors for OAC are listed in Table 1.1. Symptomatic gastro-oesophageal reflux disease 
(GORD) is one of the strongest risk factors, although preceding symptoms are said to be infrequent 
or absent in more than 40% of patients who develop the disease. 18 Obesity, which is increasing 
dramatically worldwide, is also a risk factor for both OAC in its own right and for GORD. 19, 20  
 
In cases of longstanding GORD, the lower oesophagus may come to be lined by columnar mucosa, a 
condition referred to as Barrett’s oesophagus or Barrett’s metaplasia (BM). 9 At endoscopy, proximal 
extension of pink columnar mucosa can be seen replacing the pearly-white squamous epithelium of 
the lower oesophagus. 9 Initially, this transformation in epithelium is in the form of tongues 
extending up from the gastric cardia, but as it develops it may come to represent a complete 
cylinder of columnar epithelium that can occupy much of the distal half of the oesophagus. 9  
 
Microscopically, BM consists of columnar epithelium, containing goblet cells and intervening mucus-
producing cells which both secrete intestinal-type mucins (a form of intestinal metaplasia). 9 Whilst 
the initial change from squamous epithelium to a gastric-type mucosa is accepted as being a 
response to acid reflux, the development of intestinal-type features cannot be explained solely as a 
response to acid. 9 Other factors, such as bile reflux, are also likely to play a role. 9 
 
The reported prevalence of BM in the general population is 1.6%. 21 In patients undergoing 
endoscopy for GORD type symptoms it is 10-15%. 22 As well as GORD, abdominal obesity is a risk 
factor for the development of BM. 23 
 
5 
 
BM is the strongest risk factor for OAC and its presence is estimated to increase the risk of 
developing OAC by 30 to 125 fold. 24, 25, 26 The annual conversion rate of BM to OAC has been 
estimated to be as high as 0.5% per year with the risk being greatest in patients with high-grade 
dysplasia of the oesophagus (which progresses to OAC in 16-59% of cases). 17, 27, 28, 29, Genetic 
abnormalities present in BM (e.g. chromosomal instability, cell cycle abnormalities, expression of the 
proto-oncogene c-Myc, p53 mutational status and KI67 staining) have all been postulated as 
potential biomarkers of progression to OAC although none have been conclusively validated. 17, 30 
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Table 1.1 Risk factors for oesophageal SCC and OAC 
Squamous Cell Carcinoma (SCC) Adenocarcinoma (OAC) 
Tobacco use Symptomatic gastro-oesophageal reflux disease 
Alcohol consumption Barrett’s oesophagus 
Mutations in alcohol metabolising enzymes Obesity 
Achalasia Tobacco use 
Caustic injury Previous thoracic radiation 
Previous thoracic radiation Diet low in vegetables and fruit 
Poor oral hygiene Increased age 
Nutritional deficiencies Male sex 
Non-epidermolytic palmoplantar keratoderma Medications that relax lower oesophageal sphincter 
Low socioeconomic status Family history 
 
Adapted from Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. 
The Lancet 2013; 381: 400-12. 17 
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1.2.3 The Genetic Basis of Oesophageal Cancer 
 
Understanding of the molecular events surrounding the development and progression of 
oesophageal carcinoma has until recently been somewhat limited. Recent progress in molecular 
biology, however, has revealed a number of genetic and epigenetic alterations that are found in 
both the SCC and OAC subtypes. 31 
 
Commonly mutated genes within both SCC and OAC include Tumour Protein p53 (TP53) and 
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA).31 TP53 is a major 
tumour suppressor gene whilst PIK3CA is a kinase activator of the phosphoinositide 3-kinase 
(PI3K)/AKT pathway. 31 32 33 
 
Of note, comparisons of mutated genes found within non-dysplastic Barrett’s epithelium, high grade 
dysplasia and OAC revealed that the majority of recurrently mutated genes in OAC, with the 
exception of TP53 and SMAD4, were also mutated in non-dysplastic Barrett’s epithelium. 34 SMAD4 
(Mothers against decapentaplegic homolog 4), like TP53 is known to function as a tumour 
suppressor. 31 
 
A number of genes have also been shown to undergo amplification or loss of heterozygosity in 
oesophageal carcinoma. 31 Of note, epidermal growth-factor receptor (EGFR), Myc, K-ras and PIK3CA 
have all demonstrated amplification in SCC, whilst TP53, cyclin-dependent kinase inhibitor 2A 
(CDKN2A) and the adenomatous polyposis coli (APC) gene have shown loss of heterozygosity. 31 
Again, all of the latter genes function as tumour suppressors. In addition, amplification or 
overexpression of the oncogene human epidermal growth-factor receptor 2/neu (ERBB2) has been 
observed in around 25% of OAC. 35  
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Epigenetic alterations arising from hyper or hypo methylation of genes (including APC and CDKN2A) 
and also manipulation of gene expression through the action of microRNAs (small, noncoding RNA 
molecules that can also induce epigenetic modifications) have also been demonstrated in both SCC 
and OAC. 31 
 
1.2.4 The Management of Oesophageal Cancer 
 
1.2.4.1 Diagnosis and Staging 
 
Dysphagia (difficulty in swallowing) is the most common symptom of oesophageal carcinoma 
although this often develops insidiously. 16, 17  In patients with SCC, the most common presentation is 
dysphagia, typically associated with a history of smoking, long-term alcohol intake and accompanied 
by weight loss 16 
 
Patients with OAC are typically white men with a history of GORD who have recently developed 
dysphagia. 17 Physical examination often reveals little, except in advanced cases where wasting, 
hepatomegaly (due to metastasis), a Virchow’s node in the left supraclavicular fossa or hoarseness 
(as a result of recurrent laryngeal nerve involvement) may be present. 16 
 
Definitive diagnosis is reached through direct visualisation of the tumour at endoscopy and 
subsequent biopsy and histological confirmation. 17  
 
Once the diagnosis of oesophageal carcinoma is made, accurate staging of the disease must be 
performed in order to determine disease extent, plan appropriate treatment and define prognosis. 
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The staging work-up involves a number of approaches including history, physical examination, 
endoscopy, endoscopic ultrasonography (EUS, to assess the local extent of the tumour into the 
oesophageal wall) , computerised tomography (CT) scans of the chest and abdomen (to assess local 
disease and metastasis), positron emission tomography (PET) scans (to assess distant metastasis), 
and bronchoscopy (to assess thoracic invasion). 36 Laparoscopy may also be performed to exclude 
occult distant metastasis prior to consideration of definitive surgical resection. 17 
 
Oesophageal cancer is staged using the tumour, node and metastasis (TNM) classification (Table 
1.2). 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
Table 1.2 The TNM staging system for oesophageal carcinoma 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis High-grade dysplasia 
T1 Tumour invades lamina propria, muscularis mucosa, or submucosa 
T1a Tumour invades lamina propria or muscularis mucosa 
T1b Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
T4a Resectable tumour invading pleura, pericardium, or diaphragm 
T4b Unresectable tumour invading other adjacent structures,  
such as the aorta, vertebral body and trachea 
Regional lymph nodes (N) 
NX Regional lymph node(s) cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
Adapted from the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in 
oncology. Oesophageal and oesophagogastric junction cancers. Available at 
http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. 38 
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1.2.4.2 Treatment of Oesophageal Cancer 
 
Locally advanced disease, as defined by the extent of the primary tumour and involvement of loco-
regional lymph nodes (higher than stage T2, node positive without distant metastasis, or both) is 
generally treated with curative intent comprising a multimodal approach that includes surgical 
resection of the tumour. 17 Advanced (metastatic or disseminated) and recurrent disease are treated 
with palliative intent through chemotherapy to extend survival or local therapies, such as 
radiotherapy and endoscopically sited stents, to relieve dysphagia. 17 
 
1.2.4.2.1 Neoadjuvant Therapy 
 
Chemotherapy prior to surgical resection (neoadjuvant) can be used to control the early spread of 
systemic disease. 39 The UK Medical Research Council Oesophageal Cancer Working Group study 
demonstrated that the use of chemotherapy before surgery significantly improved 3 year survival 
compared to surgery alone. 40 In this study, the group of patients given Cisplatin and 5-fluorouracil 
(5-Fu) in 2 cycles followed by surgery had a median survival of 16.8 months compared to 13.3 
months in the group undergoing surgery alone. 40 These results were supported by the MAGIC trial 
which demonstrated that the administration of Epirubicin, Cisplatin and 5-Fu (ECF) for 3 cycles pre 
and post surgery significantly improved 5 year survival compared to surgery alone (36 vs. 23%, 
P=0.009). It was also noted that the resected tumours were significantly smaller and less advanced in 
the group given chemotherapy. 41 
 
A number of studies have also investigated the role of chemoradiotherapy followed by surgery 
compared with surgery alone in patients with potentially resectable oesophageal carcinoma. 42, 43, 44, 
45, 46, 47, 48 Most thus far have demonstrated non-significant results, although a meta-analysis of over 
1200 patients demonstrated a significant 13% absolute difference in survival at 2 years in patients 
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given neoadjuvant chemoradiotherapy followed by surgery compared with those receiving surgery 
alone. 48  This compared with an absolute survival benefit of 7% at 2 years in patients given 
chemotherapy alone followed by surgery. 48 
 
1.2.4.2.2 Adjuvant Therapy 
 
Adjuvant chemotherapy for oesophageal carcinoma treated with primary resection may be of 
benefit, especially in patients with node positive disease. 17 A study of 556 patients randomised to 
either surgery alone or surgery followed by chemoradiotherapy (5-Fu, Leucovorin and radiotherapy) 
demonstrated both increased median survival in the group given adjuvant therapy (36 vs. 27 
months) and reduced risk of relapse. 49  
 
Randomised trials of adjuvant therapy with radiation alone have been inconclusive and its indication 
is currently restricted to positive resection margins or residual disease following resection. 17 
 
1.2.4.2.3 Advanced Disease 
 
A significant proportion of patients with oesophageal carcinoma have advanced or metastatic 
disease at diagnosis (approximately 50-75%).50
,
 51 In these patients curative treatment is not possible 
and median overall survival with best supportive care is around 3 months. 52  Palliative 
chemotherapy may be given and is chosen on the basis of projected efficacy, the patient’s co-
morbidities and the side effect profiles of proposed chemotherapy agents. 17  
 
Few palliative regimens have been validated in phase III trials. The REAL-2 study of 1002 patients 
with oesophagogastric cancers assessed three-drug regimens that included Epirubicin plus either 
Oxaliplatin or Cisplatin and 5-Fu or Capecitabine. 52 Median survival in the group given Epirubicin 
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plus Oxaliplatin and Capecitabine (EOC) was greatest, although still only 11.2 months.  A recent 
Cochrane review comparing chemotherapy with best supportive care for advanced oesophageal 
carcinoma did not demonstrate any survival benefit with chemotherapy. 51 Furthermore, the authors 
concluded that there was no consistent benefit of any specific chemotherapy regimen utilised and 
that there is a need for well designed, adequately powered, phase III trials comparing chemotherapy 
versus best supportive care for patients with metastatic oesophageal cancer. 51 
 
There is without doubt a need for the development and investigation of new drugs and treatment 
regimens to improve prognosis in these patients. With this in mind, agents containing small 
molecules and antibodies that have been created on the basis of tumour biology are being 
incorporated into multimodal therapies. 53 The most commonly used agents include the 
angiogenesis inhibitor Bevacizumab and the epidermal-growth-factor receptor (EGFR) inhibitors 
Panitumumab and Cetuximab. 17  
 
The REAL-3 study compared chemotherapy with EOC to EOC plus Panitumumab in patients with 
untreated, metastatic or locally advanced oesophagogastric adenocarcinoma. 54 Median overall 
survival was actually shorter in the group given Panitumumab (8.8 months vs. 11.3 months) and the 
combination was significantly less well tolerated than the standard EOC regime.  
 
The ToGA trial investigated the efficacy of Trastuzumab (Herceptin, a monoclonal antibody directed 
at HER-2) in combination with Cisplatin and fluoropyrimidine chemotherapy in 594 patients with 
HER-2-positive advanced gastric or oesophagogastric junction adenocarcinoma. 55 The combination 
of the antibody with chemotherapy significantly improved overall survival (median 13.8 vs. 11.1 
months) without additional toxicity or adversely affecting quality of life. 55 Although promising, 
however, it should be noted that only around 25% of patients with oesophageal cancer are HER-2 
positive and many patients exhibit either primary or acquired resistance to Trastuzumab. 56 
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1.3 Cancer of the Colon and Rectum 
 
1.3.1 Structure and Function of the Colon and Rectum 
 
The large intestine comprises the caecum, appendix, colon (further divided into ascending, 
transverse, descending and sigmoid components) and rectum. 5 Its primary function includes the 
storage and elimination of food residues, the maintenance of fluid and electrolyte balance and the 
degradation of complex carbohydrates (and other nutrients) by luminal bacteria. 9 
 
The colon and rectum are lined predominantly by columnar epithelium. 9 The mucosa itself is devoid 
of villi and instead comprises perpendicular crypts extending from the flat surface down to the 
muscularis mucosae, separated by a little lamina propria. 9  
 
1.3.2 Colorectal Cancer 
 
Over 40,000 people are diagnosed with colorectal cancer in the UK each year making it the 4th most 
common cancer by incidence (after breast, lung and prostate). 3 The disease is also responsible for 
over 16,000 deaths which means that, although it carries an overall 5-year survival rate of 55% 
(significantly more favourable than that for oesophageal cancer), it is still the 2nd leading cause of 
cancer related death. 8, 57 
 
Approximately 30% of colorectal cancers arise in the rectum, 25% in the caecum and ascending 
colon and 20% in the sigmoid colon (with the remainder spread between the transverse colon, 
splenic and hepatic flexures, descending colon, appendix and anus). 58 Microscopically, colorectal 
tumours are predominantly of the adenocarcinoma type and display varying degrees of mucin 
production and differentiation. 9  
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Whilst approximately 5-10% of colorectal cancers arise secondary to inherited genetic defects, diet 
and lifestyle are without doubt the main contributing factors to the high incidence of the disease, 
particularly in Western countries. 59 Of note, individuals consuming high fat, high protein, low fibre 
diets and diets that contain significant proportions of red and processed meat have an increased risk 
of developing the disease. 9, 60, 61 Other recognised and modifiable risk factors for colorectal cancer 
include smoking, alcohol intake, physical inactivity and obesity. 9
, 60  
 
1.3.3 The Genetic Basis of Colorectal Cancer 
 
The genetic aberrations which accumulate en-route to the development of colorectal cancer have 
been well studied. 62 Mutations can occur through chromosomal instability, defects in DNA repair 
pathways and or aberrant methylation of DNA, leading to the functional silencing of tumour 
suppressor genes or the amplification of oncogenic pathways. 62 
 
The majority of colorectal adenocarcinomas arise in pre-existing adenomas, the so-called 
adenoma→carcinoma sequence, as first proposed by Vogelstein and colleagues (Figure 1.1). 63 
Evidence for this sequence comes from an understanding of the genetic and molecular events 
surrounding the inherited condition Familial Adenomatous Polyposis (FAP) and also from 
epidemiological data. 9 FAP is an autosomal dominant condition resulting from an inherited point 
mutation on the long arm of chromosome 5 leading to deletion of one copy of the adenomatous 
polyposis coli (APC) gene which encodes the tumour suppressor protein APC. 62 Loss of one copy of 
APC is inherently followed by loss of the other during life and thus the accumulation of APC loss 
within intestinal cells leads to hyperproliferation within the intestinal crypts and the formation of 
multiple polyps. 9, 62 Subsequent acquirement of additional mutations in other tumour suppressors 
and oncogenes (the so-called ‘two hit’ theory) leads to the malignant transformation of these polyps 
in almost all untreated cases by the age of 30-40. 9   
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In terms of epidemiological evidence supportive of the adenoma → carcinoma progression, the 
marked geographical variation in the incidence of polyps correlates strongly with the incidence of 
colorectal carcinoma. Furthermore, adenomas and carcinomas are frequently found together in 
resected specimens. 9 Increasing polyp size, villous growth pattern and degree of dysplasia are 
known to correlate with risk of malignancy within polyps.   
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Figure 1.1 The colorectal adenoma → carcinoma sequence 
The initial step in colorectal tumourigenesis is that of adenoma formation, associated with loss of 
the tumour suppressor adenomatous polyposis coli (APC). Larger adenomas and early carcinomas 
typically acquire mutations in K-ras, followed by loss of chromosome 18q and SMAD4 and mutations 
in p53 (often the key step in the transition to invasive adenocarcinoma). Mutations in B-raf are 
usually mutually exclusive to those in K-ras.  
 
Adapted from Walther A, Johnstone E, Swanton C et al. Genetic prognostic and predictive markers in 
colorectal cancer. Nat Rev Cancer. 2009; 9(7): 489-99. 64  
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Loss of APC leads to polyp formation through activation of the Wnt signalling pathway (Figure 1.2). 62 
Wnt signalling occurs when the onco-protein β-catenin translocates to the nucleus (following its 
accumulation within the cytoplasm) and binds to members of the T-cell factor-lymphocyte enhancer 
factor (TCF-LEF) family to create a transcription factor that regulates a number of genes ultimately 
involved in cellular growth and proliferation (including c-Myc). 62, 65, 66 The normal functioning of APC 
is crucial for the abrogation of Wnt signalling through its formation of a destruction complex 
(alongside glycogen synthase kinase 3β and AXIN (axis inhibitor)) which phosphorylates β-catenin, 
targeting it for ubiquitination and proteasomal degradation. 65 In the absence of APC, β-catenin is 
able to evade degradation and thus accumulates within the cytoplasm, precipitating subsequent 
translocation to the nucleus and activation of transcription factors.  
 
As well as in FAP, APC is known to be mutated in approximately 85% of sporadic cases of colorectal 
cancer and is the initiating mutation in the vast majority of instances. 62 In addition, a small subgroup 
of tumours that retain functioning wild-type APC have been shown to harbour mutations in β-
catenin itself that renders the protein resistant to the Wnt degradation complex. 62 
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Figure 1.2 The Wnt signalling pathway 
In the presence of Wnt signalling and functioning APC, β-catenin associates with a multi-protein 
destruction complex comprising APC, AXIN and GSK3β. β-catenin is phosphorylated by CK1/CK2 and 
GSK3β leading to its ubiquitination (through binding to β-TrCP) and degradation by the proteasome. 
Members of the TCF/LEF family remain bound in the nucleus by repressors that belong to the GRO 
(groucho-related gene) family and are therefore inactive. In the absence of APC (i.e. in the presence 
of an APC mutation), the destruction complex is no longer functional, preventing the 
phosphorylation of β-catenin, thus allowing its accumulation within the cytoplasm and subsequent 
translocation to the nucleus where it activates TCF/LEF. This in turn leads to the transcription of pro-
proliferative proteins such as c-Myc and cyclin D1.  
 
Adapted from Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of 
colorectal cancers. Mol Cancer 2003; 2: 41. 67  
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Inactivation of the tumour suppressor protein p53 through mutation of TP53 is the second key 
genetic step in the development of colorectal cancer. 62 In most tumours, the two TP53 alleles are 
inactivated, usually by a combination of missense mutation that inactivates the transcriptional 
activity of p53 and a 17p chromosomal deletion that eliminates the second TP53 allele. 62 Wild-type 
p53 mediates cell-cycle arrest and a cell-death checkpoint, which can be activated by multiple 
cellular stresses, including DNA damage, ultraviolet light and oxidative stress. 62 The inactivation of 
TP53 (present in around 35-55% of tumours) often coincides with the transition of large adenomas 
into invasive adenocarcinomas. 68 
 
Mutational inactivation of the tumour suppressing TGF-β signalling pathway is a third crucial step in 
the progression to colorectal cancer. 62  Mutational inactivation of TGFBR2 and/or mutations altering 
expression of its downstream target SMAD4 (present in around 30% of cancers) also coincide with 
the transition from adenoma to high-grade dysplasia or carcinoma. 62  
 
The mitogen activated protein kinase (MAPK) signalling cascade (Figure 1.3) can also become 
constitutively active during the development of colorectal cancer through oncogenic mutations in K-
ras and B-raf (occurring in 37 and 13% of cases respectively) resulting in the activation of numerous 
transcription factors (such as the Ets family and c-Myc). 62, 69   K-ras mutations activate the GTPase 
activity that signals directly to raf. B-raf mutations in turn signal B-raf serine-threonine kinase 
activity, which then further drives the MAPK signalling cascade. 62 This pathway can be further 
perturbed through over-expression or mutation of the epidermal growth factor receptor (EGFR; the 
up-stream regulator of MAPK) which is present in 27-77% of colorectal cancers. 69 Aberrant EGFR 
signalling (and mutations in K-ras) can also lead to constitutive activation of the phosphatidylinositol 
3-kinase (PIK3CA) signalling pathway resulting in cell-survival signalling and suppression of apoptosis. 
62 In addition, mutation of the tumour suppressor PTEN (present in 10-15% of colorectal cancers) 
also results in constitutively active PIK3CA signalling. 62 
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Figure 1.3 The MAPK signalling cascade 
The MAPK (mitogen activated protein kinase) signaling cascade (also known as the RAS–RAF–MEK–
ERK pathway) forms a phospho-relay system that translate a plethora of extracellular signals into 
diverse cellular responses. After binding of ligands, such as growth factors, to their respective 
receptor tyrosine kinase (RTK), receptor dimerization triggers the intrinsic tyrosine-kinase activity. 
This is followed by auto-phosphorylation of specific tyrosine residues on the intracellular portion of 
the receptor. These phosphorylated tyrosine residues then bind the sequence homology 2 (SH2) 
domains of adaptor proteins such as GRB2. Such a complex formation recruits SOS (son of sevenless, 
a cytosolic protein) into close proximity to RAS on the plasma membrane. Like other G proteins, RAS 
(H-ras, N-ras and K-ras) cycles between the GDP-bound inactive form and the GTP-bound active 
form. In the quiescent state, Ras exists in the GDP-bound form. The binding of SOS to Ras causes a 
change in conformation leading to the dissociation of GDP and binding of GTP. GTP-bound Ras is the 
activator of this signalling module. It initiates the signal cascade by phosphorylating Raf (A-raf, B-raf 
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or C-raf). Raf in turn phosphorylates the MEKs (MEK1 and MEK2) which then phosphorylate the ERK 
MAPKs (extracellular signal-regulated kinases, ERK1 and ERK2). Activated ERKs then translocate into 
the nucleus where they phosphorylate specific substrates that are involved in the regulation of 
various cellular responses. In addition, ERK-mediated transcription can result in the up-regulation of 
RTK ligands (such as TGFα), thus creating an autocrine feedback loop.  
 
Adapted from Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nature 
Reviews Cancer 2003; 3: 559-570. 70  
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1.3.4 The Management of Colorectal Cancer 
 
1.3.4.1 Diagnosis and Staging 
 
Patients with suspected colorectal cancer typically present electively (with abdominal bloating and 
pain, change in bowel habit, bleeding per rectum, loss of appetite, weight loss or iron deficiency 
anaemia) or as an emergency (with bowel obstruction or perforation secondary to the tumour). 9  
Patients may also present with symptoms secondary to the metastatic spread of the primary 
tumour. 9 In the UK, a screening programme has now been established meaning asymptomatic 
patients may also present following a positive faecal occult blood test. 71 
 
A definitive diagnosis of colorectal adenocarcinoma is achieved through histological examination of a 
biopsy (obtained through colonoscopy) or through examination of the resected tumour specimen (if 
an emergency operation was necessitated). 72  Following confirmation of the diagnosis, the cancer is 
then staged using CT of the chest, abdomen and pelvis and, additionally for rectal cancer, an MRI 
scan of the pelvis. 72 
 
As in the oesophagus, colorectal cancer is staged using the TNM system (Table 1.3). 73  
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Table 1.3 The TNM staging system for colorectal carcinoma 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour is confined to submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through muscularis propria (but does not penetrate) serosa 
T4 Tumour has penetrated serosa and peritoneal surface 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional lymph nodes (N) 
NX Regional lymph node(s) cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in up to 3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis (including lymph node metastasis to non-regional lymph nodes) 
 
Adapted from The National Institute for Health and Care Excellence (NICE). Staging colorectal cancer. 
Available at http://pathways.nice.org.uk/pathways/colorectal-cancer. 73 
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1.3.4.2 The Treatment of Colorectal Cancer 
 
Surgical resection of the primary tumour remains the cornerstone of curative treatment for 
colorectal cancer. 72 Laparoscopic resection has become increasingly popular in recent years, both 
for colonic and rectal lesions. 74 In addition, local excision of early stage (T1 and T2) rectal tumours 
through trans-anal endoscopic microsurgery (TEMS) is also now being offered by some centres. 75  
 
1.3.4.2.1 Neoadjuvant Therapy 
 
Short course radiotherapy or long cause chemoradiotherapy is now routinely offered to patients 
pre-operatively with rectal cancer with the aim of decreasing local recurrence rates. 72 A recently 
published meta-analysis assessed the safety and effectiveness of neoadjuvant (chemo)radiotherapy 
in rectal cancer. 76 Although neoadjuvant radiotherapy was shown to decrease local recurrence 
(hazard ratio, HR = 0.59; 95%CI: 0.48-0.72) compared to surgery alone, it had only a marginal benefit 
on overall survival (HR = 0.93; 95%CI: 0.85-1.00) and was associated with increased perioperative 
mortality (HR = 1.48; 95%CI: 1.08-2.03). Neoadjuvant chemoradiotherapy improved local control as 
compared to radiotherapy alone (HR = 0.53; 95%CI: 0.39-0.72), but again had no influence on long-
term survival. 76 
 
Neoadjuvant therapy for colon cancer is currently not routinely used, although preliminary results 
from trials investigating its efficacy in locally advanced (T3 and T4) tumours show much promise. 77 
 
1.3.4.2.2 Adjuvant Therapy 
 
Adjuvant therapy is currently advocated for the post-operative treatment of colorectal cancer 
patients with positive lymph node involvement (Stage III) or with high risk Stage II disease (T3 and T4 
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lesions). 72 Current regimens are based largely around Oxaliplatin and 5-Fu (+/- folinic acid) with 
variable results. 72
, 78 Metastatic colorectal cancer is also treated systemically with the 
aforementioned agents in combination with Irinotecan. 72 
 
1.3.4.2.3 Advanced Disease 
 
As well as the standard chemotherapeutic agents already mentioned, advanced (metastatic) 
colorectal cancer has also been the focus for the introduction of new systemic treatments targeted 
against specific features of the tumour’s biology.  
 
The monoclonal antibodies Cetuximab, Panitumumab and Bevacizumab have all been utilised (often 
in combination with existing reagents) with variable results. Cetuximab and Panitumumab are 
monoclonal antibodies directed against EGFR, whilst Bevacizumab is an anti VEGFR antibody. All 
have shown improvement in survival when given alongside existing chemotherapy regimens in 
metastatic colorectal cancer although the presence of mutations within individual tumours has been 
shown to influence response to therapy (e.g. K-ras or B-raf in the case of EGFR monoclonal 
antibodies). 79 Furthermore, tumours that were initially sensitive to the effects of these agents have 
also been shown to subsequently develop resistance. 79 Further work is undoubtedly needed within 
this area to conclusively identify biomarkers predictive of therapy response and also to delineate 
mechanisms for overcoming established therapy resistance (be it primary or secondary). 
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1.4 Iron 
 
1.4.1 Iron Absorption and Metabolism 
 
Iron plays a crucial role in the regulation of numerous cellular functions and is thus essential for life. 
80 The ability of iron, through redox cycling, to function as both an electron donor and acceptor 
means that it serves as a co-factor within the active site of several key enzymes in a number of 
critical biochemical pathways including ATP generation, oxygen transport, cell cycling and DNA 
synthesis. 80 
 
Iron exists in the diet in either the organic (heme, e.g. from red meat) or in-organic (from various 
legumes) form. The absorption of both occurs within the small intestine, predominantly in the 
duodenum. 81 There is no iron absorption within the colon or rectum. 81 
 
1.4.1.1 In-organic Iron 
 
In-organic iron is absorbed through a process which begins with the reduction of dietary ferric iron 
(Fe3+) to ferrous iron (Fe2+) through the action of the ferrireductase duodenal cytochrome b (DCYTB) 
which is highly expressed on the enterocyte brush border (Figure 1.4).  82, 83 Some reduction of ferric 
iron also takes place within the stomach secondary to the action of hydrochloric acid. 80 
 
Following reduction by DCYTB, ferrous iron is then transported into the enterocyte by divalent metal 
transporter 1 (DMT1, also known as NRAMP2/DCT1), which is found at the apical membrane. 84, 85 
Once inside the enterocyte the iron is either i) immediately utilised within the various cellular 
processes in which it participates, ii) stored in an inert form for later use bound to the protein 
ferritin or iii) exported out of the enterocyte into the systemic circulation. 86  
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Exit from the enterocyte requires the ferroxidase hephaestin (HEPH) and the basolateral iron 
transporter ferroportin (FPN, also termed IREG1 or metal transporter protein 1). 87, 88, 89 Iron is then 
transported in the serum bound to transferrin (Tf), which can bind two atoms of ferric iron. Tf-bound 
iron then interacts with transferrin receptor 1 (TfR1) on the plasma membrane of cells which take up 
iron. Finally, the iron/Tf/TfR1 complex is internalised by receptor mediated endocytosis and iron is 
released from transferrin by a mechanism requiring endosomal acidification. 90 Within the 
endosome, the acidic environment triggers the release of ferric iron from Tf and its subsequent 
reduction to ferrous iron through the ferrireductase activity of STEAP3 (six transmembrane epithelial 
antigen of the prostate 3). The Tf/TfR1 complex then recycles back to the cell surface, where 
transferrin can take part in further rounds of iron uptake. Finally, ferrous iron is transported out of 
the endosome into the cytosol by DMT1 where it joins the labile iron pool and, as in the enterocyte, 
is either used in a multitude of cellular processes or stored as ferritin. 92 
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Figure 1.4 The intestinal absorption of iron 
Iron is absorbed across the apical membrane of the enterocyte as either heme or non-heme iron. 
Once within the cell it is either immediately used for the plethora of intracellular processes for which 
it is required, stored for later use in ferritin or exported out of the cell across the basolateral 
membrane. 
Adapted from Rizvi S, Robert E Schoen RE. Supplementation with oral vs. intravenous iron for 
anaemia with IBD or gastrointestinal bleeding: Is oral Iron getting a bad rap? The American Journal 
of Gastroenterology 2011; 106: 1872-1879. 91 
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1.4.1.2 Organic Iron 
 
Organic (heme) iron is absorbed from the small intestine through a process only recently 
characterised and distinctly separate to that of in-organic iron. 92  Originally it was thought that 
heme was absorbed through passive diffusion, however, the heme carrier protein (HCP1) has now 
been shown to function within the small intestine and represents the best candidate for a heme 
transporter. 80, 93  Interestinlgy, HCP1 has also been shown to act as a folate transporter, intimating 
that folate and heme may in fact compete for absorption through this mechanism and that 
consequently there may still be other heme absorption proteins yet to be discovered. 92, 94 Once 
within enterocytes, heme is broken down into biliverdin and iron(II) by heme oxygenase-1 (HO-1). 95  
From this point, the ferrous iron obtained from heme is regulated and transported in the same 
fashion as its in-organic counterpart. 
 
1.4.1.3 Regulation of Iron Metabolism 
 
As the human body possesses no direct capacity to excrete iron (other than small amounts through 
desquamation) it has adapted several mechanisms to regulate iron absorption and thus maintain an 
appropriate iron balance. 96  
 
1.4.1.3.1 Iron-regulatory Proteins 
 
The uptake, usage and storage of iron is maintained within tight limits by the regulation of the 
various iron transport proteins at the post-transcriptional level according to the intracellular 
concentration of iron. 80 The iron regulatory proteins 1 and 2 (IRP1 and IRP2) bind to iron responsive 
elements (IREs) located in the 5’- or 3’- untranslated regions of the mRNA of the iron metabolism 
proteins (e.g. TfR1, DMT1, ferritin and ferroportin) dependent on the intracellular iron concentraton 
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(Figure 1.5). 97, 98 At times of iron depletion, the IRPs bind with IREs located at the 3’ end of the iron 
uptake protein’s mRNA (stabilising its translation) and the 5’ end of iron storage protein’s mRNA 
(inhibiting translation). This ultimately results in an increase in expression of TfR1 (and to a certain 
extent DMT1) and a reduction in the expression of ferritin and ferrportin. 97, 98 Conversely, in iron-
replete cells, IRPs are unable bind to these same IREs leading to a reduction in iron uptake and an 
increase in iron storage (IRP1 instead functions as a cytosolic acinotase whilst IRP2 is degraded). 97, 98 
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Figure 1.5 Iron-regulatory protein interactions respond to intracellular iron levels 
IRP1 and IRP2 bind to IREs present in either the 5′ or the 3′ UTR of mRNAs. IREs are found in the 5′ 
UTR of mRNAs encoding ferritin, ferroportin and hypoxia-inducible factor 2α (HIF2α), and also in the 
3′ UTR of mRNAs encoding TFR1 and IRE-containing isoforms of DMT1. Binding of IRPs to 5′ IREs 
inhibits translation, whereas binding to 3′ IREs stabilizes mRNA. IRPs bind to IREs under conditions of 
low iron levels; under conditions of high iron levels, IRP1 loses its IRE-binding activity and acquires 
enzymatic activity as a cytosolic aconitase, whereas IRP2 is degraded. Thus, under conditions of low 
iron levels, the IRE–IRP system functions to increase iron uptake (by stabilizing mRNAs that encode 
TFR1 and DMT1) and decreases iron storage and efflux (by inhibiting the translation of ferritin and 
ferroportin). Binding of IRPs to mRNAs encoding HIF2α is thought to function as a feedback loop to 
inhibit erythropoiesis when iron levels are low. 
 
Adapted from Torti S, Torti F. Iron and cancer: More ore to be mined. Nature Reviews Cancer 2013; 
13: 342-55. 99  
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1.4.1.3.2 Hepcidin 
 
Hepcidin is a peptide secreted by the liver that acts as a systemic iron regulatory hormone. 100 It 
binds to ferroportin 1, thus trigerring its internalisation and lysosomal degradation. This results in 
the inhibition of iron release from iron exporting cells (such as enterocytes and also macrophages) 
and a subsequent decrease in serum iron levels. 101  
 
1.4.2 The Redox Activity of Iron 
 
Iron possesses the unique ability to cycle between two stable configurations, the ferric (Fe3+) and 
ferrous (Fe2+) states. 80  This allows it to act as both an electron donor and acceptor.80  
 
Fe2+ + H2O2 → Fe
3+ + OH• + OH- 
Figure 1.6 The Fenton Reaction 
 
In the Fenton reaction (Figure 1.6), a hydroxyl free radical is produced through the donation of an 
electron from the ferrous iron. 99 This highly reactive free radical is able to induce cell death through 
the initiation of a series of chemical reactions ultimately resulting in DNA oxidation, mitochondrial 
damage and the peroxidation of membrane lipids. 80 In addition, excess free iron can also react with 
unsaturated lipids to produce alkoxyl and preoxyl radicals. 80  All of these oxidative reactions result in 
the impairment of cellular function and lead to the damage of cells, tissues and organs.  
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1.4.3 Iron in Health and Disease 
 
Iron is essential for life; it plays a crucial role in oxygen transport and storage (where both 
haemoglobin and myoglobin contain iron) and is equally as vital for processes such as ATP 
generation, effective DNA synthesis and cell cycle progression. 80, 102  As iron is so important within 
the body, deviation from the normal tight regulation of its metabolism can have deleterious effects.  
This is best exemplified by the clinical syndrome of iron deficiency anaemia, a condition that occurs 
when the body has insufficient amounts of iron to meet its metabolic demands. 103  The 
consequences of iron deficiency include compromised immunity, physical impairment (e.g. lethargy, 
shortness of breath) and poor cognition. 104 
 
Conversely, as the body does not possess a system for its effective excretion, excess systemic iron 
(as in the iron storage disease Hereditary Haemochromatosis or in iron-overload conditions such as 
β-thalassemia and Friedrich’s Ataxia) leads to iron deposition in a number of organs including the 
heart, pancreas and liver. 105 This in turn causes irreversible tissue damage and fibrosis through the 
action of reactive oxygen species generated by the iron. 106, 107  As such, excess iron has been 
implicated in a number of diseases including ischaemic heart disease, diabetes mellitus and 
neurodegenerative disorders. 108, 109, 110 
 
1.4.4 Iron and Cancer 
 
Iron has also been implicated in the development of cancer. 111  This is perhaps not entirely 
surprising since iron is essential for ATP production, DNA synthesis and cell cycle progression; all 
activities that are increased in cancer cells. 112 Neoplastic cells therefore have a higher requirement 
for iron and it has been shown that the perturbation of cellular iron uptake proteins arrests cell 
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growth in-vitro and in-vivo. 113 Iron may also accelerate tumour initiation by enhancing the formation 
of free radicals which, as outlined earlier, damage cells and are potentially mutagenic. 99 
 
1.4.4.1 Epidemiological Studies 
 
In an early study examining the association between biochemical markers of iron stores and cancer, 
Stevens et al analysed more than 14,000 participants in the first US National Health and Nutrition 
Examination Survey. 99, 114, 115 The authors demonstrated that transferrin saturation at the time of 
enrolment into the study was significantly higher in men who subsequently developed cancer than in 
those who did not.  
 
Studies have also investigated the incidence of cancer in patients with Hereditary 
Haemochromatosis (HH), a condition characterised by iron overload, particularly in the parenchymal 
cells of the liver, heart and endocrine organs (such as the pancreas and pituitary).116 , 117 There is a 
20-200 fold increased risk of hepatocellular carcinoma in HH patients and individuals which carry 
mutations in haemochromatosis (HFE), one of the mutated genes that underlies HH, may also be at 
an increased risk of certain extrahepatic cancers, including breast and colorectal. 118, 119, 120  
 
Conversely, a 2008 study by Zacharski and colleagues demonstrated that repeated phlebotomy over 
a period of 4.5 years in elderly men with peripheral arterial disease (inferring a reduction in total 
body iron levels) reduced both overall cancer risk (HR 0.65, p=0.036) and cancer specific mortality 
(HR 0.49; p=0.009). 121 Although the authors interpreted their results with caution, their findings 
were consistent with other observations of a decreased cancer risk of several cancers (such as liver, 
lung, colon, stomach and oesophageal) in individuals who frequently donate blood. 99, 122 
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A meta-analysis of 33 studies assessing iron intake and colorectal cancer risk revealed that 
approximately 75% of the studies included associated higher iron intake with an increased risk of 
colorectal cancer. 123 A recent study by Ward and colleagues also demonstrated an increased risk of 
oesophageal adenocarcinoma amongst individuals with a higher intake of heme iron or total iron 
from meat. 124    
 
1.4.4.2 Human Tissue Studies 
 
The up-regulation of the pertinent cellular iron transport proteins has been demonstrated in a 
number of cancers including oesophageal, colon and breast. 24, 82, 125  
 
Boult and colleagues studied human samples of BM and OAC. 24 DMT1, DCYTB and TfR1 were found 
to be overexpressed in OAC tumour samples relative to BM and increased iron acquisition occurred 
as a result. 24 Interestingly, DMT1 expression was also shown to correlate with the presence of 
metastatic OAC. 
 
A similar phenomenon has also been noted in colorectal cancer, where Brookes and colleagues 
demonstrated increased iron acquisition in human colorectal tissue along the progression from 
adenoma to carcinoma. 82 In addition, the authors also demonstrated over expression of the cellular 
import proteins DCYTB, DMT1 and TfR1 along with internalisation of the iron exporter ferroportin. It 
was concluded that these adaptations along the pathway from adenoma to carcinoma favour the 
acquisition of intracellular iron which in turn is likely to drive proliferation and repress cell adhesion. 
82 Increased iron acquisition along the progression to colorectal cancer has been demonstrated in 
other studies also. 126 
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Finally, Pinnix and colleagues demonstrated an association between decreased ferroportin gene 
expression and reduced metastasis free and disease specific survival in breast cancer patients. 125 
Paradoxically, high ferroportin and low hepcidin gene expression in samples of breast tumour 
identified a cohort of patients with >90% 10 year survival.  
 
1.4.4.3 Animal Studies 
 
A number of animal models have demonstrated the ability of iron to drive tumourigenesis, 
particularly in the presence of underlying genetic mutations. 102, 127, 128, 129  
 
Of note, Chen et al demonstrated that administration of intra-peritoneal iron dextran to rats that 
had undergone oesophagogastroduodenal anastomosis (to simulate reflux) caused an increase in 
the rate of OAC formation compared to rats without iron supplementation. 129 Interestingly, all of the 
tumours which developed occurred at the squamo-columnar junction, the area where iron 
deposition was greatest.  
 
Radulescu et al investigated the effect of dietary iron intake in combination with a pre-existing 
mutation in the tumour suppressor gene APC on intestinal tumourigenesis. 102  It was demonstrated 
that the administration of an iron deficient diet to mice genetically predisposed to the development 
of intestinal tumours (through loss of APC) significantly increased rates of apoptosis within intestinal 
crypts resulting in decreased tumour proliferation and increased survival. Conversely, administration 
of excess dietary iron was found to significantly increase rates of tumourigenesis (compared to 
controls) and negatively influence survival. 102 Furthermore, analysis of murine intestinal tissue 
revealed an up-regulation in the expression of the iron import proteins TfR1 and DMT1 following 
loss of APC.  Up-regulation of DMT1 was also noted in the intestinal tumours of APCMin/+ mice with 
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activated HIF-2α in a separate study, leading the authors to postulate that dysregulation of iron 
homeostasis was a critical factor in the progression of colorectal tumourigenesis. 130 
 
1.4.4.4 Cell Based Studies 
 
Several in-vitro studies have demonstrated a dysregulation of iron homeostasis in cancer cells.  99, 131  
Perturbation of normal iron metabolism has been demonstrated in colorectal, oesophageal, breast, 
lung, renal, hepatocellular, prostate, melanoma, pancreatic and haematological cell lines. 99 
 
Of note, iron administration has been shown to increase proliferation rates in oesophageal and 
colorectal cell lines. 24, 82 In addition, iron has also been shown to amplify Wnt signalling (the major 
oncogenic signalling pathway in the colon) in APC deficient colorectal cells resulting in elevated 
levels of c-Myc and suppression of the cell adhesion protein E-cadherin. 132 In B-cell lymphoma cell 
lines, c-Myc has been shown to increase the expression of TfR1, subsequently leading to an increase 
in cellular proliferation. 133 
 
‘Knockdown’ of IRP2 has been shown to increase ferritin expression whilst decreasing TfR1 
expression in lung and breast cancer cells.  134, 135 Moreover, suppression of IRP2 significantly 
impaired the subsequent growth of lung and breast cell xenografts. 135, 136   
 
Interestingly, down-regulation of ferritin has been shown to increase the sensitivity of breast cancer 
cells to the chemotherapeutic agents Doxorubicin and Cisplatin in-vitro.  137, 138 
 
Thus, a dysregulation of iron metabolism appears to be intimately linked to tumourigenesis; 
cancerous cells acquire an excess of iron which drives their malignant phenotype both directly 
(through DNA synthesis and ATP generation) and indirectly (through ROS generation and the 
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amplification of Wnt signalling). Furthermore, the increased expression of proto-oncogenes such as 
c-Myc (associated with Wnt) may, it seems, further enhance cellular iron acquisition (through 
increased IRP2) leading to a self-perpetuating cycle of increased tumourigenesis. 
 
1.4.5 Iron Chelators as Anti-cancer Agents 
 
Given the association between dysregulated iron metabolism and cancer, there is now significant 
interest in the investigation and development of iron chelating drugs (aimed at depriving tumour 
cells of iron) as anti-neoplastic agents. 80, 92  
 
1.4.5.1 Experimental Iron Chelators 
 
A number of synthetic iron chelators have been created and subjected to pre-clinical testing to 
evaluate their anti-neoplastic effects.  These include O-Trensox, Tachypyridine, the 
thiosemicarbazones and Triapine. 92  Several mechanisms have been proposed for the anti-neoplastic 
effects of these agents including iron depletion, induction of apoptosis, cell cycle modulation and 
redox cycling.  92  
 
Of particular note, the agent Dp44MT (a member of the thiosemicarbazone family of iron chelators) 
developed by Richardson and colleagues has shown great promise as an anti-neoplastic agent in a 
number of in-vitro and in-vivo studies. 139, 140  The drug has demonstrated anti-proliferative effects in 
over 28 different human cell lines (including lung, melanoma and breast) in-vitro and of note, is also 
able to overcome Etoposide and Vinblastine resistance in breast and epidermoid carcinoma cell lines 
respectively. 92  In-vivo, Dp44mT markedly inhibits the growth of human lung carcinoma, 
neuroepithelioma and melanoma tumour xenografts in nude mice. 139 These positive findings, 
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however, have so far been largely negated by a number of significant side effects (including weight 
loss and cardiac fibrosis) associated with the drug in experimental models. 92 
 
More recently, the 2-benzoylpyridine thiosemicarbazone (BpT) chelators have been synthesized in 
an attempt to overcome some of the side effects seen with Dp44MT. 141 In-vitro studies using these 
agents have shown them to have greater anti-proliferative activity than Desferrioxamine and 
Triapine (but crucially not Dp44MT) in SK-N-MC neuroepithelioma cell lines. 141 In-vivo, the agent 
Bp44MT is also able to reduce tumour growth and decrease levels of cyclin D1 expression in DMS-53 
lung carcinoma xenografts relative to control. 142  
 
Thus far, however, despite these promising findings, the clinical application of all experimental iron 
chelators remains limited. As such, interest has been stirred in the anti-neoplastic potential of iron 
chelating agents that are already licensed and employed safely in other diseases. 80, 92 
 
1.4.5.2 Approved Iron Chelators as Anti-cancer Agents  
 
At present there are 3 chelating agents in routine clinical use; Desferrioxamine (DFO) is the longest 
serving agent and requires subcutaneous infusions; Deferiprone and Deferasirox are newer chelators 
and have the advantage over DFO of oral administration. 80  
 
1.4.5.2.1 Desferrioxamine 
 
DFO was the first iron chelating agent to be introduced into clinical practice and has been used in 
the treatment of the iron overload associated with β-thalassemia for a number of years. 80 It is a 
hexadentate chelator capable of binding iron in a 1:1 ratio (Figure 1.7). The drug has poor 
membrane permeability (it is hydrophilic rather than lipophilic) which, when combined with its short 
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half-life and rapid metabolism, means it must be given as a subcutaneous infusion several times a 
week in order to effectively chelate iron. 92 
 
As early as 1988, it was noted that DFO demonstrated anti-tumour effects upon human 
neuroblastoma cells most likely through iron deprivation in a time and dose dependent manner. 143  
Subsequent studies have demonstrated DFO to have similar effects in several gynaecological 
malignancies and also in leukaemia. 144, 145, 146  
 
Results from clinical trials of DFO as an anti-cancer agent are varied and this, coupled with its 
laborious method of delivery, accounts for why it is unlikely to be taken forward as an anti-cancer 
agent. 147  
 
1.4.5.2.2 Deferiprone 
 
Deferiprone (Ferriprox® / L1 / CP20) was the first orally administered iron chelator introduced into 
clinical use (Figure 1.7). 92 Like DFO, it has demonstrated promising anti-proliferative effects in a 
number of cancer cell lines in-vitro including neuroblastoma, hepatocellular carcinoma, cervical 
carcinoma and leukaemia. 144, 148, 149, 150, 151 
 
Unfortunately, the drug’s in-vitro anti-neoplastic effects have not been replicated with the same 
magnitude in-vivo and this, combined with a list of potentially significant side effects seen when 
used in humans (including agranulocytosis, neutropenia, arthralgia, liver fibrosis and gastrointestinal 
disturbances), means further investigation of the drug in this context has been limited thus far. 151, 
152, 153  
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Figure 1.7 The Chemical Structure of the Approved Iron Chelators Desferrioxamine (A), 
Deferiprone (B) and Deferasirox (C) 
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1.4.5.2.3 Deferasirox 
 
Deferasirox (Exjade® / ICL670A) is also an orally administered iron chelator and was first approved 
for the treatment of transfusional iron overload associated with β-thalassaemia major in adults and 
children over the age of 6. 154, 155 
 
Deferasirox is a hydroxyphenyl-triazole, tridentate chelator and as such two molecules are required 
to form a stable complex with a single iron ion. 156   The active molecule (ICL670A, Figure 1.7) is, 
unlike DFO, highly lipophilic and 99% albumin bound. Deferasirox has a high affinity for iron 
(approximately 14 and 21 times greater than its affinity for copper [Cu2+] and zinc [Zn2+] 
respectively). 156  
 
In-vivo animal pharmacokinetic studies have demonstrated that Deferasirox is rapidly absorbed from 
the gut and is capable of mobilising iron from various organ systems including hepatocytes and 
cardiomyocytes. 156, 157 
 
Phase 1 clinical trials for the use of Deferasirox in iron overloaded individuals demonstrated that its 
serum concentration is directly proportional to the dose administered. 158 Unbound Deferasirox has 
a mean half-life of 11–19 hours and plasma levels are maintained within a therapeutic range over a 
24-hour period (20 mg/kg/day: peak levels approximately 60–100 µmol/L, trough levels 
approximately 15–20 µmol/L), providing constant chelation activity. 159 
 
The proof of concept for Deferasirox treatment in humans was achieved through a dose escalation 
study in patients with β-thalassemia and transfusional iron overload. 159 The study demonstrated 
chelation efficiency for the drug of up to 20.5%, establishing an effective dose between 20–30 
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mg/kg/day. Data from subsequent phase II and III comparative studies in transfusion dependent β-
thalassemia patients provided evidence that Deferasirox’s efficacy is comparable to DFO. 160, 161 
 
Furthermore, the recently published results of a 3 year multicentre trial assessing the efficacy of 
Deferasirox in myelodysplastic syndrome has shown that it significantly reduced serum ferritin and 
serum labile iron pool in all transfusion dependent patients with elevated levels upon treatment 
commencement. 162   
 
Deferasirox has been shown to be generally well tolerated in both adults and children. 161 A total of 
652 patients received Deferasirox during core clinical trials with the most frequent adverse events 
being transient gastrointestinal disturbances (nausea, vomiting, abdominal pain, constipation and 
diarrhoea) and skin rashes. 161, 163, 164 These events rarely required drug discontinuation and many 
resolved spontaneously. 161 Mild, non-progressive increases in serum creatinine were also observed 
in 34% of patients.  
 
The incidence of serious adverse events as a result of Deferasirox treatment appears to be low. 162 
The EPIC study reported serious drug related adverse events in 14 of 327 (4.3%) patients given 
Deferasirox. 164 Likewise, the eXtend and eXjange study documented 7 events in a total of 167 (4.2%) 
patients. 165 Serious adverse events experienced with the drug include cases of gastrointestinal 
haemorrhage, myocardial infarction, neutropenia, thrombocytopenia, lens opacity, derangement in 
liver function and acute renal failure. 165 As such, all patients commenced on the drug require 
baseline evaluation of their renal and hepatic function with subsequent monitoring during therapy. 
The drug should be discontinued if increases in creatinine greater than 33% of baseline in 2 
consecutive readings are recorded with subsequent reintroduction at a lower dosage followed by 
monitored escalation. 166 
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1.4.5.2.3.1 Deferasirox as an Anti-neoplastic Agent 
 
Over the past few years, the potential for Deferasirox to act as a cytotoxic agent has been 
investigated. 167, 168  At present results are predominantly limited to in-vitro and in-vivo laboratory 
studies. 167, 168, 169 Human data currently comprises only small case series and anecdotal case reports. 
170, 171, 172 
 
1.4.5.2.3.1.1 In-vitro and Pre-clinical Effects of Deferasirox 
 
Deferasirox administration has been shown to decrease cellular viability, inhibit DNA replication and 
induce DNA fragmentation (all with a greater in-vitro cytotoxic effect than the chelator O-trensox) in 
both human hepatoma cell lines and normal human hepatocyte primary cultures. 167  Interestingly, in 
contrast to other iron chelators, Deferasirox also induces cell cycle blockade during S-phase rather 
than G1. 
167  Furthermore, much higher concentrations of Deferasirox are required to induce 
cytotoxicity in primary hepatocyte cultures compared to hepatoma cells (25 µM versus >200 µM) 
suggesting that malignant lines may be more sensitive to Deferasirox exposure than benign tissues; 
an observation previously seen with DFO, Deferiprone and O-Trensox. 143, 167, 168  
 
Exposure to Deferasirox has also been shown to cause a marked reduction in polyamine synthesis; 
possibly through inhibition of ornithine decarboxylase (ODC) mRNA levels which in turn results in 
decreased cellular viability and DNA replication. 173  Natural polyamines (e.g. putrescine, spermidine 
and spermine) are (like iron) required for cell proliferation to occur effectively. They are considered 
to be critical for the regulation of cell growth, differentiation and death and, unsurprisingly, their 
intracellular levels and uptake are significantly enhanced in tumour cells. 174 In turn, the enzyme ODC 
is a crucial component of the polyamine biosynthesis pathway and has been labelled a putative 
proto-oncogene by some. 174  
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The anti-neoplastic effect of Deferasirox upon lung tumour xenografts was recently assessed. 169 Oral 
Deferasirox was found to significantly reduce xenograft size with no effects seen on mouse health, 
haemoglobin levels or biochemical parameters. 169 Deferasirox increased expression of the 
metastasis suppressor protein, n-Myc downstream regulated gene-1 (NDRG1) and up-regulated the 
cyclin-dependent kinase inhibitor p21CIP1/WAF1. In line with previous findings in myeloid leukaemia 
cells, the drug also increased the expression of apoptosis markers, including caspase-3 (a serine 
protease that induces apoptosis). 169, 175, 176  
 
The potential impact of Deferasirox upon the nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFκB) pathway has also been investigated. 177 NFκB plays a pivotal role in the pathogenesis of 
a number of cancers by regulating several fundamental cellular processes such as apoptosis, 
proliferation, differentiation and tumour migration. 178 It has been shown to be constitutively active 
in most tumour cell lines and has also been identified in tumour tissue from patients with multiple 
myeloma, acute myeloid leukaemia, prostate cancer and breast cancer. 178, 179, 180, 181, 182 Deferasirox 
was found to dramatically reduce NFκB activity in both leukaemia cell lines and blood samples from 
patients with myelodysplastic disorders. 177  Furthermore, the addition of ferric hydroxyquinoline 
during incubation did not reinstate NFκB activity suggesting that the effect produced by Deferasirox 
may be independent of chelation induced cell iron deprivation. 177  In addition, inhibition of the NFκB 
pathway was seen solely with Deferasirox (it did not occur with either DFO or Deferiprone). 
Interestingly, it was also noted that pre-incubation of cells with Deferasirox followed by subsequent 
incubation with Etoposide lead to an increase in the number of apoptotic cells compared to both 
drugs alone. 177  
 
Deferasirox also appears to be capable of repressing signalling through the mammalian target of 
rapamycin (mTOR) pathway by enhancing expression of the regulated in development and DNA 
damage response protein (REDD1, also known as HIF-1 responsive protein) to give anti-proliferative 
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effects on myeloid leukaemia cells. 183 The mTOR pathway is known to demonstrate aberrant activity 
in a number of cancers including ovarian, breast, colon, brain and lung.184  Over activity of this 
pathway culminates in de-regulation of the cell cycle and increased cellular proliferation. Conversely, 
inhibition of the mTOR pathway results in cytostatic effects possibly through a reduction in proteins 
ultimately required for cell cycle progression including the previously mentioned ODC and cyclin D. 
184 REDD1 has been previously identified as a stress-response gene and is strongly induced by 
hypoxia. 185  
 
Finally, Deferasirox has been shown to attenuate Wnt signalling (a major oncogenic signalling 
pathway in a number of cancers, most notably colorectal) through an iron dependent mechanism. 
102, 186  
 
1.4.5.2.3.1.2 Human Studies 
 
A number of studies have anecdotally described an improvement in red blood cell parameters 
amongst patients with myelodysplastic disorders following chelation therapy with Deferasirox.  For 
example, post-hoc analysis of a recently published 3 year prospective multicentre trial (which was 
designed primarily to assess the safety and efficacy of Deferasirox as an iron chelator in 
myelodysplastic syndrome) revealed improvement in haematological parameters amongst a sub-
group of patients within the first year of treatment. 162   
 
The results seen in the previous trial have been supported by a number of case reports. 170, 171, 172 Di 
Tucci and colleagues administered Deferasirox as chelation therapy to a patient with primary 
myelofibrosis and previous transfusion dependency.170 After 2 months of therapy the patient's 
transfusion requirement progressively decreased and ceased completely after 5 months. Guariglia et 
al. also documented the case of a 74 year old male patient with refractory thrombocytopenia given 
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Deferasirox as chelation therapy who, despite persistence of the karyotypic and morphological 
abnormality, became transfusion independent following 6 weeks of therapy. 187   Interestingly, once 
treatment with Deferasirox was stopped the patient again became transfusion dependent; 
Deferasirox was thus restarted and the patient became transfusion independent once more. 
 
Finally and perhaps of most interest, another case report documented that Deferasirox 
administration achieved complete remission in a patient with previously chemotherapy resistant 
acute monocytic leukaemia. 188 Following relapse and subsequent rejection of further 
chemotherapy, the patient underwent regular blood transfusions with the addition of Deferasirox as 
chelating therapy for 12 months. Four months after discontinuation of Deferasirox the patient’s 
blood cell count normalised and the patient became transfusion-independent. Bone marrow 
aspiration and biopsy revealed a haematological and cytogenetic complete remission.  
 
The mechanism by which chelation therapy with Deferasirox may induce haematological 
improvement remains unclear. It is known that iron chelators promote iron release from storage 
sites, facilitating its usage for haematopoietic tissue. 187, 188  Reduction in iron stores appears to up 
regulate erythropoietin response with subsequent increase in haemoglobin release. 189  In patients 
with myelodysplastic syndrome in particular, treatment with Deferasirox significantly reduces ROS, 
membrane lipid peroxidation and labile iron pools. 189 It also increases glutathione levels in red blood 
cells, neutrophils and platelets. 190  
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1.5 Conclusion  
 
Gastrointestinal cancer remains a significant health problem throughout the world. 2 In the UK in 
particular, both oesophageal cancer (with its increasing incidence and poor outcome) and colorectal 
cancer (as the 4th most common malignancy) place significant burdens on both the individuals 
affected and society as a whole. 3, 4, 7, 58   As such, the development and implementation into clinical 
practice of new treatments that are either solely effective or can enhance the efficacy of existing 
therapies would be highly desirable.   
 
Iron is intimately involved in tumourigenesis and it has been shown to have a role in the propagation 
of both oesophageal and colorectal cancers. As such, iron chelation represents a promising avenue 
in the treatment of cancer. Although experimental chelating agents have demonstrated significant 
anti-proliferative and chemosensitising properties, associated side effects mean that at present 
approved iron chelators offer the best chance of translation into clinical practice.  
 
Of the three chelators currently in clinical use, Deferasirox has the advantage of once daily oral 
administration (unlike DFO) and is well tolerated with a safety profile that appears superior to other 
chelators. The drug possesses potent anti-neoplastic effects in a number of pre-clinical cancer 
models and furthermore, these cytotoxic and anti-proliferative actions appear to be mediated 
through a number of different oncological pathways and are not merely restricted to the action of 
iron deprivation through chelation.  
 
Considering Deferasirox’s potentially multi-modal therapeutic action, ease of administration, good 
safety profile and anecdotal clinical experience to date, the drug makes for an attractive 
chemotherapeutic agent in the treatment of cancer.  
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1.6 Hypothesis and Aims 
 
Normal iron metabolism is dysregulated in gastrointestinal cancer in a way that favours the 
propagation of tumourigenesis. As such, a strategy to starve tumour cells of iron represents a 
potential novel treatment worthy of further investigation. With this in mind, iron chelation therapy 
has shown early promise in a number of malignancies. Furthermore, iron chelators have also been 
shown to possess chemosensitising properties when given in combination with existing agents in 
experimental models. None of this has been investigated before in the context of gastrointestinal 
cancer, however. Thus, the aims of this thesis are: 
 
1. To determine the efficacy of the iron chelating agent Deferasirox as an anti-neoplastic and or 
chemosensitising agent in oesophageal cancer. 
2. To determine the efficacy of the iron chelating agent Deferasirox as an anti-neoplastic and or 
chemosensitising agent in colorectal cancer. 
3. To determine the role of IRP2 in colorectal cancer in order to offer a predictive marker for 
iron chelation efficacy. 
4. To determine the ability of the iron chelating agent Deferasirox to chemosensitise a panel of 
re-purposed drugs in oesophageal and colorectal cancer. 
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Chapter 2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Cell Lines Utilised 
 
2.1.1.1 Oesophageal Cell Lines 
 
OE19 
 
Also known as JROECL19, the OE19 cell line was established in 1993 from an adenocarcinoma of the 
gastric cardia/gastroeosophageal junction in a 72 year old male patient. 191 The tumour was 
identified as pathological stage III and showed moderate differentiation.  
 
OE33 
 
Also known as JROECL33, the OE33 cell line was established from an adenocarcinoma of the lower 
oesophagus in a 73 year old female patient. 191 The cancer had developed on the background of 
Barrett’s metaplasia. The tumour was identified as pathological stage IIa and showed poor 
differentiation.  
 
OE21 
 
Also known as JROECL21, the OE21 cell line was established from a squamous cell carcinoma of the 
mid oesophagus in a 74 year old male patient. 191 The tumour was identified as pathological stage IIa 
and showed moderate differentiation. 
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TE4 
 
The TE4 cell line was a kind gift from Professor Winand Dinjens at Erasmus MC, Rotterdam, Holland. 
It was established from a squamous cell carcinoma of the oesophagus and has been shown to be 
highly resistant to chemotherapy with Cisplatin. 192    
 
2.1.1.2 Colorectal Cell Lines 
 
RKO 
 
The RKO cell line is a poorly differentiated colon carcinoma cell line taken from an 82 year old female 
patient. It expresses wild type APC, p53 and GADD45. 193    
 
SW480 
 
The SW480 cell line was established from a primary adenocarcinoma of the colon in a 50 year old 
male. The line expresses constitutively active c-Myc and K-ras along with mutated p53. It also 
contains a truncated/mutated APC. 193 
 
SW620 
 
The SW620 cell line was established from a metastatic lymph node taken from the same patient as 
the SW480 cell line 1 year later when the disease recurred. It is thus a colonic adenocarcinoma 
metastasis and is essentially isogenic with the SW480 cell line. The line expresses c-Myc and K-ras as 
well as mutant APC. 193 
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HT29 
 
The HT29 cell line was a kind gift from Dr Bert Vogelstein of the John Hopkins University, Baltimore, 
USA. It originates from a colonic adenocarcinoma in a 44 year old female and expresses the 
oncogenes c-Myc and K-ras. It also possesses mutant APC. 193 
 
This cell line was modified by Dr Vogelstein to express wild type APC following incubation with 100 
µM zinc chloride for 24 hours. 63 This occurs through the action of a zinc inducible, Hygromycin B 
resistant APC expressing vector (pSAR-MT-APC) transfected by Dr Vogelstein and confirmed through 
Western blotting. 63  The cell line has subsequently been utilised in a number of studies as a model 
for investigating the effect of APC expression on cell phenotype behaviour. 194, 195 
 
HCT116 
 
The HCT116 cell line is a colonic adenocarcinoma cell line originating from an adult male patient. It 
possesses wild type APC and p53 but has activated c-Myc and K-ras expression. 193  
 
In addition, an isogenic HCT116 p53 -/- cell line was also utilised, which was a kind gift from Dr Bert 
Vogelstein of the John Hopkins University, Baltimore, USA. This cell line has undergone targeted 
deletion of both p53 alleles and is a suitable model for studying the effects of p53 on cell growth and 
subsequent response to therapy. 196 
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Caco-2 
 
The Caco-2 cell line is a colonic adenocarcinoma cell line originating from a 72 year old Caucasian 
male. 193 In addition, when cultured under specific conditions the cells become differentiated and 
polarized such that their phenotype (morphologically and functionally) resembles the enterocytes 
lining the small intestine. 197 Thus, Caco-2 cells are most commonly cultured to a confluent 
monolayer on a cell culture insert filter (e.g. Transwell). When cultured in this format, the cells 
differentiate to form a polarized epithelial cell monolayer that provides a physical and biochemical 
barrier to the passage of ions and small molecules. 197 This Caco-2 monolayer model is widely used 
across the pharmaceutical industry as an in-vitro model of the human small intestinal mucosa to 
predict the absorption of orally administered drugs. 
 
Colo320 
 
The Colo320 cell line originates from a 55 year old female and is a Duke’s C colonic adenocarcinoma. 
It possesses mutations in both the APC and p53 tumour suppressor genes but displays wild type K-ras 
and B-raf. 193 
 
Colo205 
 
The Colo205 cell line originated from the ascitic fluid of a 70 year old male patient with colonic 
adenocarcinoma previously treated with 5-Fluorouracil. Like the Colo320 cell line, it possesses 
mutations in APC and p53, however, it also contains a BRAF V600E mutation. 193 
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Table 2.1 Genetic status and oncogene expression in certain colorectal cancer cell lines utilised 
Cell Line RKO HCT116 HT29 Colo320 Colo205 Caco-2 SW480 SW620 
APC status Wild type Wild type Mutated * Mutated Mutated Mutated Mutated Mutated 
p53 status Wild type Wild type Mutated Mutated Mutated Mutated Mutated Mutated 
K-ras  Wild type Mutated Wild type Wild type Wild type Wild type Mutated Mutated 
c-Myc 
expression 
Detected Detected Detected Detected Detected Detected Detected Detected 
PIK3CA Mutated Wild type Mutated Wild type Wild type Wild type Wild type Wild type 
B-raf Mutated Wild type Mutated Wild type Mutated Wild type Wild type Wild type 
 
*also wild type inducible 
Adapted from American Tissue Culture Collection (ATCC). Colon cancer and normal cell lines. 193 
 
RGC2 
 
The RGC2 cell line is derived from a colonic adenoma and was a kind gift from Professor Ann 
Williams, School of Cellular and Molecular Medicine, University of Bristol, UK. It possesses wild type 
APC and expresses c-Myc. 198 
 
AAC1 
 
The AAC1 cell line is derived from a colonic tubular adenoma displaying mild dysplasia. 199 It has an 
APC mutation, expresses c-Myc and also possesses a K-ras mutation. 
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2.1.2 Materials Utilised 
 
General, Cell Culture and Molecular Biology Reagents 
General, cell culture and molecular biology reagents were obtained from the following sources: 
 
Abbott, Global 
Isoflurane 
 
Amersham Pharmacia, Amersham, Buckinghamshire  
ECL reagent; Hybond PVDF, Hyperfilm x-ray film, Peroxidase linked secondary antibodies;  
 
Antec International, Sudbury, UK 
Virkon 
 
Applied Biosystems, Cheshire  
96 well optical plate; optical adhesive covers; RNAlater; TaqMan ribosomal RNA control reagent 
 
Appleton Woods, Selly Oak, Birmingham  
10 ml and 25 ml pipettes; Bijou 3 ml and 7 ml tubes; Eppendorfs; Universal 15 ml and 50 ml tubes 
 
Becton Dickinson (BD), Plymouth UK 
Falcon 5 ml round bottom counting tubes; FACS tubes (5 ml 12/75 mm); BD Matrigel 
 
Bioline, Humber Road, London, UK 
SensiMixtm II qRT-PCR probe kit 
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Bio-optica, Milano, Italy 
Tris Buffered Saline, W-CAP TEC Buffer 
 
Boehringer Mannheim, Lewes, East Sussex  
Mycoplasma detection Kit 
 
Chance Propper, Smethwick, West Midlands  
Glass coverslips 
 
DAKO UK Ltd, Cambridge, UK 
DAKO Antibody Diluent; DAKO ChemMate substrate buffer; DAKO REAL DAB and Chromogen Kit; 
DAKO Pen 
 
Eurogentec, Seraing, Belgium 
Reverse transcriptase core kit 
 
Fisher Scientific, Loughborough, Leicestershire   
BCA protein assay 
 
Geneflow, Southampton  
Acrylamide 
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Invitrogen, Paisley, Renfrewshire (incorporating Gibco BRL)  
Dulbecco's Modified Eagles Medium (DMEM) with Glutamax-1, pyridoxine and 4500mg/L glucose; 
Foetal Calf Serum; Hygromycin B; McCoy’s 5A medium; Normal goat serum; Optimem medium; 
Penicillin and Streptomycin solution; PLUS Reagent; PureLink HiPure Plasmid Filter Purification Kits – 
Maxi Prep; Puromycin; Roswell Park Memorial Institute (RPMI) medium with 25 mM Hepes buffer 
and L-glutamine; Super Ooptimal Broth with Catabolite repression (S.O.C) media; Trizol reagent; 
Trypsin EDTA. 
 
Iwaki, Stone, Staffordshire (Subsidiary of Barloworld scientific) 
25, 75 and 150 cm2 tissue culture flasks; 96 well culture plates; 12 well culture plates; 6 well culture 
plates 
 
Pall Corporation, Newquay, Cornwall  
0.2 µm filters 
 
Promega, Chilworth Research Centre, Southampton 
Dual-Luciferase Reporter Assay System; Nuclease free water 
 
Roche Applied Science, Lewes, East Sussex 
BrdU proliferation assay; Proteinase and phosphatase inhibitor cocktails 
 
Sigma Chemical Company Limited, Poole, Dorset 
Agarose; Ammonium acetate; Ammonium persulphate; -mercaptoethanol; Bromophenol Blue; 
Calcium chloride; Citric acid (tri-sodium citrate); DAB (3,3’-diaminobenzidene tetrahydrochloride) 
tablets; DAPI (4’,6-diaminido-2-phenylindole); Deoxynucleotide (dNTP) mix; Dimethyl Formamide; 
Dimethyl Sulfoxide (DMSO); Dithiothreitol (DTT); DNAse I; Ferrous sulphate; Ferrozine (3-(2-Pyridyl)-
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5,6-diphenyl-1,2,4-triazine-4,4-disulfonic acid); Formalin; Glycerol; Glycine; N-[2-
Hydroxethyl]piperazine-n’-[2-ethanesulfonic acid] (HEPES); H2DCF-DA (2,7-dichloro-fluorescein-
diacetate); Hydrochloric acid; Hydrogen Peroxide 30% w/v; Hydroquinone (1,4-Benzenediol); LB 
Broth EZMix powder; Isopropanol; Lauryl sulphate; MgCl2; Mayer’s Haematoxylin 0.1% Solution; 
Methanol; MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide); NP40; 
Paraformaldehyde; Polyoxyethylenesorbitan monolaurate (Tween 20); Phosphate buffered saline; 
Potassium Acetate; 1,2-propanediol; Propidium Iodide; RNase A; Sodium Acetate; Sodium Ascorbate; 
Sodium Carbonate; Sodium Chloride; Sodium Citrate; Sodium dodecyl sulphate (SDS); TEMED; 
Trichloroacetic Acid, Tris HCl; Trizma base; Urea; Xylene  
 
Turumo, Europe 
Capijet blood tubes 
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 2.2 Methods 
 
2.2.1 Routine Cell Culture 
 
Cell lines were cultured in an incubator at 37 C and 5% CO2 atmosphere for all experiments (apart 
from those involving the induction of hypoxia where a hypoxic chamber at 1% O2, 5% CO2, and 94% 
nitrogen was utilised). Unless stated otherwise, cells were grown in Dulbecco's Modified Eagles 
Medium (DMEM) supplemented with 10% (v/v) Foetal Calf Serum (FCS), 50 U/ml penicillin and 50 
µg/ml streptomycin. Colo320 and Colo205 cells were cultured in RPMI medium containing 10% (v/v) 
FCS, 50 U/ml penicillin and 50 µg/ml streptomycin. HT29 cells were cultured in McCoy’s 5A medium 
containing 10% (v/v) FCS, 50 U/ml penicillin, 50 µg/ml streptomycin and also 0.6 mg/ml Hygromycin 
B.  
 
All cell lines utilised grow as an adherent monolayer and were passaged at approximately 90% 
confluence by aspirating the culture medium, washing the monolayer in sterile phosphate buffered 
saline (PBS) and incubating with 5 ml of 0.05% (w/v) trypsin EDTA until cells had detached (typically 
5-10 minutes). Five ml of culture media was then added and cells were disaggregated by trituration 
and then centrifuged at 1500 rpm for 5 minutes. The cell pellet was either re-suspended in culture 
media and reseeded or was re-suspended in 1 ml of freezing medium (10% (v/v) dimethyl sulphoxide 
(DMSO), 20% (v/v) FCS, 70% (v/v) media as appropriate) and placed in a cryovial for cryopreservation.  
 
Vials were kept at –70 oC for 3 days before transfer to liquid nitrogen storage. Frozen cells were 
resurrected by rapid warming of the cryovial in a 37 oC water bath and the cells were then washed 
and suspended in pre-warmed culture media.  Cells were seeded into tissue culture flasks and 
cultured in the standard manner. All cell culture procedures were performed in a laminar flow tissue 
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culture cabinet using aseptic technique. Mycoplasma testing was performed periodically to ensure 
cells remained negative. 
 
2.2.2 Preparation of Pharmaceutical Agents  
 
Deferasirox 
 
A 10mM stock solution of Deferasirox (ICL670A, Exjade ®Novartis Pharmaceuticals, Switzerland) was 
produced by dissolving 37.34 mg of the drug in 10 ml of serum free DMEM. The resulting solution 
was sterile filtered prior to use and then diluted as appropriate for the experiment performed. 
 
Cisplatin 
 
A 100 µM stock solution of Cisplatin was prepared by adding 300 µl of 1 mg/ml Cisplatin to 9.7 ml of 
serum free DMEM. The stock solution was then diluted as appropriate for the experiment performed. 
 
5-Fluorouracil  
 
A 500 µM stock solution of 5-Fu was prepared by adding 26 µl of 25 mg/ml 5-Fu to 9974 µl of serum 
free DMEM. The stock solution was then diluted as appropriate for the experiment performed. 
 
ECF 
 
The chemotherapy combination of Epirubicin, Cisplatin and 5-Fu (ECF/ECX) is commonly used in the 
treatment of oesophageal cancer. 41 For the purposes of the experiments performed, the individual 
agents were prepared at their pre-determined IC25s of 0.5 µM (Epirubicin), 4 µM (Cisplatin) and 4 
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µM (5-Fu) and combined together in serum free media. The stock solution was then diluted as 
appropriate for the experiment performed. 
 
Trametinib 
 
The MEK (MEK1 and MEK2) inhibitor Trametinib was purchased from Santa-Cruz Biotechnology. 
Following re-suspension in DMSO the drug was added to standard media and used at the 
concentrations documented (typically 10 nM). 
 
Sorafenib 
 
The intracellular serine/threonine kinase (B-raf) inhibitor Sorafenib was purchased from Santa-Cruz 
Biotechnology and following re-suspension in DMSO was added to standard media to produce the 
documented experimental concentrations (typically 1 µM). 
 
Ferrous Sulphate 
 
A stock solution of 10 mM ferrous sulphate (FeS04) was prepared by dissolving 111.2 mg FeS04 in 40 
ml of sterile distilled water (SDW). In addition, either 395 mg (enhanced) or 7.9 mg (standard) of 
sodium ascorbate (equivalent to 50 mM and 1 mM respectively) was added to prevent the iron from 
oxidising in solution, thus maintaining an adequate pool of Fe2+ for absorption by the cells. The FeS04 
stock solution was then filtered and diluted in serum free media as appropriate for the particular 
experiment (typically 100 µM FeSO4).  
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Zinc Chloride 
 
Zinc chloride was dissolved in SDW and used at the previously published concentration of 100 µM for 
48 hours to induce APC expression in the HT29 colonic cell line. 63 
 
Library of Redeployed Drugs 
 
The library of 99 redeployed drugs was a kind gift from Professor Chris Bunce and Dr Farhat Khanim, 
School of Biosciences, University of Birmingham, UK. The library contains drugs from all sections of 
the British National Formulary (BNF). Drugs are utilised at concentrations equivalent to the peak 
serum concentration achieved through their standard dosing regimen as recommended in the BNF 
(Table 2.2). 200 
 
Drugs were initially prepared as stock solutions equivalent to 10,000x their reported peak serum 
concentration and kept at -20 0C until required. 200 For experiments, 1 µl of stock solution was added 
to standard DMEM containing 10% FCS (v/v) and 1% penicillin/streptomycin (v/v). Working solutions 
were prepared fresh for each experiment. 
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Table 2.2 Library of redeployed drugs  
 
 
Drug x10,000 stock (mM) Chlorambucil 16.173
Prednisolone 716.000 Metoclopromide 2.974
Amantidine 35.000 Domperidone 0.446
Folic acid 1.041 Thalidomide 109.000
Thiamine 1.186 Chloroquine 1.980
Ranitidine 15.500 Metformin 121.000
Fluoxetine 6.820 Niclosamide 32.000
Dexamethasone 4.332 Pravastatin 0.269
DMSO Control Nortryptyline 4.636
Vitamin K1 0.008 Dantrolene sodium 37.000
Carbamazepine 508.000 Omeprazole 26.113
Propanolol 5.105 Diclofenac 12.570
Erythromycin 52.000 Ritodrine 1.390
Retinol 10.000 Selegiline 2.011
Bendroflumethiazide 1.186 Mebendazole 16.933
Propylthiouracil 1057.000 Flupentixol 0.118
Nicotinic acid 1000.000 Acipimox 382.000
Theophylline 110.000 Ethanol Control
Nicotinamide 409.000 Desferrioxamine 132.000
Ascorbic acid 950.000 Imipramine 2.241
Acyclovir 222.000 Artemisinin 14.000
Allopurinol 460.000 Propantheline 0.468
Chlorpheniramine 0.409 Diltiazem 4.010
Neostigmine 0.150 Ampicillin 162.000
Alpha tocopheryl acetate 500.000 Methanol Control
Bromocriptine 13.750 Amphotericin b 43.000
Cyclophosphamide 2000.000 Danazol 17.780
Imatinib 51.000 Penicillin V 914.000
Zinc acetate 3234.000 Mesalazine 26.120
Valproic acid 6017.000 Finasteride 1.074
Rifampicin 122.000 Colchicine 0.175
Metronidazole 760.000 Levothyroxine 1.500
Praziquantel 350.000 Methotrexate 10.000
Flutamide 62.235 Mifepristone 4.600
Clomipramine 8.540 Nicotine 2.157
Testosterone 0.400 Cefaclor 625.000
Calciferol/ergocalciferol 0.500 Vitamin B12 0.001
Doxycycline 68.000 Medroxyprogesterone acetate 2.330
Aspirin 3330.000 Bezafibrate 83.000
Ibuprofen 1939.000 Paroxetine 1.734
Norethisterone 0.294 Trimethoprim 69.000
Itraconazole 8.800 Water Control
Methyldopa 57.200 Naloxone 0.875
Fenofibrate 26.300 Simvastatin 0.186
Clofibric acid 2330.000 Flecainide 21.000
Clobetasol propionate 0.099 Pilocarpine 3.000
Paracetamol 1323.000 Fluconazole 617.000
Alverine citrate 100.000 Acitretin 12.250
Mefenamic acid 414.000 DMEM (1) Control
Prochlorperazine 66.000 DMEM (2) Control
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Table 2.2 Library of redeployed drugs  
Drugs were utilised at concentrations equivalent to the peak serum concentration achieved through 
their conventional dosing regimens. 200 Stock solutions were made at 10,000x concentration (mM). 
Working solutions were created by adding 1 µl of stock solution to 10 ml of standard media. For 
compounds marked control, 1 µl of reagent (at standard concentration) was added to 10 ml standard 
media.  
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2.2.3 Cell Viability Assay 
 
Cells were plated out and subjected to conditions as outlined within each experimental section.  
 
After the defined time points, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assays were performed in order to determine cellular viability. The MTT assay is a colorimetric assay 
for measuring the activity of cellular enzymes that reduce the tetrazolium dye, MTT, to its insoluble 
formazan form. The more viable (and active) the cells, the more the MTT is reduced.  
 
Briefly, 10 μl of MTT solution (5 mg/ml in sterile PBS) was added to 100 µl of culture media in each 
well of the 96 well plate and incubated for 3 hours. Following this period, the media (containing the 
MTT) was aspirated and replaced with 100 μl of dimethyl sulfoxide (DMSO) to dissolve the 
accumulated formazan crystals. After 15 minutes at room temperature, the plates were placed into 
a Bio-Tek ELx800 absorbance micro plate reader and absorbance read at 490 nM. The resulting 
optical densities were used to calculate percentage viability with respect to control (normalised to 
1). 
 
2.2.4 Cell Proliferation Assay 
 
The pyrimidine analogue 5-bromo-2'-deoxyuridine (BrdU) is incorporated into cellular DNA in place 
of thymidine during replication and can therefore be used to quantify cellular proliferation. 
Incorporated BrdU can be detected by the use of a peroxidase conjugated anti-BrdU antibody 
followed by a colorimetric reaction involving tetramethyl-benzidien (TMB).  
 
After the defined experimental time point, cells were labelled with BrdU (10 µl per well, diluted 1 in 
100 v/v with plain media) for 4 hours at 37 0C, then fixed and DNA denatured with FixDenat solution 
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(200 µl per well for 30 minutes at room temperature). Cells were then incubated with anti-BrdU 
antibody for 90 minutes at room temperature (50 µl per well, diluted 1 in 100 with antibody diluent). 
Immune complexes were detected after washing, using a TMB substrate reaction (100 µl per well) 
with the subsequent product assessed at 405 nm (after 15 minutes) on a micro plate reader. The 
resulting optical densities were used to calculate percentage viability with respect to control 
(normalised to 1). 
 
2.2.5 Oesophageal Cell Line Xenografts 
 
Suspensions of OE19 cells (1 x 107 cells) were centrifuged and re-suspended in 50 µL of culture 
media. Immediately prior to injection, the cell slurry was mixed 50/50 (v/v) with Matrigel 
(extracellular matrix). The cell suspension was then subcutaneously injected into NOD-SCID (severely 
immunodeficient) mice (100 µl per mouse). After a period of tumour establishment (typically 2 
weeks), mice were divided into groups and given treatments as per the experimental protocol. 
 
Throughout the experimental period, mouse health and weight were closely monitored. Tumour 
growth was also measured weekly using calipers. Following the treatment period, mice were 
anaesthetised and exsanguinated by direct cardiac puncture and blood/plasma retained for full 
blood count and biochemical analysis (creatinine and serum iron). Tumours were removed and 
weighed to assess tumour burden. All work was carried out under Home Office approved conditions 
and in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986. 
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2.2.6 NFκB Reporter Assay 
 
The pGL4.32 vector contains five copies of an NF-κB response element (NF-κB-RE) that drives 
transcription of the luciferase reporter gene luc2P and was a kind gift from Dr Chris Dawson, School 
of Cancer Sciences, University of Birmingham, UK. 
 
Briefly, OE19, OE21 and OE33 oesophageal cells were plated out into 12 well plates and co-
transfected the following day with the pGL4.32 vector and the CMV-Renilla plasmid (Promega) using 
Lipofectamine 2000 transfection reagent. Following an overnight expression period, cells were 
treated with either control solution (standard DMEM), TNFα (20 ng/ml in DMEM, positive control) or 
Deferasirox. After being returned to the incubator again overnight whilst induction took place, 
luciferase activity was quantified using a dual-luciferase® reporter assay system the following day.  
 
After reading the plates on a Victor plate reader, the reading of the luciferase signal was corrected 
with the reading of the Renilla (as per manufacturer’s instruction). Fold change in luciferase reporter 
activity (NFκB activity) was then calculated using the formula: 
 
Fold Induction =  Average relative light units of induced cells (either TNFα or Deferasirox) 
Average relative light units of control cells 
 
Data was thus expressed as a fold change relative to control NFκB levels (normalised to 1). 
 
2.2.7 Protein Quantification Assay 
 
A protein assay was performed on cellular lysates in order to determine protein concentration prior 
to Western blotting, the ferrozine assay and the ferritin ELISA. 
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Protein concentration of samples was determined using a BCA™ (bicinchoninic acid) protein assay 
and compared with bovine serum albumin at standard concentrations between 0 and 2 mg/ml. 10 μl 
of each standard, or 10 µl of each cell lysate, were aliquoted in triplicate onto a clear flat bottomed 
96-well plate. 200 μl of BCA™ working reagent (reagent B 1:50 in reagent A) was added to each well 
and incubated for 30 minutes at 37 °C. Absorbance was then measured at 550 nm using a Bio-Tek 
ELx800 absorbance microplate reader. The sample protein concentrations were then derived from a 
graph of standard concentrations plotted against optical density at 550 nm. 
 
2.2.8 Western Blotting 
 
Cells were cultured in 6 well plates as per the desired experimental conditions. For lysate 
preparation, the media was removed and cells washed 3 times with 1 ml PBS. 160 µl RIPA lysis buffer 
(1% (w/v) NP40 (nonyl phenoxypolyethoxylethanol) (5 g); 0.5% sodium deoxycholate (2.5 g); 0.1% 
SDS (0.5 g) in 500 ml deionised water) containing protease and or phosphatase inhibitor cocktail 
tablets (as required) was then added to each well. Lysates were prepared on ice, subjected to 
ultrasound probe sonication and stored at -4°C prior to use.  
 
Prior to sample preparation a protein assay was performed (as outlined previously) so that equal 
volumes of lysate could be loaded (typically 10 or 20 µg). Lysates were mixed with loading dye (500 
μl 4x SDS + 200μl β-mercaptoethanol) at a ratio of 4:1 and then boiled for 5 minutes at 100 °C.  
 
Standard 10% resolving gels were made for all antibodies except ferritin (for which a 12.5% gel was 
utilised). The 10% resolving gel comprises 1-2 mg of ammonium persulphate; 3.5 ml deionised 
water; 10 ml gel stock 2 (0.75 M TRIS + 1 g SDS made up to 500 ml with deonised water, pH 8.8); 6.5 
ml 30% acrylamide/ 8% bisacrylamide and 60 μl TEMED). Once set, stacking gels were made (1-2 mg 
ammonium persulphate, 3.7 ml deionised water, 5 ml gel stock 1 (0.25 M TRIS + 1 g SDS made up to 
70 
 
500 ml with deionised water; pH 6.8), 1.3 ml acrylamide and 60 μl TEMED). The 12.5% resolving gel 
comprised the same components as the 10% gel except it contains 1.9 ml of deionised water and 8.1 
ml of 30% acrylamide/ 8% bisacrylamide. 
 
For 10 lane gels 20 μg of protein was loaded per well into the gel (10 µg for 15 lane gels), with one 
lane containing 2.5 μl of PageRulerTM Plus Prestained Protein Ladder (ThermoScientific) per gel. 
Samples were stacked for 10 minutes at 100 V then run at 180 V until proteins had migrated fully 
(typically 45 minutes). Running buffer comprised 10x buffer stock (30 g TRIS, 144 g glycine, 10 g SDS 
in 1 L water, (pH 8.3)) diluted 1:10 with deionised water.  
 
After samples had been run, proteins were transferred from the gel onto a polyvinylidene difluoride 
(PVDF) membrane. Transfer was carried out in 1x transfer buffer (100 ml 10x transfer buffer (30.28 g 
Tris base + 144 g glycine +1 g SDS in 1 L); 700 ml deionised water and 200 ml methanol) for 100 
minutes at 100V. Following transfer, membranes were blocked for 1 hour with 5% skimmed milk 
powder (w/v) dissolved in 1x TBST (10x TBST: 200 mls 1 M TRIS pH 8; 175.5 g NaCl; 10 ml Tween20 
made up in 1.8 L deionised water) on a horizontal mixing plate. 
 
Following blocking, membranes were incubated overnight at 4 °C with primary antibodies (as 
outlined in Table 2.3) dissolved in either 5% milk: 1xTBST (w/v) or 5% BSA: 1xTBST (for 
phosphorylated antibodies).  
 
After overnight incubation the primary antibody was removed and the membrane washed x4 in 
1xTBST (x1 immediate wash followed by x3 washes of ten minutes each). The membrane was then 
incubated for 1 hour at room temperature in either an anti-mouse or anti-rabbit secondary antibody 
as appropriate (diluted 1 in 10,000 v/v in either 5% milk:1xTBST or 5% BSA:1xTBST. After 1 hour the 
secondary antibody was removed and the membrane washed x4 as previously outlined prior to the 
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application of the ECL developing reagent (typically 4 ml ECL per membrane for 5 minutes).  The 
membranes were finally placed on hyperfilm x-ray film in a darkroom and developed.  
 
Films were subsequently scanned and analysed semi-quantitatively using ImageJ analysis software 
(Softonic®) and Microsoft Excel 2010 (Microsoft). In all cases, band intensity for the antibody of 
interest was expressed relative to expression of the ubiquitously expressed protein β-actin. 
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Table 2.3 Primary antibodies utilised in Western blotting protocols  
Target 
Antigen 
Molecular 
weight 
Source Antibody class Optimal Dilution 
β-actin 42 kDa 
Abcam 
Ab8226 
Mouse IgG anti-
human 
WB: 1/10000 
β-catenin 94 kDa 
BD Biosciences 
562505 
Mouse IgG anti-
human 
WB: 1/2000  
B-raf 95 kDa 
Santa-Cruz 
Biotechnology 
SC-5284 
Mouse IgG anti-
human 
WB: 1/200 
Ferritin 20 kDa 
Abcam 
Ab7332 
Rabbit IgG anti-
human 
WB: 1/5000 
 
HIF-1α 120 kDa 
BD Biosciences 
610958 
Mouse IgG anti-
human 
WB: 1/250 
 
IRP2 105 kDa 
Source 
Bioscience 
Lifesciences 
LS-B675 
Rabbit IgG anti-
human 
WB: 1/500 
 
p-ERK 1/2 
p-ERK 1 44 
kDa 
p-ERK 2 42 
kDa 
Cell Signalling 
Technology 
9101 
Rabbit IgG anti-
human 
WB: 1/500 
p-IκB-α 41 kDa 
Santa-Cruz 
Biotechnology 
SC-101713 
Rabbit IgG anti-
human 
WB: 1/500 
TfR1 
190 kDa 
dimer, 95 kDa 
subunit 
Invitrogen   13-
6800 
Mouse IgG anti-
human 
WB : 1/1000 
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2.2.9 Quantification of Intracellular Iron Levels by Ferrozine Assay 
 
The ferrozine assay permits the quantification of intracellular iron levels. Ferrozine forms a stable, 
water soluble, magenta complex with divalent iron that is suitable for colorimetric quantification. 
 
Cells were cultured in 6 well plates with media as per the experimental conditions. After a pre-
determined incubation period the monolayer was washed three times with 1 ml PBS. After thorough 
aspiration of the PBS, 160 µl of HEPES saline (10 mM HEPES in 0.9% (w/v) sodium chloride at pH 7.4) 
was added to the well in order to lyse the cells. The cell monolayer was then separated from the 
plate bottom using a cell scraper. 90 µl of the lysate suspension was removed and added to 200 µl 
20% (w/v) trichloroacetic acid in 4% (w/v) sodium pyrophosphate (TCA) This was boiled for 5 
minutes then re-centrifuged for a further 5 minutes at 12000 RPM. 200 µl of the supernatant was 
aspirated and added to 600 µl of Ferrozine stock solution (100 μl of 0.23 M sodium ascorbate, 80 μl 
of 10 mM ferrozine and 420 μl of 2 M sodium acetate). This solution was thoroughly mixed and 200 
μl aliquots placed in triplicate in a flat-bottomed clear 96 well plate. The colorimetric change in each 
sample was measured using a Bio-Tek ELx800 plate reader at 550 nm. The absorbance in the blank 
was used to correct each sample. The protein concentration (analogous to overall cell number) in 
each sample was determined (by performing a protein assay on the remaining 60 µl of lysate, as 
outlined previously) allowing the iron content of each sample to be expressed as a function of 
protein content (ng Fe / µg protein). 
 
2.2.10 Quantification of Cellular Ferritin Concentration by Ferritin ELISA 
 
The Spectro Ferritin MT ELISA kit (Ramco Laboratories Inc) was utilised as an alternative method (to 
Western blotting) of quantifying intracellular ferritin protein expression. 
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Cells were plated out and treated as per the desired experimental conditions. Following this, lysates 
were extracted using HEPES saline lysis buffer (as described in the ferrozine assay) and a protein 
assay performed (as previously outlined). Briefly, 10 or 5 μl (depending on protein concentration) of 
sample was then loaded per well along with the ferritin calibrator solutions (provided with the kit) at 
6, 20, 60, 200, 600 and 2000 ng/ml. To this, 200 μl of unconjugated antihuman ferritin was then 
added before incubating on a horizontal mixing plate for 2 hours. Wells were then washed with 
deionised water before the addition of 200 μl substrate solution.  Following incubation for 30 
minutes at room temperature, 100 μl of 0.24% (w/v) potassium ferricyanide was added to develop 
the colour and the plate was then read at reading at 490/595 nm using the Victor2 Multilabel 
Counter (Perkin Elmer). 
 
A595 values were subsequently subtracted from A490 values for each sample and compared to the 
calibration curve. Values were then corrected for protein concentration and expressed as ng ferritin 
/ µg protein. 
 
For all iron based experiments, cells were plated out in 6 well plates at a concentration of 
2x105/well. The following day cells were challenged for 1 hour with either standard media (control), 
media containing 100 µM FeSO4 (+500 µM Na ascorbate) or media containing Deferasirox 40 µM + 
100 µM FeSO4. Where the ability of Deferasirox to remove iron from pre-loaded cells was being 
assessed, an additional group treated with 100 µM FeSO4 for 1 hour followed by Deferasirox (40 µM) 
for 1 hour was also included. The ferrozine assay was performed immediately after the treatment 
period ended. In the case of the western blot and ferritin ELISA, standard media was placed back on 
the cells and left overnight to permit translation of ferritin protein.  
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2.2.11 Transwell Radio-labelled Iron Uptake Studies  
 
Cell culture plates (6 well) were coated overnight in rat-tail collagen and placed in ultra-violet (UV) 
light for 24 hours. Permeable transwell inserts (Corning) were then placed into each well, upon 
which Caco-2 cells were seeded at 2 x 105 cells/ml. DMEM (2 ml) supplemented with 10% (v/v) FCS, 
50 U/ml penicillin and 50 µg/ml streptomycin was then added to both the apical and basolateral 
chambers. Cells were then cultured for 14 days with a fresh media change taking place every 2 days. 
After this time the Caco-2 cells were sufficiently differentiated to form a confluent monolayer, 
complete with microvilli and tight junctions.  
 
At 24 hours prior to iron uptake experiments being performed the culture media was removed and 
replaced with minimal essential media (MEM, Sigma) containing epidermal growth factor (20 mg/L), 
triiodothyronine (0.05 µM/L), PIPES (piperazine-N,N’-bis[2-ethanesulfonic acid]) (10mM/L), 
hydrocortisone (11 µM/L), sodium selenite (0.02 µM/L ) and insulin (0.87 µM/L).  
 
After the 24 hours period cells were then stimulated with media containing 59FeCl3 (with or without 
Deferasirox at the concentrations specified within individual experiments) for 1 hour before it was 
removed and replaced with standard DMEM. The transwell inserts were finally removed 24 hours 
later and cells were washed twice with 2 ml Versene (0.2 g/L EDTA in PBS) before being lysed with 
RIPA buffer (as outlined previously). 200 µl of each lysate was subsequently removed and 
transferred to a scintillation tube where 2 ml of OptiPhase HiSafe scintillation fluid (Perkin Elmer) 
was added prior to reading on a beta/gamma counter. Counter readings were expressed as counts 
per minute (CPM) and normalised to sample protein content (using the protein assay as previously 
outlined). 
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2.2.12 Cell Cycle Analysis 
 
Fluorescence-activated cell sorting (FACS) with propidium iodide (PI) labelling was utilised in order to 
determine treatment effect upon the cell cycle.  
 
Cell lines were seeded into T25 flasks such that a confluence of 70% would be achieved at time of 
FACS. Cells were cultured as per the experimental conditions. Following treatment, the cells were 
trypsinised and centrifuged at 1500 rpm for 5 minutes. The cell pellet, following media aspiration, 
was washed by re-suspension in PBS containing 1% FCS (v/v) and then centrifuged at 1500 rpm for 5 
minutes. Upon re-suspension, cells were adjusted to 1x106 cells per 1 ml PBS. 1 ml of PBS containing 
cells was then vortexed whilst 1 ml of ice cold 95% ethanol (v/v) was added drop wise whilst to fix 
the cells. Cell suspensions were then stored at -20 0C prior to use.  
 
Prior to preparing the cells for analysis, the following solutions were made up: 
10x PI stock solution (0.5 mg/ml) – 0.5mg PI dissolved in 0.038 M sodium citrate (pH 7.0), covered 
and stored at 4 0C. 
10 ml PI working solution (50 μg/ml) - 1ml PI stock solution, 100 µl 1 M TRIS (pH 7.5), 50 µl 1 M 
MgCl2, 20 µl RNase A (20 mg/ml), 8.9 ml diethylpyrocarbonate (DEPC) H2O, covered and stored at 4 
0C. 
 
For analysis, cells were centrifuged at 2000 rpm for 5 minutes and the supernatant aspirated. The 
pellet was washed in PBS and centrifuged at 2000 rpm and the supernatant aspirated for the final 
time. The pellet was then resuspended in 500 μl PI working solution, transferred to FACS tubes and 
incubated at 37 0C for 30 minutes in the dark. Cells were then gently vortexed immediately prior to 
being analysed on a Coulter® EPICS XL® analyser and Multicycler for Windows. Cells were sorted into 
G0-G1 and S-G2-M pools. 
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2.2.13 Mouse Models of Colorectal Tumourigenesis 
 
A number of transgenic murine models of in-situ colorectal tumourigenesis were utilised in order to 
test drug effects upon intestinal phenotype and mouse survival. 
 
The Villin-CreER+ Apcfl/fl mouse contains a lox-flanked APC allele on an oestrogen inducible Cre 
background. Following induction of the Cre recombinase with a single dose of intraperitoneal 
Tamoxifen (80 mg/kg), both copies of the APC gene are lost throughout the whole intestine (villus 
and crypt). As a result, a hyper-proliferative phenotype develops over the following 4 days where the 
normal crypt-villus architecture is distorted, such that crypt like cells occupy the vast majority of the 
crypt-villus axis. 201 Mice are taken on day 5 as they would become rapidly unwell if left beyond this. 
This model permits analysis of the effects of a single dose of a drug upon the intestinal phenotype 
through quantification of the number of mitotic figures and apoptotic bodies present within the 
crypts. 102   
 
Lgr5-CreER+ APCfl/fl mice are similar to Villin-CreER+ Apcfl/fl mice except that the Apc deletion which 
occurs post Tamoxfen induction (80 mg/kg intraperitoneal injection on 2 consecutive days) is solely 
within the intestinal stem cells. 202 Again, this represents a rapid model of intestinal tumorigenesis 
with an increase in crypt size seen and mice subsequently developing numerous adenomas within 
50 days following Cre induction. 102 As this is a less aggressive model of intestinal tumorigenesis than 
the Villin-CreER+ Apcfl/fl, it permits analysis of the effect of multiple doses of a drug on both intestinal 
phenotype and ultimately mouse survival (as used in this project).  
  
Lgr5-CreER+ APCfl/fl Ptenfl/fl mice also have an inducible deletion in the Pten tumour suppressor gene 
which becomes activated (along with the APC deletion) upon injection of a single dose of 
intraperitoneal Tamoxifen (80 mg/kg intraperitoneal x1). 203 This is a more aggressive model of 
78 
 
tumourigenesis than the Lgr5-CreER+ APCfl/fl as the superimposed Pten deletion permits the 
development of invasive adenocarcinomas. 203 Again, this model can be used to examine the effect 
of multiple doses of a drug on both intestinal phenotype and ultimately mouse survival (as used in 
this project). 
 
Mice were gavaged Deferasirox as per the individual experimental conditions and all work was 
carried out under Home Office approved conditions. 
 
2.2.14 Immunohistochemistry 
 
Murine Tissue 
 
Murine intestines (duodenum, small intestine and colon) were harvested immediately after the 
animal was culled. Guts were washed with tap water (using a 200 µl pipette tip and 5 ml syringe), 
opened longitudinally and placed on filter paper before being submerged in methacarn (4 parts 
methanol : 2 parts chloroform : 1 part acetic acid) for at least 4 hours. Following this period, the guts 
were rolled longitudinally in a proximal to distal intestinal direction and placed in formalin. Samples 
were then transferred to the University of Birmingham Human Biomaterials Resource Centre (HBRC) 
where they were embedded into paraffin blocks.  
 
When required for immunohistochemistry, slides were sectioned at 5 µm intervals and applied to 
SuperFrost glass slides. Slides were dewaxed via submersion in xylene for 10 minutes (x2) before 
being hydrated in successive ethanol washes (2 x 5 minutes in 100% ethanol, 1 x 5 minutes in 95% 
ethanol, 1 x 5 minutes in 70% ethanol and 1 x 5 minutes in tap water).  
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Antigen retrieval was achieved via submersion of slides in dilute citrate buffer (27 mls of 21% (w/v) 
citric acid added to 123 mls of 2.9% (w/v) sodium citrate in a total volume of 1.5 L deionised water, 
ph 6)  in a microwavable pressure cooker.  Once the pressure had been optimised, the slides were 
removed from the pressure cooker and permitted to cool for 30 minutes at room temperature 
(whilst remaining in the citrate buffer). 
Slides were then blocked for 20 minutes using Envision+ 2% (v/v) hydrogen peroxide solution prior 
to being washed x3 in PBS and then incubated for 45 minutes in 10% (v/v) normal goat serum. 
 
The primary antibody (activated/cleaved caspase-3, 1 in 800 dilution with 1% BSA, rabbit polyclonal, 
R&D Systems, AF835; phospho-histone H3, 1 in 500 dilution with 1% BSA, rabbit polyclonal, Cell 
Signalling Technology, 9701 ) was then left on overnight at 4 0C. 
  
Slides were then removed from the primary antibody and washed x3 in PBS before incubation with 
the secondary antibody (Envision+ labelled polymer HRP-conjugated) for 1 hour at room 
temperature. Slides were then washed again x3 in PBS. 
 
Positive staining was visualised using the DAB+ chromogen (3,3´-diaminobenzidine 
tetrahydrochloride) in DAB substrate buffer  (1 drop of chromogen : 1ml of solution substrate 
buffer), with approximately 200 µl applied to each slide for approximately 5 minutes. Slides were 
then washed x3 in PBS before being transferred to water. 
 
Counterstaining was performed with 0.1% Mayer’s haemotoxylin (for 30 seconds) prior to the slides 
being dehydrated in increasing concentrations of ethanol (1 x 2 minutes in 70% ethanol, 1 x 2 
minutes in 95% ethanol, 2 x 2 minutes in 100% ethanol and finally 2 x 5 minutes in xylene). Slides 
were then mounted with Depex and a coverslip applied.  
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NB For haemotoxylin and eosin staining, slides are dewaxed and hydrated as previously described. 
Slides are then stained with 0.1% Mayer’s hemotoxylin (for 30 seconds) prior to being rinsed in 
running tap water and then submersed in 0.3% acid alcohol (700 ml ethanol, 300 ml deionised 
water, 3 ml hydrochloric acid). Slides are then washed again in running tap water and submersed 
in Scott’s tap water substitute (2 g sodium hydrogen carbonate, 20 g magnesium sulphate, 1 L 
deionised water) before being rinsed in tap water again and finally stained for 2 minutes in 1% 
eosin.  Slides were then dehydrated and mounted as previously described.  
 
Images were visualised from paraffin sections using a Nikon Eclipse E600 microscope and digital 
image captured using a Nikon DXM1200F camera (Surrey, UK). Nikon ACT-1 version 2.62 software 
was used for image acquisition (Surrey, UK). 
 
Slides were analysed blindly and scored by expressing the total number of mitotic figures and 
apoptotic bodies per half crypt as a percentage of the total number of cells within that crypt (50 half 
crypts scored for each hematoxylin and eosin (H&E) stained slide). 102 For slides stained with cleaved 
caspase-3 and or phosphor-histone H3 antibodies the total number of positive cells per crypt (for 25 
whole crypts) were expressed as a percentage of total cell number in the same crypt. 
 
Human Tissue 
 
Paraffin embedded sections from 32 patients with colorectal adenocarcinoma undergoing surgical 
resection were collated from archive and processed by the University of Birmingham Human 
Biomaterials Resource Centre (HBRC) for use in immunohistochemistry. Full ethical approval to use 
the samples was obtained by Dr Chris Tselepis, School of Cancer Sciences, University of Birmingham. 
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Slides were stained using automated Ventana® platforms (Roche) using the UltraView Universal DAB 
Detection Kit (Roche) at Birmingham Heartlands Hospital. Antigen retrieval was carried out using the 
high pH, cell conditioning 1, setting for 64 minutes at 99 °C. Following treatment with Universal DAB 
inhibitor, containing 3% hydrogen peroxide solution, slides were incubated for 32 minutes at 37 °C 
with IRP2 primary antibody (Table 2.3). A secondary antibody multimer, active against mouse, goat 
and rabbit IgG and labelled with horseradish peroxidase was used to oxidise universal DAB+ 
chromogen detector. Between each stage, sections were washed by the Ventana platform and 
evaporation minimised by application of a liquid coverslip. 
 
Following preparation, slides were independently scored by a Consultant Histopathologist based on 
intensity of staining (0- none, 1- mild, 2- moderate, 3-strong staining) and percentage of cells stained 
(0, 0-24%; 1, 25-49%; 2, 50-74%; 3-75-100%). The assigned values were then multiplied to give a 
total score for each section out of nine. 24  Chi-Square analysis was then performed using Minitab® 
17.0 (Minitab Inc). 
 
2.2.15 RNA Extraction and cDNA Generation  
 
RNA extraction from frozen tissue 
 
Matched frozen tumour and normal tissue obtained from 41 patients with colorectal 
adenocarcinoma undergoing resection was thawed on ice and homogenised in 750 µl Trizol reagent 
using a PolyTurrax homogeniser. 
  
Samples were then incubated for 5 minutes at room temperature to allow complete dissociation of 
nucleoprotein complexes. 100 µl of chloroform was added and vortexed for 15 seconds and then 
incubated at room temperature for 15 minutes. Samples were then centrifuged at 12,000 g for 15 
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minutes at 4 oC and the upper aqueous phase harvested. RNA was precipitated by addition of 250 µl 
isopropanol and incubated for a further 10 minutes at room temperature. RNA was pelleted by 
centrifugation at 12,000g at 4 oC for 10 minutes and washed with 75% ethanol. The 75% ethanol was 
then aspirated and the residual volume allowed to evaporate followed by RNA re-suspension in 10 µl 
of nuclease free water. Optical density of the re-suspended RNA was measured at 260 nm on a 
spectrophotometer and the concentration of RNA calculated using the equation 1 OD unit= 40 µg/ml 
RNA. RNA was stored at -80 oC. 
 
RNA extraction from cells 
 
Cells were cultured in 6 or 96 well plates as per experimental conditions. Following removal of 
media, cells were washed twice with filter sterilised PBS and 100 or 500 µl Trizol was added to each 
well of 96 or 6 well plates respectively. Cells were incubated for 10 minutes at room temperature 
before aspirating well contents; samples were stored at -20 °C until use and then processed for RNA 
as per tissue samples. 
 
cDNA Generation 
 
cDNA was synthesized from RNA using a reverse transcription system (Eurogentec). A Nanodrop-
1000 spectrophotometer (Thermo Scientific) was used to determine the mRNA concentration of 
samples extracted from Trizol. 1 µg RNA was used per sample, dissolved in a total volume of 14 µl 
nuclease free water. 6 µl of SuperScript®VILO® mastermix (4 µl 10x SuperScript®Enzyme mixed with 
2 µl of 5x VILOTM Reaction Mix) (InvitrogenTM) was added to each sample. Samples were run on a 
thermal cycler (MyCycler®, Bio-rad) at 25 °C for 10 minutes, 42 °C for 60 minutes and 85 °C for 5 
minutes before storage at -20 °C. 
 
83 
 
2.2.16 qRT-PCR 
 
TaqMan® Gene Expression Assays (Applied Biosystems®) were used to detect IRP2 and TfR1 mRNA 
expression. Master-mixes comprised 0.04 µl ROX solution 25 µM (Bioline Reagents Ltd), 7.5 µl 
SensiMix® II Probe (SensiMix® II Probe Kit (Bioline Reagents Ltd)), 1 µl of TaqMan® probe, 0.075 µl 
18s yy probe 6.5 µM (Eurogentec), 0.15 µl 18s primer mix 10 µM (Eurogentec) and 5.235 µl nuclease 
free water per reaction. 14 µl was added to 1 µl template in separate wells of a 96 well plate; the 
plate was then sealed and centrifuged at 1200 rpm for 2 minutes prior to reading. PCR was carried 
out using ABI FAST Realtime PCR and 7500 RT PCR Systems (both Applied Biosystems®) using the 
following cycle: 50 °C for 2 minutes, 95 °C for 10 minutes, 40 repeats of 95 °C for 15 seconds and 60 
°C for 1 minute. All experiments were carried out in triplicate. 
 
Cycle threshold (ct) values were normalised relative to 18s control to give dCt. Fold changes relative 
to control were calculated based on 2-ddCt (where ddCt is dCT of cancer minus dCT of normal for each 
pair) and statistical analysis of differences between groups performed as appropriate.   
 
2.2.17 IRP2 siRNA ‘Knockdown’ 
 
Cells were seeded at 5x104/ml in 96 well plates or 5x105/ml in 6 well plates. IRP2 Silencer®siRNA (Life 
Technologies®, sequence: (5'-3') GGAACAUUUUCUUCGCAGAtt; antisense 
UCUGCGAAGAAAAUGUUCCtg) was re-suspended in nuclease free water to create a 100 µM stock 
solution. A 10 µM working stock was made using nuclease free water immediately prior to use. 
siRNA and lipofectamine®2000 were diluted in Opti-MEM® Medium (Gibco®, Life Technologies®) 
before being combined to give a final concentration of 20 pmol SiRNA to 6 μl lipofectamine per 100 
μl and left for 5-10 minutes at room temperature. 10 µl or 250 µl of working solution was then 
added to cells in a 96 or 6 well plate respectively. Cells were harvested at 24 hours.  
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Silencer® Select Negative Control siRNA #1 was prepared in exactly the same way and used as a 
control in all experiments.  
 
All ddCt values were calculated relative to negative control SiRNA. Expression levels were compared 
by conducting statistical analysis on 1 divided by the average dCT value for each group. 
 
2.2.18 Preparation of B-raf V600E Inducible Cell Lines 
 
A construct containing a B-Raf V600E mutation was successfully created and transfected into 
HCT116 colorectal adenocarcinoma cell lines. In short, a doxycycline-inducible HA epitope-tagged B-
Raf V600E cDNA was constructed in a puromycin resistant pTIPZ lentiviral vector using a pEF-myc-B-
RafV600E construct kindly donated by Dr Richard Marais (Institute of Cancer Research, London, United 
Kingdom).   
 
Following PCR amplification of B-RafV600E from pEF-myc-B-RafV600E using primers encoding a HA-
epitope tag at the N-terminus the PCR product was digested with Sbf1 and Asc1 restriction enzymes 
and ligated into pTIPZ lentiviral vector which had also been cut at the same sites. Samples were 
transformed into competent bacteria by heat shock before plating on agar plates containing 100 
g/ml ampicillin and incubation at 32 0C overnight. Bacterial clones were inoculated into broth and 
grown overnight at 37 0C and 150 rpm before isolation of pTIPZ plasmid DNA using a Qiagen 
Miniprep kit. Successful ligation of the vector and B-Raf V600E insert was confirmed through gel 
electrophoresis (1% agarose gel) following Sbf1/Asc1 diagnostic digest. Positive clones were sent for 
DNA sequencing to definitively confirm the presence of the correct HA-B-Raf V600E insert. 
 
pTIPZ HA-B-Raf V600E and a control empty pTIPZ vector (EV) were delivered into the HCT116 
colorectal cell line via lentiviral infection. Lenti-viruses were manufactured by 293T cells following 
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transfection of the pTIPZ HA-B-Raf V600E and pTIPZ EV constructs with viral packaging plasmids. 
Viral supernatant from transfected HEK293T cells was collected two days later and diluted 1:1 with 
normal growth media. The target HCT116 cells were seeded into 6 well plates at a concentration of 
4x105 cells per well 24 hours prior to the infection. On the day of infection, the standard media was 
aspirated from each well and replaced with viral supernatant. The plates were incubated at 37°C for 
12-18 hours before the viral media was aspirated and replaced with standard media containing 
antiobiotic selection. The pTIPZ plasmid contains a puromycin resistant gene to allow for selection of 
virus infected cells. Selection of infected HCT116 cells was achieved with 0.5 µg/ml of puromycin in 
standard growth media. 
 
Following successful outgrowth of puromycin resistant cells a doxycycline dose response curve was 
performed and Western blotting carried out in order to confirm increasing HA-B-Raf V600E 
expression with increasing doxycycline concentration. 
 
 
 
Figure 2.1 HCT116 V600E doxycycline dose response curve 
Western blot demonstrating increasing B-raf expression with increasing concentration of 
doxycycline. Cells were incubated for 48 hours, lanes indicate doxycycline concentration in µg/ml. 
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2.2.19 Sulforhodamine Colorimetric (SRB) Assay  
 
The SRB cytotoxicity assay permits cell density determination through quantification of cellular 
protein content. 204 Cells were seeded into 96 well plates at an approximate density of 5x104/ml and 
treated as per the experimental conditions outlined. At the end of the experimental period cells 
were fixed through the addition of 20 µl 20% trichloroacetic acid (w/v) and incubated at 4 0C for 30 
minutes. The excess solution was then removed from each well and the plates washed x3 with 
deionised water before being left to dry for at least 2 hours at room temperature. 100 µl of 0.4% SRB 
was then added per well and left for 10 minutes at room temperature before the SRB was removed 
and the wells washed using 1% acetic acid (v/v). The plates were then left again to dry for several 
hours, before 200 μl of 50 mM Tris solution (pH 8.8) was added to each well to dissolve the SRB 
crystals. Once all crystals had fully dissolved, the absorbance was read at 510 nm using a microplate 
reader. 
 
Values were expressed as a fold change relative to the control group’s mean absorbance (normalised 
to 1). 
 
2.2.20 Statistical Analysis 
 
Analyses of data were performed using Minitab 17.0 (Minitab Inc. 2013) and Microsoft Excel 2010 
(Microsoft 2010). Kolmogorov-Smirnov testing was performed to ascertain if data conformed to the 
normal distribution. Normally distributed data was then analysed using Student’s T-test and non-
parametric data analysed using the Mann-Whitney U test or the 1-sample Wilcoxon test as 
appropriate. Comparison between categorical variables was made using the Chi-squared test and 
formal correlation assessed with Spearman’s Rank co-efficient. Significance was accepted at α-level 
87 
 
of 5% (p≤0.05) and all data means presented with ± standard error of the mean (SEM). Where shown, 
univariate and multivariate analyses were performed using Strata 12.1 (Stata Corp LP®). 
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Chapter 3.  A Role for Deferasirox as an Anti-neoplastic and Chemosensitising Agent in 
Oesophageal Carcinoma 
 
3.1 Introduction 
 
Carcinoma of the oesophagus is an increasingly significant cause of morbidity and mortality. In 2008 
alone there were approximately 482,300 new cases worldwide and the disease was responsible for 
over 400,000 deaths. 205 In the United Kingdom, overall 5 year survival rates remain around 13% as 
most patients have advanced disease on presentation meaning that only around 25% can undergo 
potentially curative surgical resection.  14, 206, 207  
 
There are two main histological types of oesophageal carcinoma; squamous cell carcinoma (SCC) and 
oesophageal adenocarcinoma (OAC). Of note, there is now an emerging body of evidence 
implicating iron in the development and propagation of OAC. 119, 129, 208, 209, 210, 211    
 
Data from a number of human studies identifies a positive association between increased intake of 
heme iron from red meat and OAC risk. 124, 212, 213, 214  Of note, a higher intake of haem iron (quartile 4 
versus quartile 1 for intake) from meat sources was associated with an odds ratio of 3.04 (95% 
confidence interval 1.2-7.72) for the development of OAC in one population-based case-control 
study. 124 Furthermore, in terms of specific daily intake of red meat, a 2013 meta-analysis 
demonstrated an increased relative risk for OAC of 1.45 (95% confidence interval 1.09-1.93) per 100 
g/day increase in red meat intake. 212 
 
In further support of an association between iron and OAC, the conversion of BM into OAC has been 
shown to be associated with increased cellular iron loading and overexpression of the cellular iron 
import proteins DMT1 and TfR1 in human tissue samples. 24 Excess iron has also been shown to 
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exacerbate OAC tumourigenesis in animal models and cause an increase in OAC cell line proliferation 
in-vitro. 24, 82, 129 All of these associations are not entirely surprising, since iron is essential for a 
number of key cellular processes including DNA synthesis, ATP generation and cell cycle progression; 
all activities that are increased in cancer. 112 
 
Iron chelating agents have demonstrated anti-neoplastic effects in a number of previous studies. 80, 
92 To date, however, the majority of this data has been derived from experimental iron chelators 
which possess a number of potential side effects and remain unlicensed for human use. 139  
 
A number of licensed iron chelators are already in routine clinical use, however, albeit limited to the 
treatment of iron overload associated with conditions such as β-thalassaemia and multiple blood 
transfusions. Of these, the orally administered iron chelator Deferasirox® (Novartis, Switzerland) has 
shown promise as an anti-neoplastic agent in a number of pre-clinical studies and anecdotal case 
reports of clinical experience. 167, 169, 170, 171, 172, 175, 177 Of note, a recent paper from our group 
demonstrated that Deferasirox can inhibit cellular iron uptake (by as much as 20-50%) and reduce 
intracellular iron levels in oesophageal cancer both in-vitro and in-vivo. 215  
 
Interestingly, Deferasirox appears to have an increased efficacy against malignant cells (compared to 
their ‘normal’ counterparts) and may achieve its anti-neoplastic effects via a number of different 
mechanisms (not merely just iron deprivation by chelation alone) including inhibition of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB) signalling pathway (which is known to 
be dysregulated and influence response to therapy in OAC). 175, 177, 216, 217, 218  
 
The efficacy of Deferasirox in oesophageal malignancy (particularly OAC) is therefore worthy of 
further investigation. 
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3.2 Chapter Aims 
 
The value of licensed iron chelators and in particular the orally administered agent Deferasirox in 
oesophageal carcinoma have not been fully addressed, thus the aims of this chapter are: 
 
1. To assess the efficacy of the licensed oral iron chelator Deferasirox as an anti-neoplastic 
agent in oesophageal carcinoma (in-vitro and in-vivo). 
2. To assess the efficacy of the licensed oral iron chelator Deferasirox as a chemosensitising 
agent in oesophageal carcinoma (in-vitro and in-vivo). 
3. To assess the effect of the licensed oral iron chelator Deferasirox on the NFκB signalling 
pathway in oesophageal carcinoma. 
4. To assess the iron status of patients presenting with oesophageal adenocarcinoma in order 
to determine suitability for a future trial of Deferasirox in humans.  
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3.3 Results 
 
3.3.1 The efficacy of Deferasirox as an anti-neoplastic agent in oesophageal carcinoma in-vitro 
 
3.3.1.1 Overview 
 
The OAC cell lines OE19 and OE33 and the SCC cell line OE21 were seeded into 96 well plates and 
cultured in media with or without Deferasirox at varying doses (0-40 µM) for 24, 48 and 72 hours. 
Cells were counted and seeded (4x104/ml following optimisation) such that an approximate 
confluence of 70% was achieved in the control group (0 μM Deferasirox) at time of assay.  
 
After the defined time points, MTT assays were performed in order to determine cellular viability (as 
previously outlined) relative to the control group. 
 
3.3.1.2 Results 
 
Following 24 hours incubation, Deferasirox did not reduce cellular viability across any of the 
oesophageal cell lines tested (Figure 3.1). Indeed, at doses of 2 (OE19 and OE21), 10 (OE19 and 
OE21) and 20 µM (OE21) a statistically significant increase in MTT readout was actually seen. This 
enhancement in viability, however, did not persist in any of the cell lines beyond 24 hours. 
 
By 48 hours, Deferasirox had significantly reduced cellular viability at concentrations of 10-40µM. 
The largest reduction in viability seen was 57.5% at 40 µM in the OE19 OAC cell line (38.1 and 50.0% 
at the same concentration in the OE33 and OE21 lines respectively, all p<0.05 vs. control). 
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At 72 hours, 40µM Deferasirox had significantly reduced cellular viability by 73.2, 58.4 and 69.2% in 
the OE19, OE33 and OE21 cell lines respectively (all p<0.05 vs. control). 
 
Across all 3 cell lines tested, the approximate IC50 of the drug equated to 40 µM at 48 hours and 20 
µM at 72 hours. 
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Figure 3.1 Deferasirox decreases OAC and SCC cellular viability in-vitro                                   
The OAC cell lines OE19 (A) and OE33 (B) and the SCC cell line OE21 (C) were co-cultured alongside increasing doses of Deferasirox (as specified) for a period of 24-
72 hours. Deferasirox did not suppress cellular viability within the first 24 hours of incubation, however, it did cause a significant reduction in cell viability across all 
3 cell lines in a time and dose dependent manner beyond the 48 hour time point. Data presented as mean fold change relative to standard media control 
normalised to 1, error bars denote ±SEM, p values for corresponding fold changes are shown in (D) where shaded boxes represent p<0.05. 
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3.3.2 The efficacy of Deferasirox as a chemosensitising agent in oesophageal carcinoma in-vitro 
 
3.3.2.1 Overview 
 
The chemotherapy regimen of Epirubicin, Cisplatin and 5- Fluorouracil (ECF) is typically used in the 
treatment of OAC and SCC with variable results. 41 Cellular viability (MTT) and proliferation (BrdU) 
assays were performed in order to assess whether pre and or concomitant treatment with 
Deferasirox (20 or 2 µM) could enhance the efficacy of this regimen.  
 
Various treatment combinations (as outlined in Table 3.1) were administered to OE19, OE21 and 
OE33 cells over 24-72 hours before MTT and BrdU assays were performed (as previously outlined) to 
assess cellular viability and proliferation respectively.  
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Table 3.1 Treatment regimens applied to cells for the ECF combination chemotherapy experiment 
Regimen Day 2 (24 hours) Day 3 + 4 (48-72 hours) 
1 Control media Control media 
2 Control media ECF 
3 Deferasirox ECF 
4 Control Deferasirox + ECF 
5 Deferasirox Deferasirox + ECF 
6 Deferasirox Control media 
7 Control media Deferasirox 
8 Deferasirox Deferasirox 
 
Deferasirox was used at a concentration of 20 or 2 µM. Epirubicin, Cisplatin and 5-Fluorouracil were 
used at their pre-determined IC25 of 0.5, 4 and 4 μM respectively. MTT (viability) and BrdU 
(proliferation) assays were performed after 72 hours treatment in total.  
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3.3.2.2 Results 
 
All 3 of the oesophageal cell lines tested demonstrated a marked and highly significant sensitivity to 
48 hours of treatment with ECF therapy in terms of both viability and proliferative activity (mean 
reduction of 46.4 and 64.0% in viability and proliferation respectively across all 3 cell lines, Figure 
3.2). Despite this, pre-incubation with 20 μM Deferasirox for 24 hours prior to the ECF alone for the 
following 48 hours further reduced cellular viability and proliferation across all 3 cell lines compared 
to ECF alone (mean additional reduction of 28.2 and 25.0% on MTT and BrdU respectively). 
Interestingly, pre-treatment with the lower dose of 2 µM Deferasirox also resulted in a significantly 
enhanced reduction in OE19 and OE21 cellular viability and OE19, OE33 and OE21 cellular 
proliferation compared to ECF alone.  
 
Of note, at both of the Deferasirox concentrations tested, there was no additional statistical 
advantage in continuing the chelator alongside ECF in any of the cell lines after it had already been 
given as a pre-treatment (Deferasirox/Deferasirox+ECF). Likewise, there also appeared to be no 
additional advantage in giving Deferasirox alongside ECF (Control/Deferasirox+ECF) to the OAC cell 
lines at either of the doses tested. This was not the case in OE21 SCC cell line, however, where an 
additional reduction in cellular viability of 24.5 and 17.6% was seen with 20 and 2 µM Deferasirox 
respectively. 
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Figure 3.2 Pre-treatment of OAC and SCC cell lines with Deferasirox can enhance subsequent 
response to chemotherapy with ECF in-vitro 
OE19 (A-C), OE33 (D-F) and OE21 (G-I) cell lines were subjected to various treatment regimens (as 
outlined) for a total period of 72 hours prior to cellular viability (MTT) and proliferation (BrdU) assays 
being performed. The chemotherapy regimen of Epirubicin, Cisplatin and 5-Fluorouracil (ECF) was 
utilised, comprising each of the constituent drugs at their pre-determined IC25. The addition of 
Deferasirox for 24 hours as a pre-treatment before ECF administration significantly enhanced the 
reduction in cellular viability and proliferation seen, even at the lower dose of 2 µM Deferasirox.  
 
Data presented as mean fold change relative to standard media control normalised to 1, error bars 
denote ±SEM, treatment given for first 24 hours indicated prior to / and treatment given for 
subsequent 48 hours indicated post /. Corresponding fold changes shown in (C), (F) and (I) where * 
denotes p<0.05 vs. control, # p<0.05 vs. control/ECF and $ p<0.05 vs. Deferasirox/Deferasirox.   
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As expected, administration of Deferasirox alone at a concentration of 20 µM (for a total of 72 
hours) resulted in a significant reduction in both cellular viability and proliferation across all of the 
lines tested that was at least comparable to 48 hours of ECF alone. In the OE19 OAC cell line, 
Deferasirox monotherapy for 72 hours was actually statistically more efficacious that ECF alone, this 
was not the case, however, in either the OE33 or OE21 cell line. 
 
Of note, Deferasirox monotherapy at 20 µM for 72 hours was broadly statistically comparable to the 
Deferasirox/ECF pre-treatment regimen in terms of the effect on both cellular viability and 
proliferation. This was not the case, however, with the lower Deferasirox dose of 2 µM, where, as 
would be expected, monotherapy was broadly significantly less efficacious than both ECF alone and 
the Deferasirox/ECF pre-treatment regimen. 
 
Interestingly, unlike in the previous experiment (Figure 3.1, page 92) where Deferasirox 
concentrations of 20 µM (OE21) and 2 µM (OE19 and OE21) for 24 hours did show stimulatory 
activity, this was not seen in this experiment in any of the cell lines tested. This may be related to the 
timing of assay, as in the previous experiments the assay was performed immediately after the 24 
hour time period, whereas in this series of experiments the drug was removed and replaced with 
standard media at 24 hours but the assay was not performed until 72 hours in total had passed. This 
indicates Deferasirox may still have an effect on cell viability and proliferation even after its removal. 
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3.3.3 The ability of Deferasirox to overcome established chemotherapy resistance in oesophageal 
carcinoma in-vitro 
 
3.3.3.1 Overview 
 
In order to assess whether Deferasirox therapy may be effective in overcoming established 
chemotherapy resistance (both as monotherapy and in combination with existing agents), a Cisplatin 
resistant ‘clone’ of OE33 OAC cells was created by co-culturing them alongside progressively 
increasing doses of the drug over several months. In addition, the Cisplatin resistant TE4 
oesophageal SCC line was also utilised. 192   
 
For experiments, cells were again seeded into 96 well plates and cultured alongside standard media, 
media containing Cisplatin, media containing Deferasirox and Cisplatin and media containing 
Deferasirox alone for 72 hours. MTT assays (as previously described) were utilised to determine 
cellular viability after 72 hours of treatment. 
 
3.3.3.2 Results 
 
The OE33 OAC ‘clone’ cell line demonstrated Cisplatin resistance up to 2 µM at 72 hours (Figure 
3.3A). The cell line retained sensitivity to 20 µM Deferasirox alone (9% reduction in viability, p<0.05 
vs. control), however, the drug appeared less efficacious than when used at an equivalent dose in 
the parental oesophageal cell line in previous experiments (sections 3.3.1 and 3.3.2). When 
Deferasirox (20 µM) and Cisplatin (2 µM) were given in combination, however, a highly significant 
39.8% reduction in cellular viability was seen. This was statistically significant (p<0.05) compared to 
control and both Cisplatin and Deferasirox alone. A similar reduction in cellular viability (40%) was 
seen when Deferasirox was given in combination with the higher dose of 4 µM Cisplatin.  
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Figure 3.3 Treatment with Deferasirox can overcome established Cisplatin resistance in OAC and 
SCC cell lines in-vitro 
Cell viability assay (MTT) demonstrating ability of Deferasirox to overcome Cisplatin resistance when 
given alone and or alongside Cisplatin at the concentrations specified to a ‘clone’ OE33 cell line (A) 
and the TE4 SCC cell line (B and C). Data shown represent mean fold change relative to standard 
media (normalised to 1), error bars denote ±SEM, *p<0.05 vs. control, # p<0.05 vs. equivalent dose 
of Cisplatin, $ p<0.05 vs. equivalent Deferasirox alone, ^ p<0.05 vs. parental cell line. Cisplatin 
utilised at specified concentrations apart from in C, when used at 2 µM throughout. 
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As expected, the TE4 cell line demonstrated no significant reduction in cellular viability when treated 
with Cisplatin alone (up to a concentration of 8 µM, Figure 3.3B). Again, however, Deferasirox alone 
(20 µM) significantly reduced viability by 52.3% compared to control. Interestingly, in this cell line, 
there was no additional effect seen by giving Deferasirox (20 µM) alongside any of the Cisplatin 
doses tested (2, 4 and 8 µM). A significant combinatorial reduction in cellular viability (35.2%) was 
seen, however, when a sub-therapeutic dose of Deferasirox (5 µM) was combined with low dose, 
sub-therapeutic Cisplatin (2 µM, Figure 3.3C). 
 
3.3.4 Deferasirox as an anti-neoplastic and chemosensitising agent in a murine xenograft model of 
oesophageal adenocarcinoma 
 
3.3.4.1 Overview 
 
In order to assess the potential for Deferasirox to act as an anti-neoplastic and or chemosensitising 
agent in-vivo (and validate our previous in-vitro findings) a murine xenograft model using OE19 OAC 
cells was created. 
 
Briefly, suspensions of OE19 cells (1 x 107 cells) were centrifuged and re-suspended in 50 µL of 
culture media. Immediately prior to injection, the cell slurry was mixed 50/50 (v/v) with Matrigel 
(extracellular matrix). The cell suspension was then subcutaneously injected into NOD-SCID mice 
(100 µl per mouse under general anaesthesia) and following a period of tumour establishment, mice 
were divided into groups and given one of 6 treatment regimens: 
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1. Control vehicle 
2. Deferasirox alone (20 mg/kg on alternate days for 3 weeks via oral gavage)  
3. Cisplatin alone (0.75 mg/kg every 3rd day for 3 weeks by intra-peritoneal injection; a pre-
determined sub-optimal dose)  
4. Deferasirox (20 mg/kg on alternate days) and Cisplatin (0.75 mg/kg every 3rd day) in 
combination for 3 weeks 
5. Deferasirox (20 mg/kg) alone on alternate days for 1 week followed by 3 weeks of Cisplatin 
treatment alone (0.75 mg/kg every 3rd day) 
6. Deferasirox (20 mg/kg) alone on alternate days for 1 week (commenced at the same time as 
5.) followed by no further treatment during the experimental period 
 
The vehicle for gavage consisted of 30% 1,2-propanediol/70% sterile 0.9% sodium chloride solution; 
Cisplatin was dissolved in sterile distilled water. Following treatment, mice were anaesthetised and 
exsanguinated by direct cardiac puncture and blood/plasma retained for full blood count and 
biochemical analysis (urea, creatinine and serum iron). Tumours were removed and weighed to assess 
tumour burden. All work was carried out under Home Office approved conditions. 
 
3.3.4.2 Results 
 
Deferasirox administration alone on alternate days for 3 weeks resulted in a significantly smaller final 
xenograft size compared to the control group (83.5% reduction, 35.5 mg vs. 214.9 mg, p=0.032) without 
any effect on haemoglobin, serum iron or creatinine levels (Figure 3.4).  At the dose used, Cisplatin alone 
for 3 weeks also reduced xenograft size although this failed to reach the threshold for statistical 
significance (68.0 mg vs. 214.9 mg, p=0.064).   
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Figure 3.4 Deferasirox significantly reduces murine OE19 xenograft size when administered orally 
for 3 weeks 
Deferasirox (20 mg/kg) given orally on alternate days for 3 weeks resulted in a significantly smaller 
xenograft size relative to control (83.5% reduction, p=0.032, (A)). Pre-treatment of mice with oral 
Deferasirox for just 1 week followed by 3 weeks of Cisplatin therapy (0.75 mg/kg) administered 
intra-peritoneally every third day also resulted in a significantly smaller xenograft relative to control 
(75.9% reduction, p=0.044), however, this was not significantly smaller than the group given 
Cisplatin alone (23.9% reduction relative to Cisplatin alone, p=0.455). Deferasirox was well tolerated 
by the mice as indicated by the parameters shown in (B) (error bars denote ±SEM, *p<0.05 vs. 
control).  
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The combination of Deferasirox with Cisplatin for 3 weeks did not improve tumour response compared 
to either control, Cisplatin alone or Deferasirox alone (69.9 mg Deferasirox + Cisplatin vs. 214.9 mg 
control, p=0.067 vs. control, p=0.941 vs. Cisplatin alone, p=0.124 vs. Deferasirox alone). Pre-treatment 
of mice for 1 week with Deferasirox prior to 3 weeks of Cisplatin monotherapy did, however, result in a 
significantly smaller xenograft compared to control (51.71 mg vs. 214.9 mg, p=0.044) albeit at the 
expense of a small rise in serum creatinine levels (38.18 vs. 35.83 µM/L, p=0.045 vs. control). 
 
Treatment of mice for 1 week with Deferasirox resulted in a final xenograft size of 75.7 mg (p=0.075 vs. 
control) which was statistically larger than the group given 3 weeks of Deferasirox monotherapy (75.7 
mg vs. 35.5 mg, p=0.047). 
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3.3.5 The effect of Deferasirox upon the NFκB signalling pathway in oesophageal carcinoma 
 
3.3.5.1 Overview 
  
In order to assess the potential efficacy of Deferasirox upon the NFκB signalling pathway in 
oesophageal carcinoma a dual luciferase reporter assay was utilised using the OE19, OE33 and OE21 
cell lines. In addition, Western blotting was performed against the phosphorylated form of the IκBα 
protein. IκBα forms a complex with NFκB, keeping it in an inactive state; phosphorylation of the 
protein at Ser32 and Ser36 leads to activation of NFκB. Thus, p-IκBα can be used as a surrogate 
marker of NFκB activity. 219 
 
3.3.5.2 Results 
 
All 3 oesophageal carcinoma cell lines demonstrated activation of the NFκB signalling pathway. TNFα 
is known to be a potent inducer of NFκB activity (as demonstrated in Figure 3.5 where TNFα (20 
ng/ml) significantly induced NFκB activity in all 3 oesophageal cell lines tested). Of note, the 
induction in NFκB by TNFα was greatest in the OE21 SCC cell line (10.64 fold) compared to 1.07 and 
1.92 in the OE19 and OE33 OAC lines respectively.  
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Figure 3.5 Deferasirox reduces NFκB activity in OAC and SCC in-vitro 
Dual luciferase reporter assay demonstrating that 24 hours Deferasirox administration significantly 
reduces NFκB signalling activity compared to control across all 3 cell lines tested. Data presented as 
mean fold change in NFκB reporter activity relative to standard media control, error bars denote 
±SEM, *p<0.05 vs. control. 
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Deferasirox administration (160 µM overnight) significantly reduced NFκB reporter activity in all 3 
cell lines (0.18, 0.09 and 0.38 fold in OE19, OE33 and OE21 lines respectively, p<0.05 vs. control). 
 
Western blotting for p-IκBα was then performed on the OE19 OAC cell line as this had shown the 
highest baseline activity in the reporter assay (as inferred by response to TNFα).  Deferasirox (20 
µM) administration significantly reduced p-IκBα protein expression after 48 hours (71.6% reduction, 
p<0.05 vs. control, Figure 3.6). 
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Figure 3.6 Deferasirox administration reduces P-IκBα expression in OE19 OAC cells 
Western blot (A and C) demonstrating that administration of Deferasirox (20 µM) reduces P-IκBα 
expression in OE19 OAC cells. In blot (A), Deferasirox was administered for 24, 48 and 72 hours at 20 
µM. In blot (C), Deferasirox was administered for 48 hours at 20 µM (lanes 1-3 = control media, lanes 
4-6 = Deferasirox).  P-IκBα expression was normalised to β-actin and displayed as a fold change (B 
and D) relative to control (normalised to 1). Error bars denote ±SEM, *p<0.05 vs. control. 
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3.3.6 Determination of the iron status of patients presenting with oesophageal adenocarcinoma 
 
3.3.6.1 Overview 
 
Deferasirox has been shown to significantly reduce serum ferritin and serum labile iron pool in 
patients with iron overload. 162  The drug appears to be well tolerated across these groups with a low 
incidence of serious adverse events to date. 162 The haematological and biochemical effects of iron 
chelator administration to a non-systemically iron overloaded group of patients, however, are not 
known. As such iron chelators may have the potential to induce anaemia; a state known to be 
associated with gastrointestinal cancers. 220   
 
Previous studies in oesophageal cancer have estimated the incidence of anaemia on presentation to 
range from 20-45%. 221, 222 Clearly, any benefit seen for patients treated with iron chelation therapy 
through Deferasirox in terms of anti-neoplastic activity or chemosensitisation would be substantially 
negated by the development of iron-deficiency and or anaemia and its associated side effects. The 
incidence of anaemia and or iron-deficiency in patients presenting with OAC thus needs to be 
formally quantified before any hypothetical trial of iron chelation therapy could commence. 
 
The determination of the systemic iron status of patients presenting with OAC to a tertiary upper 
gastrointestinal resectional centre was therefore achieved through a retrospective analysis of 
prospectively collected haematological and biochemical data. Inclusion criteria were all patients 
presenting with oesophageal OAC (including Siewert types I, II and III) in a 2 year period (2008-10). 
All patients had histologically proven malignancy and were included in the study with informed 
consent and regional ethics approval. Patient demographics were recorded and blood samples taken 
at presentation for haematological and biochemical iron parameters. Patients were followed 
through the normal multidisciplinary team cancer evaluation and treatment pathways. All 
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haematological and biochemical quantification was performed on automated high through put 
analysers at the host institution’s department of haematology and biochemistry. Data collected 
included haemoglobin, serum ferritin, serum iron and soluble transferrin receptor (sTfR). The soluble 
transferrin receptor – ferritin index (sTfR-F index) was also calculated by sTfR/log ferritin. Derivation 
of sTfR-F was performed as it has been shown to accurately distinguish between iron-replete and 
iron-deplete anaemic patients and also to detect the non-anaemic stages of iron deficiency. 223 
 
The normal reference ranges used were: 
Haemoglobin concentration (Hb): male 13.5-18 g/dL and female 11.5-16.5 g/dL 
Serum ferritin: 18-360 µg/L and female 10-320 µg/L 
Serum iron: male 10-32 µmol/L and female 5-30 µmol/L 
sTfR: male and female 2.0-3.6 mg/L 
sTfR-F index: male and female >1.8  equates to storage iron depletion, >2.2 indicates iron deficient 
erythropoiesis and >2.8 iron deficiency anaemia 223 
 
3.3.6.2 Results 
 
In total, 71 patients presenting with OAC were included with a mean age of 65.5 years. 
 
Fifty-five (78%) OAC patients were male. Mean Hb for male OAC patients was 13.8 g/dL and 11.8 
g/dL for females. Mean serum ferritin was 265 µg/L and 91 µg/L for males and females respectively 
and serum iron 13.4 µmol/L and 12.3 µmol/L. Mean sTfR was 2.64 mg/L for males and 2.92 mg/L for 
females. Mean sTfR-F index values were 1.35 for males and 1.72 for females, both within normal 
reference ranges. 
 
117 
 
No significant difference in any tested parameter was observed between resectable and advanced 
OAC at presentation. 
 
A full iron profile was available for 11 patients in total who underwent neoadjuvant chemotherapy 
with Epirubicin, Cisplatin and 5-Fluorouracil/Capecitabine (ECF/ECX). A significant fall in mean Hb 
concentration was evident post neoadjuvant treatment (13.9 g/dL to 12.5 g/dL; p=0.019 pre vs. post 
treatment respectively). No significant differences were observed in mean serum ferritin (161 µg/L 
vs. 280 µg/L; p=0.34), serum iron (13.1 µmol/L vs. 13.8 µmol/L; p=0.81) or sTfR (2.63 mg/L vs. 2.79 
mg/L; p=0.33). Although a significant drop in mean Hb was noted pre and post chemotherapy, no 
change in mean sTfR-F index values was seen (1.47 vs, 1.43; p=0.89 for pre and post treatment 
values) indicating systemic iron levels remained unchanged. 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
Table 3.2 Patients presenting with OAC are systemically iron replete  
 
Key haematological parameters pertaining to systemic iron status were obtained from 71 patients with OAC presenting to a tertiary referral centre. Chemotherapy 
administered is known as ECX and comprised Epirubicin, Cisplatin and Capecitabine (pro-drug converted to 5-Fluorouracil). Data presented as mean, () denotes 
standard deviation, * p<0.05 vs. pre ECX.  
 
NB Section 3.3.6 has been adapted from Ford SJ, Bedford M, Pang W et al. A comparative study of the iron status of patients with oesophageal adenocarcinoma to 
determine suitability for a clinical trial of iron chelation therapy. Annals of the Royal College of Surgeons of England 2014; 96(4): 275-8. 
I gratefully acknowledge Dr Weehaan Pang for data collection, Mr Samuel Ford for assistance with data analysis/interpretation and Ms Olga Tucker for overall 
conception, design and lead of this study.  
119 
 
3.4 Discussion 
 
The incidence of oesophageal carcinoma and in particular the OAC subtype is increasing at an 
alarming rate. 13, 14 The disease continues to carry an abysmal 5 year survival rate of around 13%, 
largely driven by the high percentage of patients presenting with advanced, irresectable disease and 
the subsequent paucity of systemic reagents effective against it. 14, 17, 40, 41, 43, 45, 47, 54, 55 Thus, the 
discovery and development of new agents that are solely effective against the disease or can 
enhance the efficacy of existing therapies would be highly desirable. 
 
Iron metabolism appears to be dysregulated in the development of OAC, as illustrated by the 
increase in cellular iron import and deposition seen with the progression from pre-malignant BM to 
OAC. 24 Furthermore, iron has been to shown to both exacerbate tumourigenesis in murine models 
of OAC and increase OAC cellular proliferation in-vitro. 24, 129 Similar phenomena have also been 
demonstrated in other cancers, particularly breast and colorectal. 82, 99, 102, 125  
 
Iron chelators therefore offer great potential as anti-neoplastic agents, although there is little data 
available pertaining to the efficacy of pre-existing licensed agents. 80, 92 Deferasirox is one such agent 
and, unlike the original clinically available chelator Desferrioxamine, has an oral route of 
administration making it an attractive agent to investigate further in the context of cancer. 157   
 
It has been demonstrated in the current study that Deferasirox significantly impairs both OAC and 
SCC cell viability in-vitro in a time and dose dependent manner. The drug displays an IC50 of 
approximately 40 µM at 48 hours incubation and 20 µM at 72 hours. Moreover, Deferasirox also 
demonstrated a marked and significant suppression in OAC xenograft growth when given to mice at 
a dose of 20 mg/kg on alternate days for 3 weeks (83.5% reduction in tumour size, p=0.032 vs. 
control). Again, this was a significantly greater effect than when the drug was given to mice for just 
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one week (mean final xenograft size 35.5 mg vs. 75.7 mg, p=0.047), demonstrating a time dependent 
response to therapy. Crucially, Deferasirox monotherapy was well tolerated with no differences seen 
in final animal weight, haemoglobin, serum iron or serum creatinine compared to the control cohort.  
 
These results are immensely promising and support the findings published in a recent paper from 
our group demonstrating that Deferasirox inhibits oesophageal cellular iron uptake (by as much as 
20-50%) and is also capable of stripping iron from inside cells. 215 In addition, oesophageal xenografts 
harvested from mice given Deferasirox (20 mg/kg) for 3 weeks had a significantly reduced iron 
content (up to 57%) which was also reflected by significant up-regulation in TfR1 expression and 
concomitant down-regulation in H-ferritin and ferroportin expression (at both the mRNA and protein 
levels). 215 Deferasirox has also demonstrated efficacy in in-vivo models of lung cancer and leukaemia 
thus indicating that the effects of the drug are not cell line dependent. 169, 183  
 
Iron is essential for a number of key cellular processes including DNA synthesis, ATP generation and 
cell cycle progression; all of these are activities that by definition are increased in cancer and thus 
malignant cells are known to have a higher requirement for iron than their normal counterparts. 112 
The fact that Deferasirox is able to both inhibit cellular iron uptake and facilitate the removal or iron 
from within oesophageal cancer cells means that the primary mechanism for its anti-neoplastic 
effects when given as a monotherapy is likely to be cellular iron deprivation through chelation. It is 
known that cellular iron depletion results in cell cycle arrest at the G1/S checkpoint and subsequent 
induction of apoptosis. 224 Iron deprivation is also known to inhibit activity of the R2 subunit of the 
enzyme ribonucleotide reductase (which catalyzes the conversion of ribonucleotides into 
deoxyribonucleotides during DNA synthesis) and decrease expression of cyclins A, B and D (all of 
which are vital for cell cycle progression). 225  
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Current response rates to chemotherapy in oesophageal carcinoma are variable, as such the finding 
that Deferasirox can overcome established Cisplatin resistance, both as a monotherapy and when 
given at low ‘sub-optimal’ doses in combination with Cisplatin, in both OAC and SCC cell lines in-vitro 
is of significant interest. 52 Furthermore, the demonstration that pre-treatment of oesophageal cell 
lines with Deferasirox, even at low concentrations, in-vitro for 24 hours prior to administration of the 
ECF chemotherapy regimen results in a significant additional reduction in both cellular viability and 
proliferation raises the potential that the drug may act as a chemosensitiser. 
 
Obviously, a counter argument to this could be that Deferasirox is merely acting through a different 
mechanism of action to existing reagents (i.e. iron chelation rather than DNA cross-linking in the 
case of Cisplatin) and in the case of pre-treatment, any beneficial effects seen are merely achieved 
through the addition of an extra drug that has been commenced earlier, and it is not actually 
genuine chemosensitisation per se. There are, however, a number of additional mechanisms of 
action for the drug proposed in the literature which offer potential routes to chemosensitisation 
including upregulation of the metastasis suppressor n-Myc downstream regulated 1 (NDRG1), the 
cyclin dependent kinase inhibitor p21CIP1/WAF1 and the pro-apoptotic protein Caspase-3 as well as the 
inhibition of polyamine synthesis, mTOR signalling, Wnt signalling and the NFκB pathway. 169, 173, 175, 
177, 183, 186  
 
Thus, of particular interest is the demonstration in this study (by both reporter assay and Western 
blotting) that Deferasirox can inhibit signalling through the NFκB pathway in OAC. NFκB signalling 
plays a pivotal role in the pathogenesis of a number of cancers by regulating several fundamental 
cellular processes such as apoptosis, proliferation, differentiation and tumour migration. 178 It has 
been shown to be constitutively active in most tumour cell lines and has also been identified in 
tumour tissue from patients with multiple myeloma, acute myeloid leukaemia, prostate cancer and 
breast cancer. 178, 179, 180, 181, 182 In OAC, NFκB expression has been shown to increase in a stepwise 
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manner along the progression from normal mucosa (nil) to BM (40%) to OAC (61%). 216  NFκB activity 
pre-therapy (chemo/radiotherapy) for OAC has also been shown to correlate with lack of 
subsequent complete pathological response, increased metastatic progression and decreased 
disease-free and overall survival.  216, 217  NFκB has been shown to be activated in OAC in-vitro by 
common chemotherapeutic drugs (such as 5-Fu) leading to inhibition of apoptosis. 218 Interestingly, 
chemosensitivity can be restored following treatment with an NFκB inhibitor. 218 Furthermore, NFκB 
inhibitors have been shown to suppress oesophageal tumour growth both in-vitro and in-vivo and 
also enhance sensitivity to 5-Fu and Cisplatin in-vitro. 226 As such, the demonstration that NFκB 
signalling is active in OAC cell lines but can be significantly suppressed (by as much as 71.6%) 
through the administration of Deferasirox therapy at a concentration of 20µM is highly relevant and 
offers a mode of action for how the drug may be able to sensitise cells to chemotherapy. Previous 
studies have identified a link between ferritin expression and NFκB signalling. 227 Of note, ferritin has 
been shown to induce NFκB signalling in hepatic stellate cells, which may explain in part the ability of 
Deferasirox (through suppression of intracellular ferritin) to inhibit NFκB signalling. 228 Furthermore, 
down-regulation of ferritin has been shown to increase the sensitivity of breast cancer cells to the 
chemotherapeutic agents Doxorubicin and Cisplatin.  229, 230 
 
The data shown in the current study clearly demonstrates that Deferasirox monotherapy is highly 
efficacious both in-vitro and in-vivo against OAC. The drug is also effective at decreasing viability in 
cell lines that are resistant to therapy with Cisplatin and may enhance the efficacy of existing 
chemotherapeutic reagents when given as a pre-treatment or at a lower dose in combination. It 
should also be noted, however, that the combination of Deferasirox with either ECF (in-vitro) or 
Cisplatin (in-vitro and in-vivo) does not confer any additional benefit over chemotherapy alone and 
indeed in the OE19 in-vivo xenograft model, the addition of Cisplatin to Deferasirox actually 
appeared to reduce the efficacy of the chelator.  This in part may be explained by previous studies 
looking at Cisplatin based combination therapies in germ cell tumours demonstrating that Cisplatin 
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induced cell death occurs predominantly in cells during G2/M of the cell cycle and that use of agents 
which induce G1/S arrest (which is likely to be the case with an iron chelator) is unlikely to offer any 
synergistic advantage. 231 
 
The demonstration that patients presenting with OAC are not systemically iron deplete and that 
chemotherapy with ECX does not negatively impact on iron levels is an important finding. Although 
the data presented here was from a relatively small number of patients drawn from a single, tertiary 
upper gastrointestinal resectional centre, these results will help to justify the design of any future 
clinical trial of Deferasirox therapy in patients with OAC (even though it has also been demonstrated 
here in mouse models that Deferasirox therapy is unlikely to impact on either haemoglobin or serum 
iron levels). 
 
In conclusion, it has been demonstrated that the iron chelator Deferasirox displays significant anti-
neoplastic properties both in-vitro and in-vivo in the context of OAC. Crucially, Deferasirox 
monotherapy was well tolerated in mice treated with the drug with no negative effects on mouse 
health, haemoglobin, serum iron or serum creatinine levels seen. The drug is efficacious in-vitro 
against cells that are resistant to Cisplatin and can improve subsequent response to chemotherapy 
when given either at a low dose alongside or as a pre-treatment prior to existing therapy regimens. 
The drug also appears to reduce signalling through the NFκB pathway, offering an additional 
mechanism of action beyond iron chelation alone. Finally, evidence within this study demonstrated 
that patients presenting with OAC are systemically iron replete and are therefore candidates to be 
entered into any future clinical trial of Deferasirox as an anti-neoplastic agent in oesophageal 
carcinoma. 
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Chapter 4. A Role for Deferasirox as an Anti-neoplastic and Chemosensitising Agent in Colorectal 
Adenocarcinoma 
 
4.1 Introduction 
 
Cancer of the colon and rectum is the 4th most common cancer in the United Kingdom overall (being 
the 3rd most common in men and women when analysed separately). 4  Five year survival rates for 
the disease are 59%, with survival being strongly correlated to disease stage at the time of 
presentation (93.2% of patients with Duke’s A disease survive 5-years, compared to 6.6% with 
Duke’s D disease). 232, 233 
 
As with oesophageal carcinoma, surgery remains the cornerstone of curative treatment for 
colorectal adenocarcinoma, however, for those with locally advanced or systemic disease, 
chemotherapy continues to comprise an important component of the treatment armamentarium. 234 
Again, response to chemotherapy is variable and as such the development of new agents efficacious 
against the disease is highly desirable. 235 
 
Iron appears to be intimately linked to colorectal tumourigenesis. 82, 102  Individuals harbouring a 
mutation in haemochromatosis (HFE), one of the mutated genes that underlies Hereditary 
Haemochromatosis, have also been shown to be at an increased risk of certain extrahepatic cancers, 
including colorectal. 118, 119, 120  Furthermore, a meta-analysis of 33 studies assessing iron intake and 
colorectal cancer risk revealed that approximately 75% of the studies included associated higher iron 
intake with an increased risk of colorectal cancer. 123  It has also been demonstrated that men who 
regularly donate blood may have a lower risk for developing several cancers including colorectal. 122  
Colorectal adenocarcinoma typically develops through the normal mucosa → adenoma → 
adenocarcinoma sequence. 236 With this in mind, increased iron acquisition has been demonstrated 
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in samples of human tissue taken along this progression to adenocarcinoma together with a 
corresponding overexpression in the cellular iron import proteins TfR1 and DMT1 and an 
internalisation of the main cellular iron export protein ferroportin. 82 The systemic iron regulatory 
hormone hepcidin (which through internalisation of ferroportin precipitates cellular iron loading) 
has also been shown to be ectopically expressed in colorectal cancer tissue and correlates with 
tumour T-stage when measured in the urine of patients with the disease. 237 Likewise, iron loading of 
colorectal adenocarcinoma cell lines in-vitro has been shown to stimulate cellular proliferation and 
also repression of the cell adhesion protein E-cadherin. 82 
 
Iron has been shown to amplify Wnt signalling (the major oncogenic pathway in the colon) in-vitro 
following loss of the tumour suppressor APC (an event which occurs in the vast majority of colorectal 
cancers). 132 Furthermore, an upregulation in the expression of TfR1 and DMT1 was seen in 
adenomas extracted from the intestines of transgenic mice harbouring an APC mutation (APC Min/+). 
102 Interestingly, the increase in TfR1 and DMT1 seen was also shown to correlate with expression of 
the proto-oncogene c-Myc, a known Wnt target which has also been shown to activate TfR1 
transcription. 102, 238 Furthermore, in the same study it was demonstrated that ApcMin/+ mice fed a low 
iron diet developed fewer tumours that were also significantly smaller. 102 Conversely, a 2-3 fold 
amplification in tumourigenesis was seen in mice fed a high iron diet compared to the control group. 
Finally, mice fed a low iron diet were shown to have increased overall survival, whereas those on a 
high iron diet had a significantly decreased overall survival (p<0.05 vs. control). 102 The authors 
concluded that excess luminal iron in the context of APC loss was a potent stimulator of intestinal 
tumourigenesis. These findings support similar observations for a propagating effect of iron (both 
luminal and systemic) on murine colorectal tumourigenesis that have been shown previously. 239 
 
Malignant cells have an increased requirement for iron, owing to its vital role in DNA synthesis, ATP 
generation and cell cycle progression. 112 It therefore appears that iron has a dual role in the 
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propagation of colorectal tumourigenesis; firstly, by acting crudely as a ‘fuel in the tank’ for 
malignant cells, driving their increased rate of proliferation through the processes it is crucial to; and 
secondly, through the amplification of oncogenic signalling pathways such as Wnt, further increasing 
cell proliferation, survival and evasion of apoptosis whilst enhancing the cell’s ability to acquire 
further iron and drive proliferation on again (thus forming an almost self-perpetuating cycle). 
 
It thus seems logical that iron chelation may be efficacious in the treatment of colorectal 
adenocarcinoma, however to date, this treatment avenue remains largely unexplored. 
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4.2 Chapter Aims 
 
Given the weight of evidence implicating iron in the propagation of colorectal tumourigenesis, it is 
pertinent to investigate whether iron chelation represents an efficacious and novel treatment option 
for the disease. As such, the aims of this chapter are: 
 
1. To assess the efficacy of the licensed oral iron chelating agent Deferasirox as an anti-
neoplastic agent in colorectal adenocarcinoma in-vitro. 
2. To delineate the effects of Deferasirox administration upon colorectal cellular iron 
metabolism and cell phenotype in-vitro.  
3. To assess the ability of Deferasirox to overcome established chemotherapy resistance in 
colorectal adenocarcinoma in-vitro. 
4. To assess the effect of pertinent genetic mutations and hypoxia upon Deferasirox efficacy in-
vitro. 
5. To assess the efficacy of the licensed iron chelator Deferasirox in colorectal adenocarcinoma 
in-vivo. 
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4.3 Results 
 
4.3.1 Deferasirox as an anti-neoplstic agent in colorectal adenocarcinoma in-vitro 
 
4.3.1.1 Overview 
 
The colorectal adenocarcinoma cell lines RKO, SW480 and HT29 were seeded into 96 well plates and 
cultured in media with or without Deferasirox at varying doses (0-320 µM) for 24, 48 and 72 hours. 
Cells were counted and seeded (4x104/ml following optimisation) such that an approximate 
confluence of 70% was achieved in the control group (0μM Deferasirox) at time of assay.  
 
After the defined time points, MTT assays were performed in order to determine cellular viability (as 
previously outlined) relative to the control group. 
 
4.3.1.2 Results 
 
Deferasirox decreased colonic cell line viability in a time and dose dependent manner (Figure 4.1). 
 
At 24 hours the drug resulted in a significant reduction in cell viability across all 3 lines tested at a 
dose of 320 µM (mean viability 54.5% vs. control), with the drug surpassing the IC50 mark in the 
HT29 cell line. Lower doses of the drug (10 µM in the RKO and 40 µM in the HT29) also generated 
statistical reductions in cell viability after 24 hours.  
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Figure 4.1 Deferasirox administration reduces colonic adenocarcinoma cell line viability in-vitro in 
a time and dose dependent manner 
MTT cell viability assay demonstrating the effect of increasing concentrations of Deferasirox on the 
colorectal adenocarcinoma cell lines RKO (A), SW480 (B) and HT29 (C). Data points represent mean 
fold change compared to standard media control (normalised to 1). Error bars denote ±SEM. P 
values for individual fold changes (relative to control) displayed in (D) (shaded boxes denote p<0.05 
vs. control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
At 48 hours the drug had further decreased cell viability across all 3 cell lines. The IC50 was 
surpassed by 160 µM in both the RKO and HT29 cell lines (where even 5 µM registered a significant 
reduction) and by 320 µM in the SW480 (where 20 µM was the lowest concentration to register a 
significant reduction in cellular viability). The average reduction in cell viability seen was 41.8% at 40 
µM Deferasirox and 46.3% at 80 µM across the 3 lines. 
 
By 72 hours Deferasirox had reduced cell viability across all 3 lines by an average of 57.8% at 40 µM 
increasing to 85.5% at the highest concentration tested of 320 µM. 
 
4.3.2 The effect of Deferasirox upon colorectal cellular iron metabolism and phenotype in-vitro 
 
4.3.2.1 Overview 
 
The effect of Deferasirox upon colorectal cellular iron loading was assessed by both ferrozine assay 
and through radio-labelled iron uptake studies. The ability of Deferasirox to remove iron from cells 
that had already been iron loaded was determined by ferrozine assay, Western blotting and a ferritin 
ELISA. The protocols for all of these procedures are described in chapter 2. 
 
To delineate the effect of treatment with Deferasirox upon the cell cycle FACS was utilised. This 
analysis of cell phenotype was augmented by BrdU (proliferation) and MTT (viability) assays. In 
addition, the effect of pre-incubation of Deferasirox with iron (100 µM FeSO4) upon cellular viability 
was assessed through the performance of an additional MTT assay over 48 hours of treatment. 
Finally, the ability of Deferasirox to suppress iron induced hyperproliferation of colorectal 
adenocarcinoma cells was assessed by performing a BrdU analysis on HT29 cells prior loaded with 25 
µM FeSO4 for 24 hours. HT29 cells were utilised in this section as RKO cells have previously been 
shown not to increase their proliferation rate in response to iron loading. 102, 132 All of the 
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aforementioned experimental procedures were carried out as previously outlined in the methods 
section. 
 
4.3.2.2 Results 
 
Deferasirox significantly inhibited the uptake of iron by colonic cells by both ferrozine assay and 
radio-labelled iron (Figure 4.2). RKO cellular iron uptake was significantly impaired when Deferasirox 
was co-incubated alongside FeSO4 for 1 hour (49.6% reduction vs. FeSO4 alone, p<0.05). A similar 
result was obtained in the radio-labelled Caco-2 trans-well system (20.4% reduction vs. FeSO4 alone, 
p<0.05). 
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A 
 
B 
Figure 4.2 Deferasirox inhibits colonic cellular iron uptake in-vitro 
Ferrozine assay demonstrating the ability of Deferasirox (40 µM) to suppress RKO cellular iron 
uptake when administered alongside 100 µM FeSO4 for 1 hour (A). The drug also significantly 
suppressed the uptake of radio-labelled FeSO4 (100 µM) in a trans-well model of colonic 
adenocarcinoma utilising Caco-2 cells (B). Error bars denote ±SEM, * p<0.05 vs. control. 
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The administration of Deferasirox (40 µM) to RKO cells that had been pre-loaded with 100 µM FeSO4 
resulted in a significantly reduced intracellular iron content (28.2% reduction vs. FeSO4, p<0.05, 
Figure 4.3A), thus demonstrating Deferasirox’s ability to strip iron from within colonic cells. This was 
further exemplified by a reduction in subsequent ferritin protein expression by both Western blot 
(62.1% reduction vs. FeSO4, p<0.05, Figure 4.3B) and ferritin ELISA (98.2% reduction vs. FeSO4, Figure 
4.3C). Interestingly, in the ferritin ELISA Deferasirox decreased ferritin expression in the iron loaded 
cells to an even lower level than the control group.    
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Figure 4.3 Deferasirox administration significantly decreases intracellular iron levels and subsequent ferritin 
expression 
Ferrozine assay demonstrating the ability of Deferasirox (40 µM) to decrease RKO intracellular iron levels when 
administered to cells pre-loaded with 100 µM FeSO4 (A). This is supported by decreased ferritin levels, as shown 
by western blot (B, lanes 1-3 100 µM FeSO4, lanes 4-6 100 µM FeSO4 then Deferasirox 40 µM) and ferritin ELISA 
(C).  Semi-quantitative analysis of blots was performed through normalisation to β-actin and subsequent 
expression as a fold change relative to control (normalised to 1). Error bars denote ±SEM, * p<0.05 vs. control. 
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A significant increase in the proportion of cells in G1 phase of the cell cycle was seen following the 
administration of Deferasirox (40 µM) to RKO cells for 48 hours (83.4 vs. 57.1%, p<0.05 vs. control, 
Figure 4.4A). As expected, this was also reflected by a significant reduction in cellular proliferation as 
demonstrated by BrdU assay (69.1% reduction vs. control, p<0.05, Figure 4.4B). Finally, a significant 
reduction in RKO cellular viability (MTT) of 46.1% (p<0.05 vs. control) was also seen following the 
administration of Deferasirox for 48 hours (Figure 4.4C). 
 
Deferasirox efficacy in RKO cells was maintained across all concentrations tested despite pre-
incubation of the chelator with iron (Figure 4.5). At doses of 40, 80 and 360 µM, however, there was 
a statistical reduction in efficacy compared to when the drug was administered in the absence of 
iron (19.5, 12.5 and 22.2% reduction in comparative efficacy respectively, p<0.05). 
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Figure 4.4 Deferasirox administration results in decreased proliferation through cell cycle arrest 
and ultimately leads to a decrease in colonic cellular viability 
Cell cycle analysis through FACS (with propidium iodide) demonstrating the accumulation of RKO 
cells treated with Deferasirox (40 µM for 48 hours) in G1 phase of cell cycle (A). The same dosing 
regimen also resulted in a significant decrease in cellular proliferation (BrdU assay, (B)). Cellular 
viability (MTT assay, (C)) was also significantly reduced at the corresponding dose. Values plotted 
represent mean fold change relative to matched control (normalised to 1), error bars denote ±SEM, 
* p<0.05 vs. matched control. 
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Figure 4.5 The effect of Deferasirox upon colonic adenocarcinoma cell line viability persists despite 
pre-incubation with iron 
Cell viability assay (MTT) demonstrating that Deferasirox remains efficacious against RKO cells when 
administered following a period of prior incubation with 100 µM iron. Both regimens were 
statistically significant against control at all concentrations of Deferasirox >10 µM. Data points 
represent mean fold change vs. control, error bars denote ±SEM, * p<0.05 vs. equivalent dose of 
Deferasirox with iron. 
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The colonic cell line HT29 readily increased its intracellular iron content when cultured in the 
presence of media containing iron (Figure 4.6A). This ability to load iron was associated with a 
significant increase in cellular proliferation (14.3-28.9%, p<0.05 vs. control) as measured by BrdU 
assay (Figure 4.6B). Deferasirox administration for 48 hours at 40µM post iron administration, 
however, significantly ablated the iron induced increase in proliferation seen (reducing the 
proliferation of the iron loaded cells by 50.5% overall, p<0.05, Figure 4.6C) and crucially, reduced 
their proliferation to well below baseline (fold change 0.57 vs. control, p<0.05). 
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A              B            C 
Figure 4.6 Deferasirox can suppress the iron induced increase in proliferation seen in colonic adenocarcinoma cells in-vitro 
Ferrozine assay (A) demonstrating that the intracellular iron levels of HT29 colonic cells increase significantly when they are exposed to media containing FeSO4. This is 
turn leads to an increase in cellular proliferation (by BrdU assay, (B)) above that seen with standard media alone. Deferasirox (40 µm for 48 hours) is capable of 
suppressing this enhancement in proliferation and indeed even reduces it significantly below the baseline level seen with standard media alone (C). Data points 
represent mean fold change relative to standard media control (normalised to 1), error bars denote ±SEM, * p<0.05 vs. control, # p <0.05 vs. iron, $ p<0.05 vs. 
Deferasirox alone.  
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4.3.3 The ability of Deferasirox to overcome chemotherapy resistance in colorectal 
adenocarcinoma in-vitro 
 
4.3.3.1 Overview 
 
The colorectal adenocarcinoma cell line SW480 and its metastatic clone SW620 were seeded into 96 
well plates (100 µl per well at 4x104 cells/ml) and cultured with increasing doses of the 
chemotherapeutic agent 5-Fu (2-128 µM) for 48 hours. In addition, the same cell lines were treated 
with Deferasirox at 20 or 40 µM over the same time period.  
 
In addition, a 5-Fu resistant clone of the HT29 cell line was created by co-culturing them alongside 
progressively increasing doses of the drug over six months. Following this, the cells were seeded into 
96 well plates and incubated with media containing 5-Fu alone (32 µM), Deferasirox (20 µM) or 
Deferasirox + 5-Fu for 72 hours. In addition, the parental HT29 cell line along with RKO and SW480 
cells were also treated with 5-Fu for the same time period as a positive control for 5-Fu efficacy. MTT 
assays were again performed at the end of the treatment period to quantify effect on cellular 
viability. 
 
4.3.3.2 Results  
 
SW480 cells were significantly more sensitive to the effects of treatment with 5-Fu than their 
metastatic counterpart SW620 (Figure 4.7A and B). Indeed, the SW620 cells were completely 5-Fu 
resistant up to and including a concentration of 64 µM. Furthermore, lower concentrations of 5-Fu 
(2-8 µM) actually statistically increased SW620 viability by up to 24.9% (p<0.05 vs. control). In 
contrast, 8 µM 5-Fu was sufficient to decrease SW480 viability by almost 25%.  At every 
concentration of 5-Fu tested, the SW620 line was statistically more resistant than the SW480 cell 
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line (p<0.05, Figure 4.7B). Deferasirox therapy (20 and 40 µM) resulted in a statistically significant 
reduction in cellular viability in both the SW480 and SW620 cell lines (Figure 4.7C), with no 
difference seen in efficacy between the 2 lines. 
 
As expected, the HT29 5-Fu resistant ‘clone’ demonstrated no significant decrease in viability 
following exposure to 5-Fu at a concentration of 32 µM (Figure 4.7D). In contrast, the parental HT29, 
SW480 and RKO lines suffered decreased viability in the region of 60-70% (Figure 4.7D). Deferasirox 
monotherapy was again capable of significantly reducing viability (19.8% reduction vs. control, 
p<0.05) in the ‘clone’ line which was significantly enhanced further (to 29.9%) following combination 
with the previously ineffective 5-Fu dose of 32 µM (p<0.05 vs. control, 5-Fu alone and Deferasirox 
alone, Figure 4.7D). 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
 
A 
 
B 
 
C 
146 
 
 
D 
Figure 4.7 Deferasirox can overcome colonic 5-Fu resistance in-vitro 
Cell viability assay demonstrating the varying response to 5-Fu seen in the colonic cell lines SW480 
and SW620 (A). The SW620 cell line is 5-Fu resistant up to a concentration of 128 µM and actually 
increases its viability at lower doses (2-8 µM) compared to control (B). Despite this, Deferasirox 
induces a significant reduction in cellular viability when administered (C) with no difference in 
efficacy seen between the 2 cell lines at the doses tested. Deferasirox (20 µM) is also capable if 
inducing a significant reduction in cellular viability when administered to a ‘clone’ of HT29 cells that 
are 5-Fu resistant (up to 32 µM, (D)). In this model, the combination of Deferasirox (20 µM) with the 
previously ineffective 5-Fu dose of 32 µM generated a significant reduction in cellular viability 
greater than that seen compared to both control and Deferasirox alone. Data points represent mean 
fold change relative to standard media control (normalised to 1), error bars denote ±SEM, * p<0.05 
vs. matched control, # p<0.05 vs. 32 µM 5-Fu alone, $ p<0.05 vs. Deferasirox alone. 
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4.3.4 The efficacy of Deferasirox in colorectal adenoma cell lines  
 
4.3.4.1 Overview 
 
In order to compare the efficacy of Deferasirox in colorectal adenoma and adenocarcinoma cell lines 
the colorectal adenoma cell lines AAC1 and RGC2 and the adenocarcinoma cell lines RKO and SW480 
were treated with either standard media (control) or media containing Deferasirox (40 µM). 
Following 48 hours of treatment cellular proliferation was assessed by BrdU assay (as previously 
outlined). 
 
4.3.4.2 Results 
 
Deferasirox therapy had a profound effect on cellular proliferation across all 4 of the lines tested, 
reducing cellular proliferation to 60.3, 57.8, 30.9 and 25.6% of control in the AAC1, RGC2, RKO and 
SW480 cells respectively (p<0.05 vs. control for each, Figure 4.8). Of note, Deferasirox was 
statistically more effective in both the RKO and SW480 adenocarcinoma lines. 
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Figure 4.8 Deferasirox appears to be more efficacious in more advanced colonic adenocarcinoma 
cell lines 
Cellular proliferation assay (BrdU) demonstrating the difference in efficacy seen when Deferasirox 
(40 µM for 48 hours) was administered to 2 colonic adenoma (AAC1 and RGC2) and 2 colonic 
adenocarcinoma (RKO and SW480) cell lines. Data points represent mean fold change relative to 
matched standard media control, error bars denote ±SEM, * p<0.05. vs. matched control for each 
cell line, # p<0.05 vs. AAC1 and RGC2.  
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4.3.5 The effect of pertinent genetic mutations and hypoxia upon Deferasirox efficacy in-vitro 
 
4.3.5.1 Overview 
 
Following the demonstration in section 4.3.4 that Deferasirox appeared to be more efficacious in 
advanced adenocarcinoma lines than it was in pre-cursor adenomas, the effect of genetic mutations 
key to the development of colorectal adenocarcinoma (Apc and p53) upon Deferasirox efficacy were 
investigated. In addition, the effect of incubation with the drug in a hypoxic environment was also 
investigated as this is known to play a key role in cancer therapy resistance. 240 
 
To delineate the effect of APC status upon Deferasirox efficacy the HT29 APC wild type inducible cell 
line was utilised. This cell line expresses wild type APC following incubation with zinc chloride (100 
µM) for 24 hours. 63 APC expression was inferred through a Western blot of β-catenin expression 
(after 48 hours of treatment with zinc chloride) and a BrdU cell proliferation assay. 
 
The effect of p53 mutation on Deferasirox efficacy was delineated by use of the isogenic cell lines 
HCT116 p53 wild type (WT) and HCT116 p53-/-. 196 Following confirmation of p53 status via Western 
blotting, both p53 WT and -/- cells were seeded into 96 well plates and subjected to increasing 
concentrations of Deferasirox (0-160 µM) for 48 hours. Both cell lines were also exposed to 
increasing concentrations of 5-Fu (0-128 µM) as a positive control for the effect of p53 status on 
treatment efficacy. MTT cell viability assays were then performed. 
 
Finally, the effect of hypoxia on Deferasirox efficacy was ascertained by exposing HCT116 p53WT 
cells to a 1% O2 chamber for 18-24 hours prior to treatment with the drug (0-80 µM). Induction of 
hypoxia was confirmed through Western blotting for HIF-1α expression. Again, a control group 
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treated exactly the same except for exposure to hypoxia was included. An SRB proliferation assay 
was then performed on both groups (as previously outlined in chapter 2.2.19). 
 
4.3.5.2 Results 
 
Exposure of HT29 cells to 100µM zinc chloride for 48 hours resulted in a decrease in β-catenin 
protein expression and a concomitant reduction in cellular proliferation as per BrdU (Figure 4.9A). 
When Deferasirox was administered to the HT29 APC WT and MT lines, an increase in efficacy was 
evident in the cells still harbouring an APC mutation compared to those now expressing APC. This 
increase ranged from 16.2-35.6% (depending on the dose) and was statistically significant at all 
doses used except 160 µM (Figure 4.9B). 
 
HCT116 p53WT and HCT116 p53-/- are isogenic and differ only in p53 status (Figure 4.10A). P53 
status significantly effected HCT116 response to treatment with 5-Fu (Figure 4.10B), with the p53-/- 
cells demonstrating a marked reduction in response to the drug (14.2-52.4% reduction in efficacy, 
p<0.05 vs. p53WT for all doses, Figure 4.10B). Deferasirox therapy, however, did not appear to be 
influenced by p53 status (Figure 4.10C), with no statistical difference seen in efficacy between any of 
the doses tested. 
 
HIF-1α expression (and thus hypoxia) was markedly induced following exposure of HCT116 cells to 
1% O2 for 18-24 hours (Figure 4.11A). Although a trend for a reduction in cellular proliferation with 
Deferasirox under hypoxic conditions was seen across all concentrations tested, Deferasirox therapy 
did not achieve a statistically significant reduction compared to control at any of the doses tested 
(Figure 4.11B). In contrast, statistically significant suppression of cellular proliferation was achieved 
across all concentrations when the drug was used under normoxic conditions (Figure 4.11B).  
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Figure 4.9 Deferasirox appears to be more efficacious in the background of an APC mutation 
Western blot (A) demonstrating reduction in β-catenin expression when HT29 cells are exposed to 
100 µM zinc chloride for 24-48 hours. This reduction in β-catenin is taken as inference of restoration 
of APC expression and thus, as would be expected, a significant reduction in cellular proliferation 
(BrdU, (A)) is also seen. Subsequent cell viability assay (MTT, (B)) demonstrating the increased 
efficacy of Deferasirox in the presence of increased β-catenin (and thus an APC mutation). P values 
for % increase in efficacy with an APC mutation at equivalent doses of Deferasirox are displayed in 
the table in (B). Data points represent mean fold change relative to standard media control 
(normalised to 1), error bars denote ±SEM, * p<0.05 vs. standard media control.    
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Figure 4.10 Deferasirox efficacy is not influenced by p53 status in-vitro 
Western blot (A) confirming the p53 status of the isogenic cell lines HCT116 p53WT and HCT116 p53-
/-. The HCT116 p53-/- cells have a significantly reduced response to 5-Fu across all concentrations 
tested (cell viability assay, (B)). This is not the cases with Deferasirox, however, which displayed no 
statistical differences in magnitude of cell viability reduction (C) dependent on p53 expression across 
the range of concentrations tested. Data points represent mean fold change relative to matched 
standard media control (normalised to 1), error bars denote ±SEM, * p<0.05 vs. matched control. 
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Figure 4.11 Deferasirox did not induce a significant reduction in cellular proliferation under 
hypoxic conditions 
Western blot demonstrating increased HIF 1α expression following exposure of HCT116 p53WT cells 
to 1% p02 for 24 hours (A, lane N = normoxia, lane H = hypoxia). SRB assay demonstrating the 
inability of Deferasirox to induce a statistically significant reduction in the same colonic cells once 
hypoxia had been induced (B). Data points represent mean fold change relative to standard media 
control (normalised to 1), error bars denote ±SEM, * p<0.05 vs. equivalent dose of Deferasirox in 
normoxia, grey boxes within table denote p<0.05 vs. matched control. 
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4.3.6 The effect of Deferasirox administration upon murine intestinal phenotype 
 
4.3.6.1 Overview 
 
To further delineate the efficacy of Deferasirox as a potential therapy for colorectal 
adenocarcinoma, the drug was administered orally to Villin-CreER+ Apcfl/fl transgenic mice. Tamoxifen 
administration intraperitoneally on day 1 (80 mg/kg) deletes both copies of the APC gene 
throughout the intestine and a hyper-proliferative phenotype rapidly develops over the ensuing 
days.  
 
Deferasirox was administered orally as a single dose on day 5 and the mice were then taken 6 hours 
post treatment. The intestine was immediately harvested and processed for H&E, Caspase-3 and 
Phospho-Histone H3 staining as outlined in the methods section. Slides were then scored as 
previously described. 
 
Deferasirox was administered at a dose of either 20 or 200 mg/kg as a single 200 µl oral gavage using 
30% 1,2-propanediol/70% sterile 0.9% sodium chloride solution as a vehicle. In addition, the drug 
was also administered at a dose of 100 mg/kg in a modified vehicle of 30mM sodium carbonate / 3 
mM TRIS (again 200 µl single gavage). The latter vehicle was utilised in an attempt to see if improved 
drug solubility improved subsequent efficacy. 
 
4.3.6.2 Results 
 
At a dose of 20 mg/kg Deferasirox administration did not significantly alter either mitosis or 
apoptosis (Figure 4.12 A + B). When utilised at the higher dose of 200 mg/kg, however, a statistically 
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significant suppression in mitosis (52.4% reduction vs. control, p<0.05, Figure 4.13) and an induction 
of apoptosis (65.2% increase vs. control, p<0.05) was seen (Figure 4.14).  
 
The administration of Deferasirox at a dose of 100 mg/kg (in the Na2CO3/TRIS vehicle) to APC wild 
type mice significantly suppressed mitosis (Figure 4.15) but had no effect upon apoptosis. A 
statistically significant increase in apoptosis was seen (64.3% increase vs. control, p<0.05, Figure 
4.16), however, when Deferasirox was utilised at a dose of 100 mg/kg in the Villin-CreER+ Apcfl/fl 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
      10x             40x 
 
A 
 
B 
Vehicle 
Deferasirox 
160 
 
Figure 4.12 Deferasirox did not significantly alter intestinal proliferation when given at a dose of 
20 mg/kg to Villin-CreER+ Apcfl/fl mice 
Representative H&E images (A) of intestinal crypts (i and ii = Vehicle, iii and iv = Deferasirox) 6 hours 
post exposure to Deferasirox at a dose of 20 mg/kg orally. Circles indicate mitotic figures, arrows 
indicate apoptotic bodies. Mitotic and apoptotic indexes (B) indicative of proportion of cells per 
intestinal crypt in mitosis or apoptosis. Data points plotted indicate mean index score, error bars 
denote ±SEM.  Higher powered images taken at 40x, lower at 10x. 
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Figure 4.13 Deferasirox significantly suppresses mitosis within intestinal crypts when given at a 
dose of 200 mg/kg to Villin-CreER+ Apcfl/fl mice 
Representative H&E images (A) of intestinal crypts (i and ii = Vehicle, iii and iv = Deferasirox) 6 hours 
post exposure to Deferasirox at a dose of 200 mg/kg orally. Circles indicate mitotic figures, arrows 
indicate apoptotic bodies. Mitotic and apoptotic indexes (B) indicative of proportion of cells per 
intestinal crypt in mitosis or apoptosis. Data points plotted indicate mean index score, error bars 
denote ±SEM, * p<0.05 vs. vehicle.  Higher powered images taken at 40x, lower at 20x. 
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Figure 4.14 Deferasirox significantly stimulates apoptosis within intestinal crypts when given at a 
dose of 200 mg/kg to Villin-CreER+ Apcfl/fl mice 
Staining of intestinal crypts for the mitosis marker Phospho-Histone H3 (A + B) and the apoptosis 
marker Caspase-3 (C and D) on tissue obtained 6 hours post exposure to Deferasirox at a dose of 200 
mg/kg PO. Representative images (A and C) demonstrating positively stained cells within crypts (red 
circles delineate examples of positive staining). Error bars denote ±SEM, * p<0.05 vs. vehicle. Images 
taken at 20x. 
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Figure 4.15 Deferasirox significantly suppresses mitosis within intestinal crypts when given at a 
dose of 100 mg/kg to WT APC mice 
Representative H&E images (A) of intestinal crypts (i and ii = Vehicle, iii and iv = Deferasirox) 6 hours 
post exposure to Deferasirox at a dose of 100 mg/kg orally. Circles indicate mitotic figures, arrows 
indicate apoptotic bodies. Mitotic and apoptotic indexes (B) indicative of proportion of cells per 
intestinal crypt in mitosis or apoptosis. 
 
Staining of intestinal crypts for the mitosis marker Phospho-Histone H3 (C + D) and the apoptosis 
marker Caspase-3 (E and F) on tissue obtained 6 hours post exposure to Deferasirox at a dose of 100 
mg/kg PO. Representative images (C and E) demonstrating positively stained cells within crypts (red 
circles here exemplify positive staining).  
 
Data points plotted indicate mean index score, error bars denote ±SEM, * p<0.05 vs. vehicle.  Higher 
powered images taken at 40x, lower at 20x. 
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Figure 4.16 Deferasirox significantly stimulates apoptosis within intestinal crypts when given at a 
dose of 100 mg/kg to Villin-CreER+ Apcfl/fl mice 
Representative H&E images (A) of intestinal crypts (i and ii = Vehicle, iii and iv = Deferasirox) 6 hours 
post exposure to Deferasirox at a dose of 100 mg/kg PO. Circles indicate mitotic figures, arrows 
indicate apoptotic bodies. Mitotic and apoptotic indexes (B) indicative of proportion of cells per 
intestinal crypt in mitosis or apoptosis. 
 
Staining of intestinal crypts for the mitosis marker Phospho-Histone H3 (C + D) and the apoptosis 
marker Caspase-3 (E and F) on tissue obtained 6 hours post exposure to Deferasirox at a dose of 
100mg/kg PO. Representative images (C and E) demonstrating positively stained cells within crypts 
(red circles exemplify positive stained cells).  
 
Data points plotted indicate mean index score, error bars denote ±SEM, * p<0.05 vs. vehicle.  Higher 
powered images taken at 40x, lower at 20x. 
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4.3.7. The effect of Deferasirox upon murine survival 
 
4.3.7.1 Overview 
 
In order to ascertain whether or not the effects of Deferasirox upon murine intestinal phenotype 
translate into increased survival, the Lgr5-CreER+ APCfl/fl and Lgr5-CreER+ APCfl/fl Ptenfl/fl transgenic 
mice models were utilised. 
 
Mice were induced with Tamoxifen (as outlined in the methods section) and commenced treatment 
with Deferasirox at either 200 mg/kg (30% 1,2-propanediol/70% sterile 0.9% sodium chloride 
solution as a vehicle) or 100 mg/kg (30 mM sodium carbonate / 3 mM TRIS vehicle)  or vehicle alone 
(as a control) as a 200 µl oral gavage 3 times per week. Mouse health was monitored daily 
throughout treatment and mice were taken immediately upon showing any signs of deteriorating 
health.  
 
4.3.7.2 Results 
 
Deferasirox failed to increase murine survival in the Lgr5-CreER+ APCfl/fl murine model in either of the 
dosing regimens tested (Figure 4.17 and 4.18). 
 
Interestingly, in the more aggressive Lgr5-CreER+ APCfl/fl Ptenfl/fl model Deferasirox showed a trend 
towards increased survival compared to vehicle (52.3 days vs. 39.8 days)), although this was not 
statistically significant (p=0.512 vs. vehicle, Figure 4.19). 
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Figure 4.17 Deferasirox did not significantly extend survival when given to Lgr5-CreER+ APCfl/fl mice 
at a dose of 200 mg/kg 
Survival plot for Lgr5-CreER+ APCfl/fl mice treated with either vehicle or Deferasirox (200 mg/kg) by 
oral gavage 3 times per week. P value quoted is for log-rank test of survival between the 2 groups.  
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Figure 4.18 Deferasirox did not significantly extend survival when given to Lgr5-CreER+ APCfl/fl mice 
at a dose of 100 mg/kg 
Survival plot for Lgr5-CreER+ APCfl/fl mice treated with either vehicle or Deferasirox (100 mg/kg) by 
oral gavage 3 times per week. P value quoted is for log-rank test of survival between the 2 groups.  
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Figure 4.19 Deferasirox did not significantly extend survival when given to Lgr5-CreER+ APCfl/fl 
Ptenfl/fl mice at a dose of 100 mg/kg 
Survival plot for Lgr5-CreER+ APCfl/fl Ptenfl/fl mice treated with either vehicle or Deferasirox (100 
mg/kg) by oral gavage 3 times per week. P value quoted is for log-rank test of survival between the 2 
groups.  
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4.4 Discussion  
 
Locally advanced and or systemic colorectal cancer is treated with (neo)adjuvant therapy, often with 
variable response and therefore, as with oesophageal cancer, the development of new agents with 
increased efficacy is highly desirable. 235 
 
Cancer cells have an increased requirement for iron and there is now a significant body of evidence 
linking iron to the propagation of colorectal tumourigenesis. 82, 102 As such, iron chelators represent a 
promising group of anti-neoplastic agents worthy of further investigation in this setting. 80, 92, 112, 113 It 
has already been demonstrated in chapter 3 that the orally administered iron chelating agent 
Deferasirox displays significant anti-neoplastic properties both in-vitro and in-vivo in oesophageal 
adenocarcinoma. The main aim of this chapter was therefore to ascertain whether or not these 
effects were also observed in the colon and rectum as this has not been investigated before. 
 
As in the oesophagus, Deferasirox administration significantly suppressed colorectal 
adenocarcinoma cell line viability in-vitro in a time and dose dependent manner.  
 
The drug significantly inhibited cellular iron uptake (by up to 49.6% compared to control, p<0.05) 
and was also capable of reducing intracellular iron content in cells pre-loaded with iron (as 
demonstrated by reductions in both total intracellular iron by ferrozine and the iron storage protein 
ferritin). This ultimately resulted in an accumulation of cells in the G1 phase of the cell cycle, a 
consequent reduction in cellular proliferation and a subsequent decrease in cell viability. Previous 
studies of Deferasirox have also demonstrated the induction of cell cycle arrest, although 
interestingly in S phase rather than G1. 167 The iron chelator Desferrioxamine is also known to induce 
cell cycle arrest and in particular has been shown to be capable of arresting cells independently in 
both mid-G1 and S phase. 241 
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As stated previously, malignant cells have a higher requirement for iron than their normal 
counterparts, something that is unsurprising given the element’s crucial role in DNA synthesis, ATP 
generation and cell cycle progression; all activities that by definition are increased in cancer. 112, 113 
Cellular iron deprivation is known to cause arrest of the cell cycle at the G1/S checkpoint and 
subsequent accumulation of cells in the G1 phase (as demonstrated in the current study by a 45.9% 
increase in cells in G1 phase following treatment with Deferasirox for 48 hours, p<0.05 vs. control). 
224, 225 Iron deficiency inhibits activity of the R2 subunit of the enzyme ribonucleotide reductase 
(which catalyzes the conversion of ribonucleotides into deoxyribonucleotides during DNA synthesis) 
and decreases expression of cyclins A, B and D (all of which are vital for cell cycle progression). 225 
 
Deferasirox displayed significantly increased efficacy in the colorectal adenocarcinoma cell lines RKO 
and SW480 compared to the adenoma lines AAC1 and RGC2. This is in part is likely to be explained 
by the increased metabolic rate of the adenocarcinoma lines and thus an increased requirement for 
iron, rendering them more sensitive to the effects of cellular iron deprivation through chelation. 
Previous studies have demonstrated that, although adenomas load iron to a much greater extent 
than normal colonic mucosa, adenoma iron content is not as great as that of adenocarcinomas. 82, 242 
Current chemotherapeutic regimens in colorectal cancer are accompanied by a plethora of well 
documented side effects resulting from the various drug’s non-targeted mechanisms of action. 243  
As such, the demonstration that Deferasirox may be more effective against cancer cells than their 
‘less malignant’ counterparts raises the potential that the drug may be selectively targeted to 
neoplastic cells, thus offering improved efficacy and a reduction in off-target side effects. Previous 
studies using Deferasirox have also demonstrated that much higher concentrations of the drug were 
required to induce cytotoxicity in primary hepatocyte cultures compared to hepatoma cells (25 µM 
vs. >200 µM) again suggesting that malignant lines may be more sensitive to Deferasirox exposure 
than benign tissues. 167 Similar observations have also been made with alternative iron chelators 
(DFO, Deferiprone and O‐Trensox). 143, 167, 168 
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Deferasirox also appears to be more efficacious in the background of an APC mutation, giving further 
support to the idea that iron chelation therapy may offer targeted treatment of cancer cells. Across 
the concentrations tested, Deferasirox was up to 35.6% more efficacious (at the equivalent dose) in 
HT29 cells with an APC mutation compared to their APC wild type counterparts. In part, this may 
again be explained by the fact the HT29 APC mutant cells had a significantly increased rate of 
proliferation (55.2% increase vs. APC wild type, p<0.05) and hence a higher requirement for iron 
than HT29 APC wild type cells. There is also, however, an additional explanation for the increase in 
Deferasirox efficacy seen. Mutation of the tumour suppressor APC permits activation of the Wnt 
signalling pathway through translocation of accumulated cytosolic β-catenin to the nucleus with 
subsequent activation of Wnt targets including the proto-oncogene c-Myc. Increased intracellular 
iron has previously been shown to amplify Wnt signalling in the background of an APC mutation. 132 
This in turn results in increased c-Myc, which further increases cellular proliferation (and subsequent 
requirement for iron) and has also been shown to increase expression of the pertinent cellular iron 
import proteins TfR1 and DMT1, thus permitting the cell to increase iron acquisition and further 
exacerbate Wnt signalling (an almost self-perpetuating cycle). Deferasirox therefore may serve to 
break this cycle through both the induction of intracellular iron deprivation and inhibition of Wnt 
signalling. Support for this can be found in a previous study identifying Deferasirox as a potent 
inhibitor of Wnt signalling in SW480 colorectal adenocarcinoma cells. 186  The same study also 
reported an increase in the expression of genes activated by iron depletion (including HIF-1α) and 
noted an abrogation of these effects when the iron chelator was subsequently incubated alongside 
FeSO4, indicating that the inhibition in Wnt signalling seen was achieved entirely through the 
chelation of iron. 186  
 
The findings of this latter study, however, despite offering support for the findings made within this 
thesis, do not agree with all of the results demonstrated here. Firstly, Deferasirox efficacy in 
reducing colorectal cell line viability was not completely abrogated through pre-incubation alongside 
181 
 
FeSO4 in our study. Secondly, treatment of cells pre-loaded with iron resulted in intracellular ferritin 
levels that were not only significantly lower than the untreated iron-loaded cells (as may be 
expected) but that were also significantly lower than the untreated, non iron-loaded control cells. 
Finally, Deferasirox not only significantly suppressed the induction of proliferation seen in HT29 cells 
following incubation with iron but actually reduced it to well below baseline control proliferation 
rates. All of this indicates that Deferasirox may actually be more efficacious at binding iron (and thus 
suppressing proliferation) in the setting of increased intracellular iron levels (as in colorectal 
adenocarcinoma). 82     
 
The tumour suppressor p53 plays a crucial role in mediating cell cycle arrest and functions as a cell-
death checkpoint following activation by multiple cellular stresses including DNA damage, oxidative 
stress and osmotic shock. 244 The protein activates a number of downstream targets, including the 
cyclin-dependent kinase inhibitor p21 CIP1/WAF1, thus initiating cycle arrest at G1/S and ultimately 
apoptosis if DNA damage cannot be repaired. 244 The gene encoding the p53 protein (TP53) is 
mutated in around 35-55% of cases of colorectal cancer and is known to influence response to 
chemotherapy, including 5-Fu. 245, 246 Similar findings were demonstrated in this study, where 
treatment of the colonic cell line HCT116 p53-/- with 5-Fu resulted in a significantly less efficacious 
response (in terms of effect on cellular viability) than when the drug was given to HCT116 p53WT 
cells. Deferasirox efficacy, however, was not significantly altered by cellular p53 status at any of the 
doses tested. This may be explained by the observation that Deferasirox is primarily exerting its 
effects through cellular iron deprivation, which is completely independent of p53 activity. In 
addition, however, previous studies have also demonstrated the ability of Deferasirox to up-regulate 
p21 CIP1/WAF1 expression and also expression of the metastasis suppressor NDRG1, which in turn has 
been shown to further increase p21 CIP1/WAF1 expression in a p53 independent manner. 169, 247 Thus, it 
would seem that p53 expression is not required for Deferasirox to exert its effects upon the cell 
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cycle. This is in contrast to previous studies using the iron chelator Desferrioxamine, which has 
shown decreased efficacy in the context of a p53 deletion in the same cell line. 248 
 
Deferasirox can overcome chemotherapy resistance (this time to 5-Fu) in colorectal adenocarcinoma 
cell lines. The adenocarcinoma cell line SW620 (a metastatic clone of the SW480 line) displayed 
marked resistance to 5-Fu (unlike the SW480 line) but was equally sensitive to Deferasirox. Likewise, 
a 5-Fu resistant ‘clone’ of HT29 cells also demonstrated sensitivity to Deferasirox and yielded an 
additional reduction in cellular viability when Deferasirox was combined with 5-Fu. Again, these 
findings may merely indicate that Deferasirox is acting through a different mechanism of action to 5-
Fu (i.e. iron chelation) thus circumventing the therapy resistance, however, the demonstration of an 
additive effect by combining 5-Fu and Deferasirox in the HT29 ‘clone’ cell line again raises the 
possibility that the drug may serve as a chemosensitiser. The mechanism through which this may 
occur has not been investigated further within this study, however, the NFκB signalling pathway has 
been shown to be activated in colorectal cancer and therefore its inhibition with Deferasirox may 
offer a putative mechanism for subsequent chemosensitisation.249   
 
The ability of Deferasirox to overcome 5-Fu resistance is somewhat tempered by its reduced efficacy 
in the context of hypoxia. Hypoxia is a common feature of many solid tumours, including colorectal, 
and its presence triggers a number of adaptive responses which can promote tumour progression 
and also resistance to therapy. 250 One explanation for the decrease in efficacy seen is that the 
exposure of cells to a hypoxic environment results in an initial reduction in cellular proliferation, 
which is likely to lower their requirement for iron and thus decrease sensitivity to the effects of iron 
chelation. An alternative explanation is that iron chelation is known to induce expression of HIF-1α, 
the central protein in the co-ordination of the cellular response to hypoxia, through inhibition of 
prolyl hydroxylase domain proteins (which require iron for their activity). 251  Elevated levels of HIF-
1α are known to activate hypoxia-responsive genes (such as vascular endothelial growth factor, 
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platelet derived growth factor and nitric oxide synthase) and the initiation of anaerobic glycolysis, 
which in turn lead to the stimulation of proliferation, metabolism, angiogenesis, invasion, metastasis 
and therapy resistance. 250 Thus, iron chelation with Deferasirox may serve to exacerbate and 
enhance the cellular response to hypoxia. In addition, HIF-1α is known to induce cellular iron uptake 
through increasing the expression of IRP2 and subsequently TfR1 and DMT1. 99 It is also known to up-
regulate expression of haem oxygenase 1 (which degrades haem into bilverdin, carbon monoxide 
and iron) which further increases intracellular iron availability. 99 As such, it may be that under 
hypoxic conditions increased intracellular iron levels mean a significantly higher dose of chelator is 
required to generate significant effects (thus overcoming the potential for chelator saturation). 
 
The demonstration of an in-vivo effect of Deferasirox administration upon Villin-CreER+ Apcfl/fl 
murine intestinal phenotype (albeit at a significantly higher dose than that used in the previous 
oesophageal xenograft experiments) is immensely promising. Deferasirox administration 
significantly increased expression of the apoptotic marker cleaved caspase-3 by 65.2 and 64.3% at 
doses of 200 mg/kg and 100 mg/kg (in the propylene glycol and sodium carbonate based vehicles 
respectively, p<0.05 vs. control) and also reduced mitosis when used at a dose of 200 mg/kg (52.4% 
reduction vs. control, p<0.05). This result is in agreement with a previous study from our group 
demonstrating the administration of an iron deficient diet to a similar strain of mice as used here 
significantly increased rates of intestinal apoptosis (2-3x increase vs. control, p=0.015), whilst a diet 
high in iron significantly stimulated mitosis (4-5x increase vs. control, p=0.015). 102 As with the in-
vitro experiments, it is likely that crypt cellular iron deprivation through chelation results in cell cycle 
arrest and induction of cellular apoptosis. Deferasirox may also be serving as an inhibitor of the Wnt 
pathway which is known to be active in these mice (through loss of APC) and exacerbated by iron. 102 
This was not investigated in this study but could be through immunohistochemical staining of slides 
with antibodies against Wnt targets (β-catenin, c-Myc etc.) 
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Unfortunately, in this study, the increase in intestinal apoptosis seen with Deferasirox administration 
did not translate into an increase in overall survival when the drug was administered to another 
spontaneous model of intestinal tumourigenesis, the Lgr5-CreER+ APCfl/fl  mouse. Again, following 
induction, these mice lose APC within the intestinal stem cells and develop a hyperproliferative 
phenotype resulting in adenoma formation. 102 A trend for increased survival with Deferasirox was 
seen, however, when the drug was given to Lgr5-CreER+ APCfl/fl Ptenfl/fl mice. Mice given Deferasirox 
survived for an average of 54.0 days compared to 42.0 days in mice given control vehicle, this was 
not, however, statistically significant (p=0.621).  
 
The lack of statistical improvement in survival with Deferasirox may be explained by the fact that 
both of the models utilised result in rapid adenoma formation throughout the whole murine 
intestine and thus may be too aggressive for Deferasirox to exert an effect. One could repeat the 
experiment using the APCMin/+ murine model where mice develop adenomas at a slower rate, thus 
allowing smaller differences to be elicited. 102 Another explanation could be that Deferasirox is more 
efficacious in established tumours that are more phenotypically advanced and possess multiple 
genetic mutations (not merely just in APC) and as such these models may not be completely 
appropriate for the testing of the drug. The earlier finding that Deferasirox is more efficacious in 
adenocarcinoma than adenoma cell lines in-vitro would support this latter observation. The final 
potential explanation for the lack of improvement in survival with Deferasirox therapy is that the 
drug may exert its effects through a systemic route rather than a luminal one and this may limit its 
efficacy in the setting of colorectal cancer in-vivo. In their previous study, Radulescu and colleagues 
concluded that it was the luminal pool of iron that was responsible for the propagation of 
tumourigenesis and not the systemic pool. 102 This may not be true in all cases, however, as an 
increase in luminal iron is unlikely to explain the increased incidence of colorectal adenocarcinoma 
seen in patients with Haemochromatosis. 118, 119, 120  Deferasirox clearly exerts a significant 
proportion of its anti-neoplastic effects through the systemic circulation (as demonstrated by its 
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marked suppression of OAC subcutaneous xenograft growth in chapter 3), however, although 
predominantly absorbed in the duodenum (thus not reaching the colon), it is excreted within the bile 
and, as such, has been shown to retain some of its chelating capacity when it reaches the colon. 252 
Therefore, it may actually have the added benefit of being able to chelate iron at both the systemic 
and luminal levels. 
 
In conclusion, it can be said that the oral iron chelating agent Deferasirox displays marked and 
significant anti-neoplastic effects against colorectal adenocarcinoma in-vitro. The drug effectively 
inhibits cellular iron uptake and facilitates the removal of iron from within cancer cells precipitating 
cell cycle arrest and a subsequent reduction in cellular viability. The drug appears to be more 
efficacious in adenocarcinoma cells than in adenomas and also in the background of an APC 
mutation. As in oesophageal cancer, Deferasirox can overcome chemotherapy resistance in-vitro and 
its efficacy is not dependent on p53 status. Promisingly, the drug appears to increase rates of 
intestinal apoptosis and suppress mitosis when administered to APC deficient mice although this has 
not been shown to translate into an increase in overall survival in the present study. Future 
experiments should aim to identify markers predictive of response to Deferasirox and also aim to 
demonstrate an improvement in mouse survival, with a corresponding reduction in tumour burden 
and abrogation of Wnt targets within the murine intestine. Conclusive demonstration of 
Deferasirox’s safety and tolerability when administered in-vivo at the higher doses used in this 
chapter is also required. 
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Chapter 5. The role of IRP2 in colorectal adenocarcinoma: A potential biomarker for Deferasirox 
efficacy? 
 
5.1 Introduction 
 
Tumour iron accumulation has previously been demonstrated along progression through the 
colorectal adenoma to carcinoma sequence. 82 Furthermore, this is accompanied by increased 
expression of the key cellular iron import proteins TfR1 and DMT1 with concomitant internalisation 
of the basolateral iron exporter ferroportin. 82 Expression of the systemic iron regulatory hormone 
hepcidin (which facilitates the internalisation and degradation of ferroportin) has also been shown. 
237 The role of the iron regulatory proteins, the chief regulators of intracellular iron metabolism, 
within this process of tumour iron accumulation, however, has not been determined. 
 
There are 2 intracellular iron regulatory proteins (IRP1 and IRP2), the function of which is to co-
ordinate an adaptive response to iron levels within individual cells. 99 As such, IRPs increase iron 
uptake when intracellular levels are low and decrease iron import when intracellular levels are high. 
99 This process is achieved through IRP-mediated translational regulation of the proteins associated 
with cellular iron import and storage. 99 In times of cellular iron depletion, IRPs bind to iron 
responsive elements (IREs) in the 5’ untranslated region (UTR) of ferritin and ferroportin mRNA, thus 
blocking their translation and inhibiting iron storage and efflux. 80, 92, 99  Simultaneously, the IRPs also 
bind to IREs in the 3’ UTR of TfR1 (and to some extent DMT1) mRNA, stabilising its expression and 
increasing iron import. 80, 92, 99  Conversely, when iron levels are adequate or in excess, IRP1 loses its 
IRE-binding activity (instead acquiring enzymatic activity as a cytosolic acinotase) and IRP2 is 
degraded, thus permitting the translation of ferritin and ferroportin mRNA and the degradation of 
TfR1. 80, 92, 99 In addition to low cellular iron levels, IRP2 has also been shown to be stimulated by 
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hypoxia and the proto-oncogene c-Myc, whilst also being stabilised by nitric oxide and oxidative 
stress. 253, 254, 255, 256 
 
Studies directly investigating the relationship between IRPs and cancer are scarce. In lung cancer, 
over-expression of IRP1 has been shown to suppress the growth of cell line xenografts, whilst IRP2 
was shown to have a stimulatory effect. 254, 257  Micro-array gene expression profiles from breast 
cancer patients have shown tumour IRP2 over-expression to correlate with high-grade disease whilst 
the knock down of IRP2 suppresses xenograft growth in mice. 258 In colorectal cancer only 1 previous 
study has investigated IRP expression, noting a decrease in IRP1 (and TfR1) mRNA expression in 
cancerous tissue but no difference in IRP2 expression. 259 IRP2 expression was noted to be higher in 
T3 tumours relative to T1 and T2, however.  
 
As colorectal adenocarcinomas have an excess of intracellular iron, IRP2 (and subsequently TfR1 and 
DMT1) should be suppressed in tumours relative to normal mucosa, thus preventing the further 
accumulation of iron. As discussed earlier, this is not the case and thus this feedback mechanism 
must be perturbed within the process of tumourigenesis. Over or aberrant expression of IRP2 may 
therefore serve as the driver of excess iron accumulation and subsequent tumour growth. 
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5.2 Chapter Aims 
 
Colorectal adenocarcinomas load iron rendering them sensitive to the effects of iron deprivation 
through chelation. Whether or not this increase in iron import is through an IRP2 mediated response 
is not yet known. If it is, then tumour IRP2 expression could serve as a surrogate marker for iron 
dependency and thus serve as a predictor of chelation efficacy. Furthermore, the relationship 
between genetic mutations pertinent to colorectal adenocarcinoma and IRP2 expression has never 
been determined. As such, the aims for this chapter are: 
 
1. To determine the expression of IRP2 (at both the mRNA and protein level) in human 
colorectal adenocarcinoma tissue and compare this with normal mucosa. 
2. To determine how the expression of IRP2 correlates with the expression of the main iron 
import protein TfR1 in human colorectal adenocarcinoma tissue. 
3. To determine the effect of IRP2 perturbation on TfR1 and ferritin expression in-vitro 
4. To determine the effect of IRP2 perturbation on cell phenotype in-vitro. 
5. To determine the relationship between genetic mutations pertinent to colorectal 
adenocarcinoma and IRP2 expression. 
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5.3 Results 
 
5.3.1 The expression of IRP2 in colorectal adenocarcinoma  
 
5.3.1.1 Overview 
 
RNA was extracted from the frozen tissue of 41 patients undergoing surgical resection for 
histologically proven colorectal adenocarcinoma. In addition, paraffin sections were available from a 
separate cohort of 32 patients with colorectal adenocarcinoma undergoing resection. These samples 
were processed separately for immunohistochemical analysis of IRP2 protein expression.   
 
5.3.1.2 Results 
 
IRP2 was significantly over-expressed at both the mRNA and protein levels in colorectal 
adenocarcinoma compared to normal mucosa. 
 
In terms of mRNA, IRP2 expression was significantly higher in adenocarcinoma than in normal 
mucosa (median fold change 8.80, mean fold change 200.19, p<0.05 vs. normal mucosa, Figure 5.1). 
When sub-group analysis was performed, IRP2 up-regulation appeared to be a colonic (rather than 
rectal) phenomenon (Figure 5.2) and was greatest in proximal (caecum/ascending colon) and locally 
advanced (T3 and T4) lesions (Figure 5.3).       
 
At the protein level, IRP2 was ubiquitously but weakly expressed in normal colorectal crypts (Figure 
5.4 a-d) with lymphocytes staining strongly throughout. Semi-quantitive scoring of slides 
demonstrated that colorectal adenocarcinoma sections (Figure 5.4 e-p) showed greater intensity of 
staining and a larger percentage of cells with positive nuclear staining compared to normal tissue 
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(tumour median score 5 versus normal mucosa median score 3, p=0.004). Expression was 
particularly high in tumours of a mucinous phenotype (Figure 5.4 k and l) relative to all other 
tumours (median score 7.5, p=0.049) and normal tissue (p=0.0027). Normal small bowel tissue 
showed high intensity staining in the bases of crypts (Figure 5.4 q and r) where proliferation is 
known to be greatest. 
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Figure 5.1 IRP2 mRNA expression is significantly up-regulated in colorectal adenocarcinoma tissue 
relative to matched normal mucosa 
qRT-PCR analysis of 41 matched colorectal adenocarcinoma and associated normal mucosa 
demonstrating significant up-regulation in IRP2 mRNA expression in adenocarcinoma samples 
relative to control (mean fold change 200.19, p<0.05 vs. normal mucosa).  
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B 
Figure 5.2 IRP2 mRNA is significantly up-regulated in the colon but not in the rectum 
qRT-PCR (A) demonstrating that IRP2 mRNA is significantly up-regulated compared to matched 
normal mucosa in the colon (n=24) but not in the rectum (n=9). Proximal (n=13) colonic tumours 
displayed a significant up-regulation in IRP2 mRNA expression (B) on sub-group analysis.  Data points 
represent mean fold change in IRP2 mRNA relative to matched normal mucosa, error bars denote 
±SEM, * p<0.05 vs. normal mucosa, p=0.054 all colon vs. rectum. 
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Figure 5.3 IRP2 mRNA is significantly up-regulated in T3 and T4 adenocarcinomas 
qRT-PCR demonstrating that IRP2 mRNA is significantly up-regulated compared to matched normal 
mucosa in T3 (n=20) and T4 (n=10) colorectal adenocarcinomas but not T2 (n=9). Data points 
represent mean fold change in IRP2 mRNA relative to matched normal mucosa, error bars denote 
±SEM, * p<0.05 vs. normal mucosa. 
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Figure 5.4 IRP2 protein expression is significantly increased in colorectal adenocarcinoma  
Immunohistochemistry on paraffin embedded tissue sections taken from colorectal adenocarcinoma 
(e-p), adjacent normal mucosa (a-d) and small bowel specimens (q and r) stained for expression of 
IRP2. Low power images taken at magnification x20 or x40, high power images taken at x100. 
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5.3.2 Correlation of IRP2 expression with that of TfR1  
 
5.3.2.1 Overview 
 
The cDNA generated from the 41 samples of matched adenocarcinoma and normal mucosa in 5.3.1 
was utilised to quantify TfR1 mRNA expression by qRT-PCR. This was then also correlated on a 
sample by sample basis with the IRP2 mRNA expression data using the Spearman’s Rank Correlation. 
 
5.3.2.2 Results 
 
TfR1 mRNA expression was significantly up-regulated in samples of colorectal adenocarcinoma 
compared to matched normal mucosa (median fold change 12.54, mean fold change 314.11 vs. 
control, p<0.05, Figure 5.5A). Expression of TfR1 was positively and significantly correlated with that 
of IRP2 (Figure 5.5B). 
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Figure 5.5 TfR1 mRNA expression is significantly up-regulated and correlates positively with IRP2 
mRNA expression in colorectal adenocarcinoma tissue relative to matched normal mucosa 
qRT-PCR analysis (A) of 41 matched colorectal adenocarcinoma and associated normal mucosa 
demonstrating significant up-regulation in TfR1 mRNA expression in adenocarcinoma samples 
relative to control (mean fold change 314.11, p<0.05 vs. normal mucosa). This significant up-
regulation in TfR1 expression correlates with IRP2 mRNA expression (B) with a Spearman’s Rank 
Correlation score of 0.908 (p<0.001). 
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5.3.3 The effect of IRP2 perturbation on the expression of TfR1 and ferritin in-vitro  
 
5.3.3.1 Overview 
 
IRP2 expression was perturbed in RKO colorectal adenocarcinoma cells using an siRNA knockdown 
system (see methods chapter for full explanation). qRT-PCR was utilised to confirm successful 
knockdown of IRP2 at the mRNA level before the subsequent performance of Western blotting to 
determine the effect on protein expression. In addition, the effect of IRP2 knockdown on TfR1 and 
ferritin mRNA and protein expression was also delineated again through qRT-PCR and Western 
blotting respectively. A ferritin ELISA was also utilised to further quantify ferritin protein expression. 
 
5.3.3.2 Results 
 
Significant knockdown in IRP2 expression at the mRNA level was demonstrated after 24 hours 
incubation with siRNA (46.0% reduction vs. control (Silencer® Select Negative Control siRNA #1), 
Figure 5.6A). This was accompanied by a significant reduction in the expression of TfR1 (33.7% 
reduction vs. control, Figure 5.6B).  
 
At the protein level, Western blotting demonstrated that IRP2 expression was significantly reduced 
by 49.5% following siRNA knockdown (Figure 5.7A) and this was accompanied again by a significant 
reduction in TfR1 expression (60.8% vs. control, Figure 5.7B). Ferritin expression was increased 18.4 
fold (Figure 5.8A) on Western blotting, although this did not reach the threshold for statistical 
significance on semi-quantitative analysis (p=0.150). A significant increase in ferritin protein 
expression was seen, however, when a ferritin ELISA was performed on samples treated with IRP2 
siRNA (Figure 5.8B). 
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Figure 5.6 Reduction of IRP2 mRNA expression through siRNA is associated with decreased TfR1 
mRNA expression in colorectal adenocarcinoma cells in-vitro 
qRT-PCR (A) demonstrating significant knockdown of IRP2 in RKO colorectal adenocarcinoma cell 
lines after 24 hours using siRNA. This was associated with a significant reduction in TfR1 mRNA 
expression (B). Data points represent mean fold change in mRNA expression relative to control 
siRNA, error bars denote ±SEM, * p<0.05 vs. control siRNA. 
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Figure 5.7 Reduction in IRP2 mRNA expression through siRNA knockdown is associated with 
decreased IRP2 and TfR1 protein expression in-vitro 
Representative Western blot (A) demonstrating significant reduction in IRP2 protein expression in 
RKO cells following treatment with siRNA (where C=control siRNA, K=knockdown=IRP2 siRNA). This 
was accompanied by a significant reduction in TfR1 protein expression, as demonstrated by 
representative Western blot (B). Semi-quantitative analysis of blots was performed through 
normalisation to β-Actin and subsequent expression as a fold change relative to control siRNA 
(normalised to 1). Data points represent mean fold change in protein expression relative to control 
siRNA, error bars denote ±SEM, * p<0.05 vs. control siRNA. 
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Figure 5.8 Reduction in IRP2 mRNA expression through siRNA knockdown is associated with 
increased ferritin protein expression in-vitro 
Representative Western blot (A) demonstrating an increase in RKO ferritin protein expression 
following treatment with IRP2 siRNA (where C=control siRNA, K=knockdown=IRP2 siRNA). This was 
confirmed through a ferritin ELISA (B). Semi-quantitative analysis of blots was performed through 
normalisation to β-Actin and subsequent expression as a fold change relative to control siRNA 
(normalised to 1). Data points  in (A) represent mean fold change in protein expression relative to 
control siRNA, error bars denote ±SEM, * p<0.05 vs. control siRNA. Data points in (B) represent mean 
ng ferritin per µg of cellular protein, error bars denote ±SEM, * p<0.05 vs. control siRNA. 
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5.3.4 The effect of IRP2 perturbation on colorectal adenocarcinoma phenotype in-vitro  
 
5.3.4.1 Overview 
 
Following the demonstration that successful knockdown of IRP2 with siRNA at the mRNA level was 
associated with a reduction in IRP2 and TfR1 protein expression and a paradoxical increase in ferritin 
protein expression (in keeping with the classical IRP2 response), the effect of IRP2 perturbation on 
RKO cellular phenotype was assessed.  
 
RKO cells were exposed to the siRNA knockdown regimen for 24 hours as in the previous experiment 
before being treated with DMEM containing 100 µM FeSO4 (and 500 µM Na Ascorbate) for 1 hour. 
After this time cellular iron loading was assessed by way of ferrozine assay. 
 
In addition, the effect of IRP2 knockdown on colorectal cell cycle progression was evaluated using 
FACS. Cells were again treated with the knockdown regimen for 24 hours prior to being harvested. In 
addition, a 2nd group was included where cells were exposed to 100 µM FeSO4 (and 500 µM Na 
Ascorbate) for 1 hour immediately prior to being harvested for FACS. All IRP2 knockdown, ferrozine 
and FACS protocols were performed as outlined in sections 2.2.9 and 2.2.12. 
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5.3.4.2 Results 
 
RKO cells that had been subjected to the IRP2 knockdown regimen had a significantly lower iron 
loading capacity than their control counterparts (47.2% reduction in iron loading vs. control, p<0.05, 
Figure 5.9).  
 
IRP2 knockdown also resulted in an increased proportion of cells within G1 of the cell cycle (53.2 vs. 
46.9%, p<0.05, Figure 5.10) and a corresponding reduction in the proportion in G2/M (21.3 vs. 
25.0%, p<0.05). This was reversed by the addition of 100 µM iron. 
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Figure 5.9 Reduction in IRP2 mRNA expression through siRNA knockdown is associated with a 
reduction in colonic adenocarcinoma cellular iron loading in-vitro  
Ferrozine assay demonstrating decreased intracellular iron uptake in RKO cells treated with IRP2 
siRNA for 24 hours relative to control siRNA. Both groups were exposed to media containing 100 µM 
FeSO4 for 1 hour prior to the assay being performed. Data points represent mean intracellular iron 
content (nM Fe / µg cellular protein), error bars denote ±SEM, * p<0.05 vs. control. 
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Figure 5.10 Reduction in IRP2 mRNA expression through siRNA knockdown is associated with cell 
cycle perturbation in colorectal adenocarcinoma cells in-vitro  
Cells cycle analysis through FACS with propidium iodide (A and B) of RKO cells treated with IRP2 
siRNA for 24 hours. Successful knockdown of IRP2 at the mRNA level was associated with a 
significant increase in the proportion of cells in G1 and a corresponding reduction in G2/M compared 
to control siRNA (C). This phenotype was reversed by the exposure of cells to 100 µM FeSO4. Data 
points in (C) represent mean % of cells in corresponding phase of cell cycle, error bars denote ±SEM, 
* p<0.05 vs. control siRNA. 
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5.3.5 The relationship between genetic mutations pertinent to colorectal adenocarcinoma and 
IRP2 expression 
 
5.3.5.1 Overview 
 
A relationship between the dysregulation of iron metabolism and mutation of the tumour 
suppressor APC has previously been demonstrated in colorectal cancer. 102, 132 The association of APC 
with IRP2, however, has not been specifically assessed, nor has its association with other pertinent 
genetic mutations (p53, K-ras, B-raf, PIK3CA etc.).   
 
The Cancer Genome Atlas (TCGA), an online open-access repository containing tumour genetic 
mutation and protein expression data sets (cbioportal.org), was explored to identify correlations 
between gene mutation status and IRP2 protein expression levels. Mutation status was obtained for 
APC, K-ras, B-raf, c-Myc, PIK3CA and p53 genes while mRNA expression data, presented as z scores, 
was gathered for IRP2. Any positive trends found were then subjected to univariate and multivariate 
analysis.  
 
5.3.5.2 Results 
 
The only significant association demonstrated following exploration of the TCGA and subsequent 
statistical analysis was that between mutation in B-raf and IRP2 over-expression. A significant 
positive association between IRP2 mRNA expression and B-raf mutation status in 19 CRC samples 
(odds ratio 1.668 on multivariate analysis, p=0.032) was seen (Figure 5.11).   
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Figure 5.11 B-raf mutations are associated with increased IRP2 mRNA expression in colorectal 
adenocarcinoma 
The Cancer Genome Atlas was interrogated to reveal a significant positive association between IRP2 
mRNA expression and B-raf mutation status in 19 CRC samples (odds ratio 1.668 on multivariate 
analysis, p=0.032). 
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5.3.6 The influence of B-raf mutation status and MAPK pathway activity on IRP2 expression in 
colorectal adenocarcinoma in-vitro 
 
5.3.6.1 Overview 
 
To further investigate the apparent association between mutations in B-raf and IRP2 protein 
expression demonstrated in 5.3.5 a doxycycline inducible B-raf V600E construct was created and 
stably transfected into the HCT116 colorectal adenocarcinoma cell line (as outlined in the methods 
chapter). Once established, the cell line was utilised to assess the effect of both B-raf V600E 
induction and subsequent amplification of the MAPK signalling pathway upon IRP2 protein 
expression. Western blotting was performed following Doxycycline induction of the B-raf V600E 
vector using antibodies directed against B-raf, IRP2 and p-ERK (a marker of MAPK activitiy). In 
addition, the dual MEK inhibitor Trametinib and the B-raf inhibitor Sorafenib were utilised to assess 
the effect of B-raf and or MAPK inhibition on IRP2 expression. Antibodies against TfR1 and ferritin 
were also utilised to quantify effects on downstream targets of IRP2. 
 
5.3.6.2 Results 
 
Treatment of the HCT116 B-raf V600E transfected cell line with 1µg/ml of Doxycycline resulted in a 
profound and statistical increase in B-raf expression by Western blotting (12.6 fold induction, p<0.05 
vs. control, Figure 5.12). This did not, however, alter IRP2 protein expression. Of note, levels of p-
ERK were also not statistically changed, indicating activity of the MAPK signalling pathway had not 
been significantly up-regulated by the increased B-raf expression. 
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An empty vector construct (HCT116 EV) was also cloned and transfected into HCT116 cells as a 
negative control. Western blotting was next performed at baseline (in un-stimulated conditions) to 
assess p-ERK and IRP2 activity in both the EV and V600E cell lines (Figure 5.13). Interestingly, p-ERK 
activity was 4.5 fold elevated in the V600E cell line compared to the EV and IRP2 levels also exhibited 
an almost 2 fold increase.  
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Figure 5.12 B-raf mutations alone are not associated with increased IRP2 protein expression in-
vitro 
Western blot demonstrating significant increase in B-raf protein expression following incubation of 
HCT116 V600E cells with either standard media (lanes 1-3) or 1 µg/ml of Doxycycline (lanes 4-6). No 
significant difference was seen, however, in either p-ERK or IRP2 protein expression. Semi-
quantitative analysis of blots was performed through normalisation to β-Actin and subsequent 
expression as a fold change relative to control (normalised to 1). Data points represent mean fold 
change in protein expression relative to control, error bars denote ±SEM, * p<0.05 vs. control. 
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Figure 5.13 B-raf mutations are likely to increase cellular IRP2 protein expression through elevated 
p-ERK in-vitro 
Western blot demonstrating baseline p-ERK activity in HCT116 cells transfected with a BRAF V600E 
inducible vector (lanes 4-6) and those transfected with an empty vector control (lanes 1-3). IRP2 
protein expression was significantly increased in the V600E cell line.  Semi-quantitative analysis of 
blots was performed through normalisation to β-Actin and subsequent expression as a fold change 
relative to control (normalised to 1). Data points represent mean fold change in protein expression 
relative to control, error bars denote ±SEM, * p<0.05 vs. control. 
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The effect of inhibition of the MAPK signalling pathway on IRP2 expression was next assessed using 
the dual MEK inhibitor Trametinib on 3 different colorectal cell lines. SW480 and HCT116 cells 
possess wild type B-raf and a mutant K-ras, whilst the RKO cell line has a mutant B-raf and a wild 
type K-ras.  
 
Administration of Trametinib resulted in a marked and significant reduction in p-ERK protein 
expression in all 3 cell lines (66.7, 58.7 and 94.6% reduction in SW480, HCT116 and RKO cells 
respectively, p<0.05 vs. control, Figure 5.14 A-C). IRP2 protein expression was also significantly 
reduced in the SW480 and HCT116 lines (46.9 and 63.7% respectively, p<0.05) but not in the RKOs. 
TfR1 expression was significantly reduced across all 3 cell lines tested. Both the SW480 and HCT116 
cell lines demonstrated a trend towards increased ferritin expression, although this did not reach 
statistical significance on semi-quantitative analysis. A profound induction in ferritin expression 
(over 30 fold) was seen, however, in the RKO cell line. 
 
Treatment of the RKO cell line with Sorafenib resulted in a significant reduction in p-ERK, IRP2 and 
TfR1 expression (Figure 5.15). Ferritin expression was not significantly altered on this occasion, 
however. 
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Figure 5.14 Treatment of colorectal adenocarcinoma cells with the MEK inhibitor Trametinib is 
associated with a reduction in IRP2 protein expression in-vitro 
Western blots demonstrating the effect of the MEK inhibitor Trametinib (10 nM for 48 hours, lanes 
4-6) upon protein expression in the SW480 (A), HCT116 (B) and RKO (C) colorectal adenocarcinoma 
cell lines compared to standard media control (lanes 1-3). P-ERK was measured as a marker of MEK 
inhibition, TfR1 and ferritin were blotted for as downstream markers of IRP2 activity. Semi-
quantitative analysis of blots was performed through normalisation to β-Actin and subsequent 
expression as a fold change relative to control (normalised to 1). Data points represent mean fold 
change in protein expression relative to control, error bars denote ±SEM, * p<0.05 vs. control. 
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Figure 5.15 Treatment of colorectal adenocarcinoma cells with the B-raf kinase inhibitor Sorafenib 
is associated with a reduction in IRP2 protein expression in-vitro 
Western blot demonstrating change in IRP2, TfR1 and ferritin expression in RKO cells following 
exposure to either standard media (lanes 1-3) or media containing 1 µM Sorafenib (lanes 4-6) for 48 
hours. Semi-quantitative analysis of blots was performed through normalisation to β-Actin and 
subsequent expression as a fold change relative to control (normalised to 1). Data points represent 
mean fold change in protein expression relative to control, error bars denote ±SEM, * p<0.05 vs. 
control. 
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5.4 Discussion 
 
Iron is intimately involved in the propagation of colorectal tumourigenesis. Adenocarcinomas 
accumulate iron, a process aided by the increased expression of key cellular iron import proteins 
(TfR1 and DMT1) and decreased iron export through the perturbation of the basolateral transporter 
ferroportin. 82 This increased intracellular iron serves as a ‘fuel source’ for DNA synthesis, ATP 
generation and cell cycle progression; which then in turn drive cellular proliferation. Iron has also 
been shown to amplify the Wnt signalling pathway, resulting in elevated levels of downstream 
targets including c-Myc, which further serves to aid cellular proliferation and survival. 102, 132 
 
Iron metabolism is co-ordinated at the cellular level by the iron regulatory proteins IRP1 and IRP2. 99 
IRPs facilitate the increased availability of intracellular iron in times of iron depletion through 
stabilising the translation of TfR1 (and to some extent DMT1) and inhibiting translation of ferritin. In 
times of iron repletion, the IRPs are inactive (IRP1 acting instead as a cytosolic acinotase whilst IRP2 
is degraded). 99   
 
The role of the IRPs within the up-regulation of iron metabolism seen in colorectal adenocarcinoma 
has not previously been conclusively determined and thus the findings discussed herein are novel. 
IRP2 over-expression has been linked to the propagation of both lung and breast cancer and hence 
the expression (and subsequent consequences) of it were selected to be determined in colorectal 
adenocarcinoma. 254, 258   
 
In this study, IRP2 was shown to be markedly and significantly over-expressed in samples of 
colorectal adenocarcinoma compared to matched normal mucosa at the mRNA level (mean fold 
change 200.19 vs. normal tissue, p=0.000). TfR1 mRNA levels were also markedly elevated in tumour 
samples (mean fold change 314.11 vs. normal tissue, p=0.000) and correlated positively with IRP2 
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mRNA expression. On sub-group analysis the up-regulation of IRP2 mRNA appeared to be a colonic 
rather than rectal phenomenon and was greatest in tumours that were proximally located (caecum 
or ascending colon) and locally advanced (T3 or T4).  
 
Similarly, immunohistochemical staining revealed IRP2 expression to be significantly increased at the 
protein level in adenocarcinomas compared to normal tissue. Interestingly, mucinous tumours were 
shown to stain strongest for IRP2.   
 
The finding of increased IRP2 expression in colorectal cancer is novel and contradicts the findings of 
a recent study by Hamara and colleagues which demonstrated no significant change in IRP2 mRNA 
levels between tumour and normal mucosa in 73 matched samples.259 Interestingly, the authors of 
the same study also demonstrated a statistical decrease in both IRP1 and TfR1 mRNA expression (the 
opposite to our findings). In agreement with our results, however, it was demonstrated that IRP2 
was up-regulated in T3 tumours (compared to T1 and T2). 259  Increased IRP2 expression has also 
previously been demonstrated to correlate with grade of disease in breast cancer. 258 
 
The positive correlation between IRP2 and TfR1 mRNA expression demonstrates that the 
functionality of the IRE-IRP interaction persists despite the over-expression of IRP2 in colorectal 
cancer. Hamara and colleagues also demonstrated the correlation of IRP2 with TfR1 expression, 
albeit limited to early stage disease. 259 
 
IRP2 expression results in stabilisation of TfR1 translation and inhibition of ferritin mRNA translation. 
This interaction permits an increase in the amount of iron that is free for use within the cell (the so 
called labile iron pool) through increased iron acquisition and a reduction in iron storage. As 
expected, perturbation of IRP2 in this study (through the use of siRNA) resulted in significantly 
decreased TfR1 expression (at both the mRNA and protein levels) and a marked increase in ferritin 
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expression (at the protein level). In turn, this resulted in a significant decrease in the ability of 
colorectal cells to load iron (47.2% reduction vs. control, p<0.05 by ferrozine assay) and a 
subsequent increase in the proportion of cells in G1 of the cell cycle. Again, similar findings have 
been noted previously in breast cancer (where knockdown of IRP2 inhibited cell proliferation and 
stimulated apoptosis) and points to the vital role IRP2 is likely to play in facilitating both the 
increased iron acquisition required for proliferation in cancerous tissue and the amplification of 
oncogenic signalling pathways (such as Wnt). 132, 258 It would therefore be useful in future studies to 
investigate the effect of IRP2 perturbation on Wnt signalling and intracellular free radical formation, 
both processes known to be stimulated by increased labile iron.  
 
Ideally, the use of a more stable knockdown system (e.g. shRNA) would also have facilitated further 
investigation of the effects of IRP2 perturbation on cell proliferation, migration, invasion and 
sensitivity to chemotherapeutic agents (including iron chelation with Deferasirox). Unfortunately, 
this system was not available during the course of this study and therefore investigations were 
limited to the effects of transient IRP2 knockdown within a 24 hour window. 
  
In an attempt to delineate whether the increase in tumour IRP2 expression is merely a response to 
the increased cellular requirement for iron present in malignant tissue or is somehow initiated by 
factors within the tumour itself, exploration of the Cancer Genome Atlas was next performed in 
order to assess the relationship between genetic mutations pertinent to colorectal cancer and IRP2. 
A potential relationship between B-raf mutation and IRP2 protein overexpression (odds ratio 1.7, 
p=0.032) was subsequently demonstrated.  
 
Oncogenic mutations in B-raf occur in approximately 13% of colorectal cancers. 245 B-raf mutations 
signal B-raf serine-threonine kinase activity thus activating the mitogen-activated protein kinase 
(MAPK) signalling cascade (EGFR→RAS→RAF→MEK→ERK1/2) which is involved in the subsequent 
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activation of a significant number of downstream targets involved in cellular proliferation, including 
c-Myc. 245, 260 Interestingly, c-Myc has previously been shown to up-regulate IRP2 expression (but not 
TfR1) and suppress ferritin expression in B cells. 261 Of note, in the same study, the subsequent 
restoration of intracellular ferritin levels (through a vector expressing H-ferritin) inhibited cell 
clonogenicity, indicating the importance of free iron to cell growth and proliferation. In a separate 
study using B-cell lymphoma cell lines, c-Myc was shown to increase the expression of TfR1, 
subsequently leading to an increase in cellular proliferation. 133 Increased c-Myc and ERK 1/2 
phosphorylation has also been demonstrated in lung tumour xenografts expressing increased levels 
of IRP2. 254 
 
B-raf mutant colorectal adenocarcinomas are associated with proximal location, increasing age, 
female gender, microsatellite instability, high grade and mucinous histology. 262 Anecdotally, in this 
study, IRP2 expression was greatest in proximal tumours, those that were locally advanced and in 
tumours of a mucinous appearance, all features found in B-raf mutant tumours. 
 
The successful generation of a cell line transfected with an inducible B-raf V600E construct 
permitted in-vitro assessment of the interaction between B-raf and IRP2. The B-raf V600E mutation 
is the most common B-raf mutation in cancer (accounting for around 90% of mutations) and derives 
from a DNA point mutation (1799 T→A). 262 Within the limits of this study, it was demonstrated that 
induction of B-raf V600E (by almost 13 fold) did not significantly alter IRP2 expression at the protein 
level. Of note, p-ERK levels were also unaltered; a phenomenon that may be partially explained by 
the presence of a constitutively active K-ras mutation within the same cell line thus raising the 
possibility that the MAPK signalling may have already been pre-saturated and was not amenable to 
further stimulation by B-raf, an undoubted limitation of this model. 263  An attempt was made to 
circumvent this problem by repeating the transfection in Colo320 cells (expressing wild type B-raf 
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and K-ras), however, this process was unsuccessful owing to profound puromycin resistance within 
the Colo320 line. Other appropriate cell lines were unavailable within the study time period.   
 
On further investigation, however, using the HCT116 V600E and HCT116 empty vector cell lines it 
was demonstrated that elevated p-ERK signalling at base line was associated with increased IRP2 
protein expression. 
 
Further confirmation of a link between MAPK signalling and IRP2 expression in colorectal cancer was 
sought through administration of the MEK 1/2 inhibitor Trametinib and the B-raf kinase inhibitor 
Sorafenib to a panel of colorectal cell lines. MEK inhibition was associated with decreased IRP2 and 
TfR1 expression in the SW480 and HCT116 cell lines (both with mutant K-ras). In the RKO line 
(displaying mutant B-raf), however, MEK inhibition suppressed TfR1 expression but did not 
significantly alter IRP2 levels. Interestingly, ferritin expression was markedly increased (30 fold). 
Treatment of the RKO cell line with the B-raf inhibitor Sorafenib, however, did significantly suppress 
both IRP2 and TfR1 protein expression. 
 
It is likely that the link between increased MAPK signalling and elevated IRP2 expression is through 
the proto-oncogene c-Myc. IRP2 has previously been shown to correlate with c-Myc expression in 
studies using lung and haematological cell lines. 254, 261 Interestingly, mutation of the tumour 
suppressor APC is also known to elevate levels of c-Myc. 102 Further work looking at the effect of c-
Myc perturbation (either through knockout or over expression) on the link between MAPK and IRP2 
would undoubtedly be useful in delineating this relationship further. Furthermore, the effect of 
stimulation of colorectal cells with MAPK ligands (e.g. epidermal growth factor or amphiregulin) and 
subsequent effect on iron metabolism could be assessed. Anecdotally, preliminary experiments 
within this study period have indicated a dose dependent increase in IRP2 mRNA expression 
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following stimulation of RKO cells with EGF (data not shown). Further work is needed, however, 
before any conclusions can be drawn from this. 
 
It has been demonstrated in this chapter that IRP2, an important regulator of intracellular iron 
acquisition, is markedly over expressed at both the mRNA and protein levels in colorectal cancer. 
Furthermore, this over expression results in increased potential for the acquisition of iron through 
elevated levels of the iron import protein TfR1. IRP2 expression appears to be greatest in colonic 
tumours (particularly those arising proximally, that are locally advanced and of a mucinous type). 
Knockdown of IRP2 results in the classical IRE-IRP response of decreased TfR1 and increased ferritin 
expression. In turn, this decreases the ability of the cell to acquire iron and results in perturbation of 
the cell cycle that is over turned through the subsequent administration of iron.  
 
Furthermore, IRP2 over expression appears to be linked to over activity of the MAPK signalling 
cascade, a pathway known to be constitutively active in a significant proportion of colorectal 
cancers. 260 Much research has been conducted into this signalling cascade and has led to the 
development of a number of monoclonal antibodies (e.g. Cetuximab) and small molecule tyrosine 
kinase inhibitors (e.g. Sorafenib) that already serve as adjuncts to existing chemotherapeutic 
regimens. 260 Unfortunately, acquired and primary resistance to therapy with these agents is a 
problem and therefore the demonstration of a link between MAPK signalling and IRP2 protein 
expression raises the possibility that iron chelation therapy with Deferasirox could serve as an 
additional therapy adjunct. 264 Furthermore, if MAPK activation (be it through K-ras or B-raf 
mutation) is a marker of IRP2 expression (which in turn is a surrogate marker for cellular iron 
requirement) then this offers the potential for selective therapy based on the genetic status of the 
tumour at the time of therapy initiation. 
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Further work is undoubtedly required in this area before affirmative conclusions can be drawn, 
however, the work undertaken in this chapter has led to a number of novel findings which offer 
direction for future research into iron chelation as a potential treatment for colorectal cancer. 
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Chapter 6.  Drug redeployment: A useful tool in gastrointestinal cancer? 
 
6.1 Introduction 
 
Owing to the known dysregulation of iron metabolism within neoplastic cells, there is significant 
interest in the potential of iron chelators to act as anti-cancer agents in their own right. 80, 92 
Furthermore, there is also evidence that iron chelators may be capable of both overcoming 
established chemotherapy resistance and of acting as chemosensitising agents. 139, 177  At present, 
however, much of this work has been carried out using experimental agents that (in part owing to 
significant side effects in pre-clinical models) are not currently licensed for use in humans. 139, 140, 141  
Thus, the demonstration here (in chapters 3 and 4) that a licensed chelator (Deferasirox) possesses 
potent anti-neoplastic and chemosensitising properties in gastrointestinal cancer is of great promise.  
 
At present, the use of Deferasirox in clinical practice is restricted to the treatment of conditions 
associated with chronic iron overload (such as β-thalassaemia) and it has never before been used as 
a direct treatment for any form of cancer. As such, the discovery in the current study that 
Deferasirox possesses potential efficacy as an anti-cancer therapy can also be said to represent a 
form of drug repurposing or redeployment. 
 
The development of novel anti-cancer therapies is an immensely expensive and time-consuming 
process. 265 On average, it takes 13 years of research and over $1.8 billion to bring a single drug from 
the laboratory bench to the patient’s bedside.266 In addition, studies have demonstrated that only 1 
in every 5-10,000 prospective anti-cancer agents receives formal clinical approval and only 5% of 
oncology drugs entering Phase I clinical trials are ever approved for use. 265, 267 Even if a drug 
proceeds to clinical trials, the final product is often extremely expensive (in part due to the costs 
incurred by the drug companies in reaching that point) and may be associated with a number of 
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significant side effects. Furthermore, they may ultimately make only marginal improvements in 
overall disease survival. 265 As such, the approval of new anti-cancer agents for routine clinical use 
can be an immensely emotive subject as health service providers are forced to weigh up cost benefit 
ratios prior to advocating widespread adoption. Examples of this in the UK include the introduction 
of the monoclonal antibody Trastuzumab (Herceptin) for the treatment of breast cancer and, more 
recently, its successor Trastuzumab emtansine (Kadcyla), which at present has been rejected for 
clinical use by the National Institute for Health and Care Excellence (NICE) on the grounds of cost. 268 
 
Thus, alternative routes for the discovery of new agents effective against cancer are required. One 
such avenue now being extensively employed is that of drug redeployment. The field of drug 
redeployment involves the systematic screening of existing licensed compounds for efficacy in 
diseases other than those for which they are traditionally used to treat (i.e. cancer). 200 This process 
is based on the knowledge that, owing to the common molecular origins of diverse diseases, 
approximately 90% of approved drugs may possess secondary indications and could be used for 
other purposes.269 The major advantage of this approach to cancer drug development is that prior 
knowledge of the pharmacological and toxicity profiles of existing drugs (gained through their 
current use) is likely to permit entry into phase II and III trials at a much faster rate. 265 Indeed, recent 
studies have estimated that, whilst only 10 and 50% of new agents make it to market having entered 
phase II and III trials respectively, the figure is closer to 25 and 65% for redeployed agents. 265, 270 As 
well as reducing the time it takes for new agents to come to market, drug redeployment also has the 
advantage that, as agents are often older and thus off patent, final market costs are likely to be 
significantly reduced. 
 
The process of drug repurposing typically takes one of two forms: ‘on-target repurposing’ attempts 
to utilise drugs which are known to act through a relevant mechanism of action but which currently 
have a different clinical indication, whilst ‘off-target repurposing’ or systematic serendipity involves 
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the random screening of drugs with no known association, in the hope of demonstrating efficacy and 
a subsequent novel mechanism of action. 271 
 
Redeployed drugs that have been successfully shown to possess marked anti-cancer effects include 
thalidomide (which has been shown to possess anti-angiogenic and NFκB inhibiting properties in a 
number of haematological malignancies), aspirin (through inhibition of platelet aggregation, 
cyclooxygenase enzymes, Wnt signalling and also NFκB amongst other mechanisms), statins (again 
through NFκB inhibition), metformin (through inhibition of the mTOR pathway) and finally 
methotrexate. 265 
 
Of note, systematic drug redeployment screens have also revealed agents that may be ineffective 
solely yet become highly efficacious in combination with other redeployed agents. An example of 
this includes the combination of the lipid-lowering drug Bezafibrate and the sex hormone 
Medroxyprogesterone acetatate in the treatment of acute myeloid leukaemia and Burkitt’s 
lymphoma. 272, 273  This raises the potential that combining agents with an iron chelator (such as 
Deferasirox) may also yield efficacious combinations. 
 
The use of drug redeployment approaches within gastrointestinal cancer, however, has thus far 
been limited. As stated previously, systemic therapy is utilised in the treatment of both oesophageal 
and colorectal cancer with variable tumour response. 41, 42, 235 Agents are typically used in 
combination in an attempt to exert effects on a number of pathways simultaneously and also in 
some instances to illicit synergy between compounds (e.g. Leucovorin and 5-Fu in colon cancer). 274 
As such, it seems logical to assess the usefulness of adopting a drug redeployment approach for the 
identification of new agents that may be effective either alone or in combination with Deferasirox 
against these diseases.  
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6.2 Chapter Aims 
 
Having already demonstrated a form of drug redeployment using the iron chelator Deferasirox (an 
on-target approach using the knowledge that cancer cells have a higher requirement for iron and 
that iron metabolism itself is dysregulated in gastrointestinal cancer), it was decided to next 
serendipitously screen a library of 99 licensed, off-patent reagents both alone and in combination 
with Deferasirox against a panel of gastrointestinal cell lineages to identify agents or combinations 
that may display anti-neoplastic properties in this area. As such, the aims for this chapter are: 
 
1. To identify any synergistic combinations between a panel of redeployed drugs and the iron 
chelating agent Deferasirox in oesophageal and colorectal carcinoma in-vitro. 
2. To identify agents with potential anti-neoplastic properties against colorectal 
adenocarcinoma in-vitro using a drug redeployment approach. 
3. To determine the effect of p53 status on the efficacy of redeployed agents in colorectal 
adenocarcinoma in-vitro. 
4. To determine the effect of hypoxia on the efficacy of redeployed agents in colorectal 
adenocarcinoma in-vitro. 
5. To identify agents with potential anti-neoplastic properties against oesophageal carcinoma 
in-vitro. 
6. To validate any promising agents in-vivo using a murine xenograft model of oesophageal 
adenocarcinoma. 
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6.3 Results 
 
6.3.1 The determination of any synergy between the redeployed drugs and the iron chelating 
agent Deferasirox in colorectal adenocarcinoma in-vitro 
 
6.3.1.1 Overview 
 
Deferasirox has previously shown potential synergy (particularly at sub-therapeutic doses) in studies 
in this thesis when given with common chemotherapeutic agents in both oesophageal (Figure 3.3C) 
and colorectal (Figure 4.7D) carcinoma. As such, the potential for Deferasirox to form synergistic 
combinations was investigated using a selection of redeployed drugs (Table 2.2) in colorectal 
adenocarcinoma.200  
 
The whole drug redeployment library was initially screened against the HCT116 p53WT cell line, with 
or without the presence of Deferasirox at the sub-therapeutic concentration of 1 µM.  MTT assays 
were performed to determine effect on cell viability. Deferasirox was utilised at a sub-therapeutic 
concentration as it had previously proved to be so potent in isolation at higher doses that any 
potential synergy could be masked in these experiments. 
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6.3.1.2 Results 
 
Following provisional screening of the redeployed library with or without the presence of 
Deferasirox (1 µM) against the HCT116 p53WT cell line (which did not identify any statistically 
significant synergistic relationships, data not shown here) promising agents were re-tested against a 
broader panel of colorectal lines (Figure 6.1). Of note, Valproic acid demonstrated synergy with 
Deferasirox across all of the lines tested. Furthermore, an additional reduction in cellular viability 
was also seen in 2 of the cell lines tested when Niclosamide was cultured alongside Deferasirox. 
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Figure 6.1 The redeployed drugs Niclosamide and Valproic acid are efficacious against colorectal adenocarcinoma cell lines in-vitro and demonstrate synergy when 
combined with a low dose of the iron chelator Deferasirox 
Cell viability assay (MTT) demonstrating the efficacy of the redeployed agents Niclosamide and Valproic acid against the colorectal adenocarcinoma cell lines RKO, SW480 
and HCT116. In addition, it appears the respective efficacy of each drug can be improved further by co-incubation with Deferasirox (1 µM). Data points represent mean fold 
change relative to control (normalised to 1), error bars denote ±SEM, * p<0.05 vs. control, # p<0.05 vs. equivalent drug without Deferasirox.  
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6.3.2 The efficacy of redeployed drugs against colorectal adenocarcinoma in-vitro 
 
6.3.2.1 Overview 
 
The library of redeployed drugs was screened alone for efficacy against a panel of colorectal 
adenocarcinoma cell lines in-vitro (RKO, SW480 and HT29). In addition, agents were also screened 
against the colorectal cell line SW620 (which is a metastatic clone arising from the same patient as 
the SW480 cell line) to see if there were any differences in efficacy between primary and metastatic 
lines. 
 
6.3.2.2 Results 
 
A number of agents demonstrated a significant effect on colorectal cell line viability (Figure 6.2 A-C). 
Of note, the anti-gout agent Colchicine and the anti-helminthic Mebendazole demonstrated marked 
effects across all 3 lines tested. 
 
Both Colchicine and Mebendazole were equally effective in the SW620 cells as they were in the 
SW480 (Figure 6.3). This was not the case with the existing chemotherapeutic agent 5-Fu, which did 
not exert a significant suppression of cellular viability compared to control and was also significantly 
less effective than in the SW480 line. 
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Figure 6.2 The effect of redeployed drugs on colorectal adenocarcinoma cell line viability in-vitro 
 
A. RKO 
Drug Fold Change (vs. Control) P Value Chloroquine 0.717 0.014
Control 1.000 Valproic acid 0.718 0.140
Mebendazole 0.213 0.001 Zinc acetate 0.719 0.204
Methotrexate 0.232 0.002 Propantheline 0.722 0.030
Colchicine 0.236 0.001 Alverine citrate 0.723 0.046
5-Fluorouracil 0.372 0.003 Fluoxetine 0.726 0.138
Nicotine 0.391 0.048 Norethisterone 0.726 0.114
Desferrioxamine 0.439 0.075 Acitretin 0.732 0.148
Trimethoprim 0.449 0.050 Thalidomide 0.732 0.125
Danazol 0.461 0.130 Artemisinin 0.733 0.160
Calciferol/ergocalciferol 0.476 0.085 Carbamazepine 0.742 0.037
Omeprazole 0.494 0.141 Chlorpheniramine 0.743 0.249
Mifepristone 0.521 0.051 Pravastatin 0.744 0.170
Naloxone 0.552 0.214 Thiamine 0.747 0.002
Domperidone 0.556 0.166 Vitamin K1 0.752 0.338
Bezafibrate 0.573 0.092 Ascorbic acid 0.755 0.277
Testosterone 0.587 0.087 Clobetasol propionate 0.755 0.052
Paroxetine 0.587 0.086 Metformin 0.756 0.058
Dantrolene sodium 0.592 0.166 Alpha tocopheryl acetate 0.757 0.075
Medroxyprogesterone acetate 0.599 0.094 Ritodrine 0.766 0.079
Acipimox 0.609 0.097 Flecainide 0.782 0.376
Nortryptyline 0.612 0.112 Paracetamol 0.784 0.060
Chlorambucil 0.616 0.046 Nicotinamide 0.787 0.135
Prochlorperazine 0.617 0.015 Praziquantel 0.787 0.473
Imatinib 0.620 0.100 Finasteride 0.788 0.153
Diltiazem 0.622 0.062 Rifampicin 0.789 0.179
Fluconazole 0.633 0.095 Methanol 0.799 0.262
Niclosamide 0.633 0.066 Ampicillin 0.801 0.259
Water 0.635 0.100 Acyclovir 0.816 0.453
Clofibric acid 0.638 0.242 Neostigmine 0.821 0.286
Itraconazole 0.640 0.027 Amantidine 0.824 0.014
Amphotericin b 0.648 0.108 Ranitidine 0.824 0.042
Mefenamic acid 0.654 0.000 DMSO 0.828 0.097
Fenofibrate 0.663 0.106 Allopurinol 0.829 0.289
Selegiline 0.674 0.039 Propanolol 0.833 0.296
Vitamin B12 0.675 0.159 Metronidazole 0.834 0.488
DMEM (2) 0.676 0.086 Doxycycline 0.840 0.125
Simvastatin 0.680 0.190 Ibuprofen 0.843 0.061
Erythromycin 0.686 0.037 Imipramine 0.849 0.086
DMEM (1) 0.690 0.175 Cyclophosphamide 0.852 0.566
Levothyroxine 0.690 0.108 Prednisolone 0.857 0.113
Methyldopa 0.698 0.030 Theophylline 0.873 0.375
Ethanol 0.703 0.279 Flutamide 0.875 0.515
Clomipramine 0.704 0.128 Bromocriptine 0.880 0.536
Penicillin V 0.705 0.047 Folic acid 0.886 0.274
Diclofenac 0.710 0.055 Nicotinic acid 0.887 0.137
Flupentixol 0.712 0.140 Dexamethasone 0.908 0.198
Mesalazine 0.713 0.124 Bendroflumethiazide 0.937 0.818
Pilocarpine 0.714 0.276 Retinol 0.967 0.804
Cefaclor 0.717 0.108 Propylthiouracil 0.973 0.846
Metoclopromide 0.717 0.220 Aspirin 1.032 0.827
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B. SW480 
Drug Fold Change (vs. Control) P Value Rifampicin 0.786 0.251
Control 1.000 Erythromycin 0.788 0.225
Colchicine 0.104 0.000 Zinc acetate 0.789 0.025
Mebendazole 0.119 0.000 DMEM (1) 0.789 0.067
Desferrioxamine 0.372 0.033 Methanol 0.789 0.105
Nicotine 0.438 0.109 Nicotinamide 0.790 0.047
Methotrexate 0.472 0.010 Praziquantel 0.793 0.073
Niclosamide 0.472 0.060 Flutamide 0.803 0.091
Calciferol/ergocalciferol 0.508 0.026 Neostigmine 0.806 0.050
Omeprazole 0.517 0.092 Ampicillin 0.809 0.023
Acipimox 0.528 0.065 Chlorpheniramine 0.814 0.187
Naloxone 0.530 0.160 Diclofenac 0.815 0.072
Danazol 0.537 0.174 Thiamine 0.820 0.258
Trimethoprim 0.552 0.014 Thalidomide 0.821 0.102
5-Fluorouracil 0.557 0.012 Propantheline 0.823 0.077
Mifepristone 0.577 0.153 Metoclopromide 0.834 0.198
Ethanol 0.578 0.164 Prednisolone 0.836 0.175
Flupentixol 0.588 0.018 Prochlorperazine 0.839 0.033
Mefenamic acid 0.622 0.093 Vitamin K1 0.846 0.006
Clomipramine 0.636 0.011 DMSO 0.847 0.163
Testosterone 0.640 0.015 Fluoxetine 0.851 0.228
Dantrolene sodium 0.647 0.033 Chloroquine 0.852 0.289
Bezafibrate 0.662 0.006 Acitretin 0.852 0.214
Amphotericin b 0.663 0.038 Vitamin B12 0.857 0.420
Clofibric acid 0.673 0.027 Folic acid 0.860 0.093
Nortryptyline 0.676 0.166 Mesalazine 0.861 0.588
Medroxyprogesterone acetate 0.694 0.050 Ranitidine 0.864 0.004
Norethisterone 0.703 0.008 Amantidine 0.867 0.032
Methyldopa 0.703 0.157 Penicillin V 0.870 0.467
Domperidone 0.707 0.160 Cefaclor 0.875 0.502
Paroxetine 0.708 0.014 Paracetamol 0.876 0.610
Itraconazole 0.724 0.051 Aspirin 0.877 0.419
Metformin 0.724 0.064 Metronidazole 0.878 0.212
Diltiazem 0.726 0.136 Bendroflumethiazide 0.879 0.315
Imatinib 0.726 0.067 Ibuprofen 0.880 0.304
Selegiline 0.727 0.018 Simvastatin 0.888 0.508
Valproic acid 0.727 0.189 Bromocriptine 0.888 0.122
Water 0.729 0.024 Dexamethasone 0.889 0.215
Fluconazole 0.734 0.142 Propanolol 0.890 0.271
Chlorambucil 0.739 0.147 Pilocarpine 0.891 0.373
Alpha tocopheryl acetate 0.742 0.065 Theophylline 0.892 0.046
Levothyroxine 0.748 0.014 Clobetasol propionate 0.892 0.522
Fenofibrate 0.753 0.024 Ascorbic acid 0.900 0.343
Alverine citrate 0.755 0.189 Acyclovir 0.922 0.172
Pravastatin 0.756 0.057 Propylthiouracil 0.928 0.227
Cyclophosphamide 0.757 0.002 Imipramine 0.928 0.615
Carbamazepine 0.758 0.090 Nicotinic acid 0.938 0.225
Artemisinin 0.760 0.009 Allopurinol 0.940 0.101
DMEM (2) 0.767 0.021 Doxycycline 0.959 0.768
Finasteride 0.785 0.095 Flecainide 1.030 0.896
Ritodrine 0.785 0.013 Retinol 1.065 0.292
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C. HT29 
 
 
 
 
Drug Fold Change (vs. Control) P Value Paroxetine 0.969 0.906
Control 1.000 Chlorambucil 0.971 0.900
Desferrioxamine 0.156 0.014 Bromocriptine 0.980 0.924
Mebendazole 0.164 0.000 Selegiline 0.984 0.914
Colchicine 0.164 0.001 Ranitidine 0.987 0.917
Danazol 0.235 0.060 Diltiazem 0.993 0.968
Nicotine 0.255 0.075 Clomipramine 0.997 0.990
Omeprazole 0.262 0.026 Ascorbic acid 0.998 0.980
Dantrolene sodium 0.321 0.042 Imipramine 1.004 0.898
Ethanol 0.342 0.108 Doxycycline 1.006 0.976
Prochlorperazine 0.407 0.049 Methyldopa 1.009 0.971
Alverine citrate 0.414 0.059 Vitamin K1 1.010 0.933
Imatinib 0.433 0.046 Propantheline 1.014 0.942
Domperidone 0.443 0.108 Levothyroxine 1.017 0.940
Methotrexate 0.469 0.007 Vitamin B12 1.018 0.944
Naloxone 0.487 0.158 Norethisterone 1.023 0.938
Amphotericin b 0.506 0.228 DMEM (2) 1.024 0.895
Zinc acetate 0.510 0.033 Bezafibrate 1.026 0.930
Mifepristone 0.511 0.286 Clobetasol propionate 1.026 0.915
Nortryptyline 0.525 0.140 Chlorpheniramine 1.037 0.872
Acipimox 0.560 0.162 Nicotinamide 1.041 0.773
Calciferol/ergocalciferol 0.603 0.161 Finasteride 1.045 0.829
Clofibric acid 0.643 0.176 Medroxyprogesterone acetate 1.046 0.877
5-Fluorouracil 0.666 0.100 Alpha tocopheryl acetate 1.049 0.820
Thalidomide 0.700 0.066 Mefenamic acid 1.055 0.882
Methanol 0.721 0.051 Metronidazole 1.057 0.810
Fluoxetine 0.756 0.091 Thiamine 1.064 0.591
Testosterone 0.762 0.378 Rifampicin 1.070 0.779
Acyclovir 0.762 0.067 Folic acid 1.074 0.583
Itraconazole 0.766 0.326 Carbamazepine 1.080 0.588
Pravastatin 0.775 0.410 Paracetamol 1.086 0.793
Flupentixol 0.783 0.209 Ibuprofen 1.087 0.795
Cefaclor 0.800 0.074 Neostigmine 1.088 0.693
Water 0.823 0.520 Acitretin 1.092 0.709
Simvastatin 0.827 0.176 Mesalazine 1.094 0.737
Metoclopromide 0.834 0.251 Fluconazole 1.095 0.682
Penicillin V 0.874 0.052 Ritodrine 1.098 0.678
Trimethoprim 0.882 0.727 Aspirin 1.103 0.730
Fenofibrate 0.884 0.440 DMSO 1.107 0.594
Metformin 0.899 0.755 Prednisolone 1.109 0.636
Niclosamide 0.902 0.704 Propanolol 1.111 0.381
Diclofenac 0.905 0.360 Dexamethasone 1.113 0.608
Chloroquine 0.913 0.702 Amantidine 1.113 0.623
Allopurinol 0.922 0.666 Retinol 1.117 0.594
Ampicillin 0.929 0.628 DMEM (1) 1.120 0.652
Flutamide 0.943 0.818 Flecainide 1.124 0.543
Artemisinin 0.948 0.730 Theophylline 1.127 0.524
Valproic acid 0.955 0.775 Pilocarpine 1.140 0.598
Erythromycin 0.955 0.705 Propylthiouracil 1.158 0.595
Praziquantel 0.961 0.846 Nicotinic acid 1.161 0.535
Cyclophosphamide 0.968 0.769 Bendroflumethiazide 1.219 0.521
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Figure 6.2 The effect of redeployed drugs on colorectal adenocarcinoma cell line viability in-vitro 
Cell viability assay (MTT) demonstrating the effects of the same panel of redeployed drugs on the 
colorectal adenocarcinoma cell lines RKO (A), SW480 (B) and HT29 (C) after 72 hours incubation. 
Data presented as mean fold change relative to control (normalised to 1), p value quoted represents 
drug vs. control. 
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Figure 6.3 Colchicine and Mebendazole are efficacious against metastatic colorectal 
adenocarcinoma cell lines in-vitro whereas 5-Fluorouracil is not 
Cell viability assay (MTT) demonstrating the effects of Colchicine, Mebendazole and 5-fluorouracil on 
the colorectal adenocarcinoma cell line SW480 and its metastatic clone SW620 after 72 hours 
incubation. Data presented as mean fold change relative to control (normalised to 1), error bars 
denote ±SEM, * p<0.05 vs. control, # p<0.05 vs. equivalent drug in SW480 cell line. 
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6.3.3 The effect of p53 status and hypoxia upon redeployed drug efficacy in colorectal 
adenocarcinoma in-vitro 
 
6.3.3.1 Overview 
 
The redeployed library of drugs was next screened against the HCT116 p53WT cell line and its 
isogenic counterpart HCT116 p53-/-. As previously demonstrated, these lines differ only in p53 
status (Figure 4.10). The library was also administered to HCT116 p53WT cells in hypoxia to identify 
potentially efficacious agents that were then re-screened against a broader panel of colorectal cell 
lines (RKO, SW480, HCT116 p53WT and HCT116 p53-/-) to confirm efficacy. 
 
Hypoxia was induced by the use of a 1% O2 chamber and confirmed through Western blotting for 
HIF-1α expression (Figure 6.4A). Effect on cellular phenotype was assessed in normoxia by use of the 
MTT cell viability assay and in hypoxia using the SRB assay. 
  
6.3.3.2 Results 
 
Mebendazole and Colchicine were again both markedly efficacious in the HCT116 p53WT cell line, 
reducing cellular viability by 68.5 and 50.7% respectively (p<0.05 vs. control). In addition, 
Niclosamide also significantly decreased viability by 74.9% (p<0.05 vs. control).  No drugs, however, 
within the redeployed library demonstrated a significant difference in efficacy based upon p53 
status alone. 
 
Screening of the entire redeployed library against the HCT116 p53WT cell line in the presence of 
hypoxia did not demonstrate any targets that were statistically efficacious in their own right (data 
not shown here). Promisingly, however, a number of agents demonstrated a non-significant trend 
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towards efficacy and therefore experiments were repeated with these in a broader panel of 
colorectal cell lines to confirm the results (Figure 6.4).  Both Niclosamide and Valproic acid were 
subsequently found to significantly impede cellular proliferation across all 4 lines tested by 81.3 and 
23.1% respectively (p<0.05 vs. control). 
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Figure 6.4 The redeployed drugs Niclosamide and Valproic acid are efficacious against colorectal 
adenocarcinoma cell lines in the presence of hypoxia 
Western blot (A) demonstrating the increase in HIF-1α seen when a panel of colorectal cell lines 
(RKO lanes 1-2, SW480 lanes 3-4, HCT116 p53 WT lanes 5-6 and HCT116 p53 -/- lanes 7-8) are 
exposed to 1% O2 for 24 hours. Lanes 1, 3, 5 and 7 represent normoxia, lanes 2, 4, 6 and 8 denote 
hypoxia. The drugs Niclosamide and Valproic acid were both efficacious against the same panel of 
cell lines despite this induction of hypoxia (SRB assay, B). The reagents were also efficacious in 
normoxia (C). Data points represent mean fold change compared to control, error bars denote 
±SEM, * p<0.05 vs. control. 
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6.3.4 The efficacy of redeployed drugs against oesophageal carcinoma in-vitro 
 
6.3.4.1 Overview 
 
In order to assess whether or not agents within the same redeployed drug library were efficacious in 
oesophageal carcinoma the OAC cell lines OE19 and OE33 and the SCC line OE21 were next screened 
against the library. Cell growth was monitored over 72 hours prior to the performance of an MTT 
assay to assess drug effect on cell viability. The experiment was then repeated using the most 
efficacious agents to permit determination of cellular proliferation using the BrdU assay. 
 
6.3.4.2 Results 
 
A number of agents within the redeployed drug library demonstrated a significant reduction in 
oesophageal cell line viability within the 72 hour time period (Figure 6.5 A-C). 
 
Of note, the iron chelating agent Desferrioxamine significantly reduced cellular viability by 69.6, 77.7 
and 75.9% in the OE19, OE33 and OE21 lines respectively (Figure 6.6A). Other agents shown to have 
a profound effect on cellular viability included Prochlorperazine (mean reduction across all 3 lines 
76.7% vs. control), methotrexate (75.7% reduction), Mebendazole (73.7% reduction), mifepristone 
(65.4% reduction) and Colchicine (62.1% vs. control). 
 
Subsequent validation of these agents using the BrdU assay demonstrated that Prochlorperazine, 
Mebendazole and Colchicine all significantly reduced cellular proliferation in the OE19 and OE33 
OAC lines. The same agents also reduced proliferation in the OE21 SCC line (Figure 6.6B). The iron 
chelator Desferrioxamine also reduced proliferation across all 3 lines tested, but owing to variability 
within experimental repeats, did not reach the required threshold for statistical significance.  
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Figure 6.5 The effect of redeployed drugs on oesophageal adenocarcinoma and squamous cell 
carcinoma cell line viability in-vitro 
 
 
A. OE19   
 
 
Drug Fold Change (vs. Control) P Value Fluoxetine 0.757 0.042
Control 1.000 Allopurinol 0.757 0.244
Mebendazole 0.285 0.002 Simvastatin 0.757 0.440
Prochlorperazine 0.288 0.026 Pravastatin 0.759 0.266
Methotrexate 0.301 0.007 Penicillin V 0.765 0.138
Desferrioxamine 0.304 0.000 Acyclovir 0.775 0.033
Colchicine 0.430 0.012 Vitamin B12 0.776 0.255
Naloxone 0.434 0.004 Clobetasol 0.778 0.123
Omeprazole 0.489 0.103 Erythromycin 0.779 0.123
Danazol 0.537 0.009 Carbamazepine 0.782 0.060
Mifepristone 0.540 0.010 Valproic acid 0.784 0.264
Domperidone 0.555 0.028 Mesalazine 0.785 0.225
Nicotine 0.574 0.045 Nicotinic acid 0.790 0.221
Clofibric acid 0.586 0.041 Thalidomide 0.794 0.135
Fenofibrate 0.587 0.016 Retinol 0.795 0.323
Itraconazole 0.603 0.069 Paracetamol 0.799 0.214
Paroxetine 0.611 0.094 Chlorpheniramine 0.802 0.428
Flecainide 0.613 0.103 Alpha tocopheryl acetate 0.809 0.208
Pilocarpine 0.614 0.020 Clomipramine 0.814 0.121
Ampicillin 0.636 0.040 Vitamin K1 0.815 0.034
Levothyroxine 0.637 0.095 Testosterone 0.815 0.075
Water 0.644 0.077 Nicotinamide 0.817 0.269
Niclosamide 0.653 0.104 Chloroquine 0.821 0.155
Diltiazem 0.663 0.049 Diclofenac 0.824 0.214
Trimethoprim 0.663 0.101 Cefaclor 0.825 0.364
Bezafibrate 0.664 0.089 Propanolol 0.827 0.022
Dantrolene 0.667 0.154 DMEM (1) 0.834 0.438
Amphotericin b 0.667 0.048 Ritodrine 0.835 0.372
Ethanol 0.669 0.075 DMEM (2) 0.839 0.349
Chlorambucil 0.671 0.105 Neostigmine 0.840 0.142
Methanol 0.681 0.061 Theophylline 0.841 0.277
Fluconazole 0.684 0.057 Ranitidine 0.857 0.079
Alverine citrate 0.685 0.097 Propylthiouracil 0.860 0.133
Acipimox 0.695 0.115 Doxycycline 0.866 0.181
Flupentixol 0.698 0.047 Norethisterone 0.867 0.415
Cisplatin 0.702 0.001 Bendroflumethiazide 0.872 0.327
Flutamide 0.703 0.098 Dexamethasone 0.876 0.321
Metformin 0.704 0.060 Imatinib 0.883 0.510
Selegiline 0.715 0.105 Zinc acetate 0.885 0.512
Nortryptyline 0.720 0.228 Imipramine 0.888 0.193
Metoclopromide 0.722 0.085 Ibuprofen 0.895 0.521
Ergocalciferol 0.728 0.166 Acitretin 0.896 0.617
Cyclophosphamide 0.728 0.112 Thiamine 0.897 0.044
Mefenamic acid 0.729 0.106 Metronidazole 0.904 0.458
Finasteride 0.736 0.111 Aspirin 0.912 0.457
Propantheline bromide 0.738 0.096 Bromocriptine 0.926 0.685
Methyldopa 0.741 0.136 DMSO 0.931 0.422
Ascorbic acid 0.743 0.021 Prednisolone 0.945 0.485
Medroxyprogesterone acetate 0.749 0.208 Folic acid 0.960 0.658
Artemisinin 0.757 0.219 Rifampicin 0.986 0.927
Praziquantel 0.757 0.141 Amantidine 0.998 0.970
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B. OE33     
  
 
 
Drug Fold Change (vs. Control) P Value Norethisterone 0.806 0.059
Control 1.000 Finasteride 0.807 0.095
Desferrioxamine 0.223 0.002 Imipramine 0.807 0.091
Prochlorperazine 0.226 0.008 Ascorbic acid 0.811 0.079
Methotrexate 0.251 0.002 Levothyroxine 0.818 0.010
Mebendazole 0.277 0.001 Thalidomide 0.820 0.001
Mifepristone 0.293 0.007 Diltiazem 0.824 0.147
Colchicine 0.411 0.001 Diclofenac 0.827 0.391
Nicotine 0.526 0.139 Doxycycline 0.827 0.424
Danazol 0.553 0.196 Flecainide 0.828 0.230
Omeprazole 0.554 0.008 Cefaclor 0.835 0.280
Niclosamide 0.568 0.069 Chloroquine 0.845 0.216
Domperidone 0.583 0.104 Cyclophosphamide 0.845 0.072
Clofibric acid 0.607 0.125 Methyldopa 0.846 0.360
Fluoxetine 0.609 0.109 Mesalazine 0.857 0.305
Water 0.620 0.219 Selegiline 0.859 0.134
Pilocarpine 0.626 0.020 Theophylline 0.859 0.047
Naloxone 0.633 0.216 Penicillin V 0.863 0.196
Ergocalciferol 0.673 0.237 Bezafibrate 0.865 0.292
Ampicillin 0.676 0.259 Zinc acetate 0.866 0.226
Cisplatin 0.684 0.002 Clomipramine 0.869 0.562
Nortryptyline 0.698 0.006 Ritodrine 0.878 0.600
Metformin 0.698 0.017 Aspirin 0.882 0.449
Itraconazole 0.701 0.221 Pravastatin 0.882 0.341
Vitamin K1 0.710 0.168 Praziquantel 0.883 0.624
Amphotericin b 0.718 0.462 Nicotinamide 0.888 0.143
Simvastatin 0.721 0.066 Methanol 0.891 0.294
Valproic acid 0.725 0.235 Dexamethasone 0.893 0.504
Fenofibrate 0.726 0.293 Imatinib 0.899 0.126
Acyclovir 0.728 0.219 Propanolol 0.902 0.182
Artemisinin 0.730 0.022 Ethanol 0.914 0.744
Flutamide 0.733 0.107 DMEM (1) 0.917 0.715
Vitamin B12 0.734 0.169 Chlorpheniramine 0.922 0.665
Alverine citrate 0.738 0.089 Flupentixol 0.923 0.756
Clobetasol 0.740 0.076 Carbamazepine 0.924 0.379
Erythromycin 0.742 0.082 Alpha tocopheryl acetate 0.936 0.560
Metoclopromide 0.752 0.242 Paracetamol 0.937 0.698
Medroxyprogesterone acetate 0.756 0.312 DMSO 0.947 0.767
Propantheline bromide 0.756 0.016 Propylthiouracil 0.952 0.712
Dantrolene 0.761 0.092 Metronidazole 0.955 0.854
Chlorambucil 0.761 0.193 Folic acid 0.955 0.287
Mefenamic acid 0.762 0.055 Prednisolone 0.964 0.789
Acitretin 0.771 0.323 Acipimox 0.969 0.875
Trimethoprim 0.780 0.419 Retinol 0.972 0.807
Fluconazole 0.784 0.189 Rifampicin 0.983 0.923
Allopurinol 0.787 0.326 Bendroflumethiazide 0.991 0.961
Ibuprofen 0.788 0.055 Thiamine 1.002 0.975
DMEM (2) 0.791 0.230 Amantidine 1.011 0.846
Paroxetine 0.792 0.219 Nicotinic acid 1.033 0.879
Testosterone 0.792 0.409 Ranitidine 1.045 0.826
Neostigmine 0.796 0.132 Bromocriptine 1.069 0.512
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C. OE21     
 
 
Drug Fold Change (vs. Control) P Value Simvastatin 0.777 0.249
Control 1.000 Ampicillin 0.779 0.144
Methotrexate 0.178 0.001 Norethisterone 0.799 0.045
Prochlorperazine 0.185 0.007 Bezafibrate 0.800 0.422
Mifepristone 0.206 0.009 Nortryptyline 0.802 0.269
Mebendazole 0.228 0.000 Chlorpheniramine 0.805 0.404
Desferrioxamine 0.241 0.002 Bendroflumethiazide 0.810 0.208
Colchicine 0.296 0.001 Acitretin 0.810 0.205
Naloxone 0.330 0.046 Pravastatin 0.815 0.092
Nicotine 0.417 0.073 Flutamide 0.815 0.069
Amphotericin b 0.490 0.115 Praziquantel 0.817 0.077
Danazol 0.533 0.133 Vitamin B12 0.821 0.391
Niclosamide 0.541 0.083 Propantheline bromide 0.822 0.320
Omeprazole 0.550 0.069 Nicotinamide 0.823 0.297
Cisplatin 0.608 0.047 Levothyroxine 0.824 0.223
Itraconazole 0.627 0.028 Selegiline 0.828 0.269
Metoclopromide 0.635 0.012 Finasteride 0.830 0.325
Imatinib 0.638 0.108 Artemisinin 0.844 0.287
Dantrolene 0.641 0.046 Metronidazole 0.848 0.174
Alverine citrate 0.647 0.064 Paracetamol 0.849 0.311
Domperidone 0.647 0.067 Aspirin 0.853 0.130
Zinc acetate 0.651 0.118 Theophylline 0.856 0.209
Water 0.669 0.178 Clobetasol 0.860 0.317
Fluconazole 0.674 0.016 Ritodrine 0.860 0.305
Valproic acid 0.679 0.072 DMSO 0.862 0.109
Ascorbic acid 0.684 0.049 Bromocriptine 0.865 0.038
Paroxetine 0.688 0.333 Dexamethasone 0.866 0.224
Acyclovir 0.689 0.109 Allopurinol 0.871 0.287
Clofibric acid 0.693 0.164 Cefaclor 0.877 0.433
Chlorambucil 0.697 0.034 Chloroquine 0.877 0.423
Methyldopa 0.703 0.046 Clomipramine 0.882 0.523
Fenofibrate 0.703 0.087 Propylthiouracil 0.884 0.425
Testosterone 0.704 0.100 Nicotinic acid 0.896 0.463
Propanolol 0.704 0.147 Mesalazine 0.901 0.564
Vitamin K1 0.719 0.117 Ibuprofen 0.905 0.553
Ethanol 0.725 0.171 DMEM (2) 0.907 0.514
Medroxyprogesterone acetate 0.728 0.224 Metformin 0.918 0.737
Trimethoprim 0.730 0.255 Alpha tocopheryl acetate 0.923 0.667
Ergocalciferol 0.732 0.319 Flupentixol 0.940 0.842
Flecainide 0.734 0.112 Penicillin V 0.943 0.643
Mefenamic acid 0.735 0.213 Thiamine 0.944 0.741
Methanol 0.736 0.150 DMEM (1) 0.946 0.564
Cyclophosphamide 0.737 0.136 Diclofenac 0.951 0.658
Fluoxetine 0.739 0.251 Thalidomide 0.961 0.849
Ranitidine 0.742 0.070 Prednisolone 0.967 0.824
Pilocarpine 0.750 0.182 Rifampicin 0.976 0.705
Erythromycin 0.753 0.123 Doxycycline 0.981 0.892
Diltiazem 0.754 0.097 Amantidine 0.982 0.899
Carbamazepine 0.760 0.113 Retinol 0.982 0.816
Neostigmine 0.764 0.185 Imipramine 1.010 0.938
Acipimox 0.768 0.306 Folic acid 1.024 0.899
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Figure 6.5 The effect of redeployed drugs on oesophageal adenocarcinoma and squamous cell 
carcinoma cell line viability in-vitro 
Cell viability assay (MTT) demonstrating the effects of the redeployed drugs on oesophageal 
adenocarcinoma (OE19, A and OE33, B) and squamous cell carcinoma (OE21, C) cell lines after 72 
hours incubation. Data presented as mean fold change relative to control (normalised to 1), p value 
quoted represents drug vs. control. 
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Figure 6.6 The effect of redeployed drugs on oesophageal adenocarcinoma and squamous cell 
carcinoma cell line proliferation in-vitro 
The effect of the top 7 redeployed agents on oesophageal adenocarcinoma (OE19 and OE33) and 
squamous cell carcinoma (OE21) was assessed by cell viability (MTT, A) and cell proliferation (BrdU, 
B) assays. Cells were incubated alongside the reagents for 72 hours. Data points represent mean fold 
change compared to control, error bars denote ±SEM, * p<0.05 vs. control. 
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6.3.5 The efficacy of redeployed agents in oesophageal adenocarcinoma in-vivo 
 
6.3.5.1 Overview 
 
Following the demonstration that the redeployed agents Prochlorperazine, Mebendazole and 
Colchicine significantly suppressed both cellular viability and cellular proliferation in-vitro, an OE19 
OAC murine xenograft model (the same as was previously used in chapter 3) was generated to 
investiagate the efficacy of these compounds in-vivo. 
 
NOD-SCID mice were divided into groups and given one of 4 treatment regimens as an oral gavage 
on alternate days for 3 weeks: 
 
1. Sterile distilled water (100 µl) 
2. Mebendazole (40 mg/kg as a suspension in a total volume of 100 µl) 
3. Prochlorperazine (1 mg/kg as a suspension in a total volume of 100 µl) 
4. Colchicine (1 mg/kg as a suspension in a total volume of 100 µl) 
 
Doses were decided upon using a combination of previously published literature (in the case of 
Mebendazole) and manufacturer’s pre-clinical drug safety data. 275 276  
 
Drug efficacy was assessed by comparing final xenograft volume (mm3) with the control group 
(water). The modified ellipsoid formula, volume = (maximal length x maximal width2) / 2, was utilised 
to calculate tumour volume (mm3). 277    
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6.3.5.2 Results 
 
Both Mebendazole and Colchicine significantly suppressed final xenograft size (56.7 and 72.1% 
reduction in final volume vs. control respectively, p<0.05, Figure 6.7).  
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Figure 6.7 Mebendazole and Colchicine suppress oesophageal adenocarcinoma xenograft growth in-vivo 
NOD-SCID mice with established OE19 OAC cell line xenografts were given 3 weeks of oral water (control), 
Mebendazole, Prochlorperazine or Colchicine on alternate days. Data presented as median xenograft volume (mm3) 
post treatment. 95% confidence range for median displayed as bars around median, * p<0.05 vs. control. 
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6.3.6 The determination of any synergy between the redeployed drugs and the iron chelating 
agent Deferasirox in oesophageal carcinoma in-vitro 
 
6.3.6.1 Overview 
 
The OE19 OAC cell line was next screened against varying concentrations of Mebendazole, 
Colchicine and Prochlorperazine with or without the presence of Deferasirox (at the sub-therapeutic 
concentration of 1 µM) for 72 hours. Cell viability assays were then performed as previously 
outlined. Mebendazole, Colchicine and Prochlorperazine were selected at they had shown the most 
promise in the earlier oesophageal screen. Deferasirox was again utilised at a sub-therapeutic 
concentration of 1 µM. MTT assays were performed to determine effect on cell viability. 
 
6.3.7.2 Results 
 
The combination of low dose Mebendazole (0.43 µM, approximately 25% of the standard dose used 
in the previous experiments) with low dose Deferasirox (1 µM) generated a marked additional 
reduction of 60.4% compared to the redeployed drug alone at that concentration. This was 
statistically significant (p<0.05) against control, Mebendazole alone and Deferasirox alone at the 
same concentrations (Figure 6.8A). In contrast, no additional benefits were seen by combining 
Deferasirox with either Prochlorperazine or Colchicine (Figure 6.8 B and C).  
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A        B            C 
Figure 6.8 Mebendazole and Deferasirox demonstrate evidence of synergy in-vitro when utilised at concentrations below the peak serum levels obtained with their 
respective conventional dosing regimens 
Cell viability assay (MTT) demonstrating dose response profile of Mebendazole (A), Prochlorperazine (B) and Colchicine (C) with or without the presence of the iron chelator 
Deferasirox (1 µM). Data points represent mean fold change compared to control (normalised to 1), error bars denote ±SEM, * p<0.05 vs. equivalent concentration of drug + 
Deferasirox 1 µM. 
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6.4 Discussion 
 
The overall aim of this chapter was to ascertain whether or not the systematic screening of a library 
of redeployed drugs could identify novel agents with potential efficacy against oesophageal and 
colorectal cancer (either in synergy with the iron chelator Deferasirox or alone). 
 
In terms of synergy between Deferasirox and redeployed agents, this study has demonstrated that 
the combination of Valproic acid with a sub-therapeutic dose of the iron chelator Deferasirox (1 µM) 
resulted in a significant additional reduction in cellular viability across a panel of colorectal cell lines 
(mean additional reduction 6.5-22.0% vs. Valproic acid alone). This finding is of interest and agrees 
with the findings of a recent study demonstrating synergy between the histone deacetylase (HDAC) 
inhibitor Trichostatin A and the iron chelators DFO and Phenanthroline in breast cancer cell lines. 278 
The authors of this study speculated that the synergy seen was likely to be a consequence of iron 
chelator inhibition of the endoplasmic reticulum chaperone protein glucose-regulated protein 78 
(which was increased by the HDAC inhibitor and appears to inhibit its anti-neoplastic effects).  
 
A number of reagents demonstrated efficacy against oesophageal adenocarcinoma and squamous 
cell carcinoma cell lines in-vitro. Of note, the traditional iron chelator Desferrioxamine (an 
alternative to Deferasirox) significantly reduced cell viability across all 3 lines tested by an average of 
74.4%.  
 
The agents Colchicine (currently used to treat acute attacks of gout), Mebendazole (an anti-
helminthic used to treat parasitic infections) and Prochlorperazine (a phenothiazine prescribed as an 
anti-emetic and anti-psychotic) induced a profound reduction in both cellular viability and 
proliferation in OAC and SCC in-vitro.  Furthermore, when administered to mice harbouring 
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established OE19 OAC xenografts both Mebendazole and Colchicine demonstrated suppression of 
tumour growth compared to control.  
 
Screening of the same redeployed library against the colorectal cell lines in-vitro also demonstrated 
that Colchicine, Mebendazole and Prochlorperazine were efficacious, reducing cellular viability by an 
average of 83.2, 83.5 and 37.9% respectively. In support of previous findings, Desferrioxamine was 
again also efficacious, inducing an average reduction in cellular viability of 67.8% across the 3 lines 
tested.  
 
Colchicine was originally discovered as an extract from plants of the Colhicum autumnale (autumn 
crocus) genus. The anti-cancer properties of Colchicine demonstrated here are likely to stem from its 
known action against microtubules. 279 Along with actin microfilaments and intermediate filaments, 
microtubules comprise the cytoskeleton and play a significant role in the process of mitosis. 279 
During the majority of the cell cycle, microtubules form an intracellular lattice-like structure, 
however, when cells enter mitosis, this microtubule network is reorganised into the mitotic spindle. 
279 The processes of depolymerizing the interphase microtubule structure and forming the mitotic 
spindle, as well as finding, attaching and separating chromosomes, require highly coordinated 
microtubule dynamics. 279, 280 Therefore, agents that interfere with microtubule dynamics inhibit the 
ability of cells to successfully complete mitosis thus limiting proliferation. 279 
 
Microtubules are comprised of α and β-tubulin heterodimers that polymerise head-to-tail to form 
protofilaments. 279 Colchicine is known to bind to tubulin at a location adjacent to a GTP-binding site 
on the α-tubulin heterodimer leading to microtubule de-polymerisation through the inhibition of 
lateral contacts between protofilaments. 279, 281, 282 Thus, the drug is a potent inhibitor of mitosis, 
which by definition means it is effective at inhibiting the proliferation of rapidly dividing cancer cells. 
Widespread adoption of Colchicine as an anti-neoplastic agent to date, however, has been largely 
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limited due to its significant toxicity (it should be noted that Colchicine was well tolerated by the 
mice at the dose used in this study, however). 279 As such, much work has been carried out into the 
development, synthesis and pre-clinical evaluation of less toxic Colchicine analogues. 279, 283, 284  
 
Mebendazole is a broad spectrum anti-helminthic drug from the benzimadazole class (which also 
includes albendazole and flubendazole amongst others). 285 At present, it is commonly prescribed to 
treat a range of parasitical worm infections, including threadworm, tapeworms, roundworms and 
other nematode and trematode infections in humans and domestic animals. 285 It is available in an 
off-patent generic form and can be administered as both an acute (days) or longer-term (several 
months) prescription. 285 As with Colchicine, the anti-neoplastic effects seen with Mebendazole are 
likely to be exerted through the inhibition of microtubule polymerisation and the subsequent arrest 
of mitosis. 286 Indeed, both Mebendazole and the other benzimadazole drugs are known to bind to 
the Colchicine binding domain on the α-tubulin heterodimer. 287 Unlike Colchicine, however, the 
drug has a good safety and tolerability profile. 285  
 
A number of pre-clinical studies have demonstrated the anti-neoplastic action of Mebendazole. 285 
Of note, the drug has been shown to suppress the growth of lung, adrenal, melanoma and 
glioblastoma xenografts. 275, 276, 288, 289 Mebendazole has also demonstrated efficacy in leukaemic, 
breast, and osteosarcoma cell lines.  285, 290, 291 Furthermore, in a recent study Nygren and colleagues 
screened  a panel of 1600 existing drugs for activity against two colon cancer cell lines (HCT116 and 
RKO) and found 64 candidate drugs, including a cluster of benzimidazoles. 290 Further analysis 
performed with Mebendazole (across a broader panel of colonic lines including HCT116, RKO, HT29, 
HT-8 and SW626) demonstrated that all displayed an IC50 of <5 μM (as in this study) and that the 
drug was largely inactive against non-malignant cell lines. 290  Of note, Mebendazole has never been 
studied before in the context of oesophageal cancer. 
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The inhibition of tubulin polymerisation by Mebendazole has been shown to result in G2/M cell cycle 
arrest and the subsequent induction of apoptosis. 275 In melanoma lines, apoptosis has been shown 
to be activated through Bcl-2 phosphorylation and a reduction in the expression of X-linked inhibitor 
of apoptosis (XIAP).  288, 292 Mebendazole has also been shown to function in a p53 independent 
manner. 292 
 
It has been postulated in previous studies that Mebendazole offers the potential to act as a 
synergistic agent with both existing chemotherapeutic drugs and other redeployed agents under 
investigation in a number of cancers. 285 Thus, it is of interest (and certainly worthy of further 
investigation) that a potentially synergistic relationship was demonstrated in the current study 
between low dose Mebendazole and a low (sub-therapeutic) dose of the iron chelator Deferasirox. 
 
No clinical trials of Mebendazole as an anti-neoplastic agent have been completed to date (although 
there are 2 currently underway for the treatment of glioma). 285 There are however, case reports 
demonstrating evidence of disease regression following Mebendazole therapy in both adrenal and 
metastatic colorectal cancer. 293, 294  
 
The phenothiazine prolchlorperazine demonstrated significant in-vitro effects in this study against 
both oesophageal and colorectal lines. Prochlorperazine was originally used as an anti-psychotic and 
is also commonly used as an anti-emetic (particularly during chemotherapy). Phenothiazines (as a 
broad class) have been studied previously as potential anti-cancer agents, although there are no 
studies using Prochlorperazine specifically nor in the context of oesophageal or colorectal cancer. 295  
Ancedotally, a decreased risk of cancer has been noted previously amongst patients with 
Schizophrenia treated long-term with phenothiazines. 296Phenothiazines have been shown to induce 
G1 cell cycle arrest with the subsequent induction of apoptosis. 297 Furthermore, in ovarian 
carcinoma xenografts, the phenothiazine derivative thioriadazine inhibited neo-vascularisation 
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resulting in a significant suppression of tumour growth. 298 The authors demonstrated that this was 
likely to be through inhibition of the PI3K signalling cascade (via suppression of Akt, PDK1 and mTOR 
phosphorylation) secondary to inhibition of VEGFR-2 phosphorylation.  Phenothiazines have also 
been shown to inhibit c-Myc, Wnt, MAPK signalling and lysosomal function, whilst demonstrating 
increased efficacy in cell lines displaying B-raf mutations.  298 299 300 301 Of note, studies have also 
demonstrated the ability of phenothiazines to reverse drug resistance and act as chemosensitisers, 
likely through the inhibition of P-glycoprotein. 295, 302, 303  
 
Whilst the redeployed agents Niclosamide and Valproic acid demonstrated significant efficacy when 
utilised in this study in the context of normoxia, they were also significantly effective in hypoxia 
(unlike Deferasirox). Niclosamide, like Mebendazole, is also used primarily as an anti-helminthic drug 
and belongs to the teniacide family of compounds. Its mechanism of action is through the inhibition 
of oxidative phosphorylation within mitochondria (via uncoupling of the electron transport chain 
from oxidative phosphorylation by increasing the proton permeability of the mitochondrial 
membrane thereby decreasing the proton electrochemical potential). 200 It is known to also inhibit 
anaerobic metabolism. 304 Niclosamide has demonstrated anti-neoplastic effects in a number of 
different cancer cell lines (including colorectal), and, in addition to its effects on cellular oxidative 
phosphorylation, has been postulated to perturb function of Wnt, NFκB, mTOR, Notch and Stat3 
signalling.  304, 305 Its efficacy in hypoxia therefore, is likely to be explained through both the direct 
effect on anaerobic metabolism and the inhibition of Stat3, a known stimulator of the cellular 
response to hypoxia. 306  
 
Valproic acid is used at present for the treatment of epilepsy. It is a HDAC inhibitor and has shown 
promise as an anti-neoplastic agent in a number of pre-clinical cancer models. 307 Of note, the drug 
has been shown to cause cellular accumulation in G1 of the cell cycle as well as decreased cellular 
motility and metastasis. 307 It has also been shown to inhibit the proto-oncogene n-Myc, suppress 
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NFκB signalling and impede angiogenesis. 307 HDACs are involved in chromatin modification, which 
plays a crucial role in the regulation of gene transcription. The addition of charge-neutralizing acetyl 
groups to lysine residues disrupts DNA-histone interaction, resulting in a more open DNA 
conformation and a transcriptionally active state. 307 It is hypothesized that, by this mechanism, 
HDAC inhibitors can achieve de-repression of silenced tumor suppressor genes. 
 
Furthermore, HDAC inhibitors have previously been shown to block the expression of HIF-1α (the 
master regulator of the cellular response to hypoxia). 308 Of note, therefore, in this study it was 
demonstrated that Valproic acid was effective against colorectal cell lines under hypoxic conditions, 
decreasing cellular proliferation by an average of 15.2-28.6% vs. control (p<0.05).  
 
In summary, it has been demonstrated within this chapter that a drug redeployment based 
screening approach does indeed offer the potential to identify targets with potential efficacy against 
both oesophageal and colorectal carcinoma. 
 
Colchicine, Mebendazole and Prochlorperazine demonstrated significant in-vitro effects against the 
oesophageal and colorectal cancer lines tested and (in the cases of Colchicine and Mebendazole) 
also evidence of in-vivo efficacy in a xenograft model of OAC. Both Niclosamide and Valproic acid 
were effective against colorectal adenocarcinoma cell lines under hypoxic conditions, whilst 
Mebendazole and Valproic acid also demonstrated evidence of synergy when cultured with sub-
therapeutic concentrations of Deferasirox against OAC and colorectal adenocarcinoma cell lines 
respectively. 
 
A thorough search of the literature demonstrated that all of the agents identified as potential ‘hits’ 
had plausible primary mechanisms of action conducive to an anti-neoplastic effect and furthermore, 
appeared to have additional effects on pathways common within cancer. 
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Much further work is needed to build on the results highlighted within this chapter. In particular, 
delineation of the top target’s mechanisms of action (particularly in the context of OAC where much 
of these findings are novel) and their potential to synergise with lower doses of Deferasirox is 
certainly worthy of further investigation. In addition, the characterisation of their in-vivo effects 
would begin to pave the way towards future human trials in cancer therapy. 
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Chapter 7. Discussion 
 
7.1 Conclusions 
 
It is now clear that iron is implicated in the propagation of both oesophageal and colorectal 
carcinoma and therefore a strategy to deplete tumour cells of iron by chelation represents an 
attractive and logical therapeutic option. 24, 82, 92, 99, 102 After all, iron is essential for a plethora of 
cellular processes including DNA synthesis, ATP generation and cell cycle progression; all activities 
that are increased in cancer. 112 Furthermore, the increased requirement of malignant cells for iron 
offers the potential that iron chelation may offer a selective therapy, sparing normal cells (and the 
patient) from the deleterious side effects associated with existing chemotherapeutic regimens. 92, 112 
 
Within this thesis it has been demonstrated that the licensed and orally administered iron chelating 
agent Deferasirox possesses significant anti-neoplastic efficacy both in-vitro and in-vivo in the 
context of oesophageal carcinoma. The drug exerted its effects in a time and dose dependent 
manner and was well tolerated when given to mice at a relatively low dose. Furthermore, 
Deferasirox was also capable of inhibiting the growth of oesophageal cells that were resistant to 
conventional therapy with Cisplatin and, through inhibition of the NFκB signalling pathway, showed 
evidence for an anti-neoplastic and chemosensitising mode of action extending beyond that of just 
cellular iron deprivation by chelation alone. This is highly relevant, as tumours are often 
heterogeneous and can develop resistance to mono-modal therapy over time. 
 
In addition to the demonstration of Deferasirox’s efficacy in the oesophagus, the finding that the 
drug is equally efficacious against colorectal adenocarcinoma is highly novel. In addition to a higher 
basal requirement for iron (that is generic across almost all tumours), colorectal adenocarcinomas 
are known to acquire iron during their development. 82, 102, 242 Furthermore, iron has been shown to 
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drive tumour proliferation both in-vitro and in-vivo. 82, 102 Here, it was demonstrated for the first time 
that Deferasirox therapy inhibits the uptake and storage of cellular iron within colorectal 
adenocarcinoma cells leading to cell cycle arrest, significantly reduced rates of proliferation and 
ultimately a reduction in colorectal cellular viability. Of note, the drug appears to be more 
efficacious in adenocarcinoma cell lines than it was in those derived from adenomas and, as in the 
oesophagus, it was capable of suppressing the viability of cells that were otherwise resistant to the 
effects of existing chemotherapeutic reagents. In contrast to previous studies using the iron chelator 
DFO, Deferasirox efficacy was not dependent on cellular p53 status and appeared to actually be 
enhanced by the presence of an APC mutation. 248 In murine models of colorectal tumourigenesis 
following APC loss, Deferasirox administration was again well-tolerated and significantly up-
regulated rates of apoptosis. Unfortunately, this did not translate into an increase in murine survival 
within the current study, although further work is ongoing within the laboratory group to investigate 
this further. 
 
The finding that the IRP-IRE interaction is maintained but inappropriately active within colorectal 
adenocarcinoma is also highly novel. IRP2 over-expression now serves as an explanation for the 
increased iron accumulation seen with malignant colorectal tissue (an increase that is above what is 
merely required to maintain adequate levels of cellular growth). Furthermore, elevated expression 
of IRP2 facilitates not only an increase in total intracellular iron levels (through increased TfR1 
expression) but also an increase in the labile or free intracellular iron pool (by the concomitant 
suppression of ferritin translation). 99, 258 This iron is thus available to drive both cellular proliferation 
and oncogenic signalling pathways, such as Wnt.  102, 132 The demonstration of an association 
between over-activity of the MAPK signalling pathway and increased IRP2 protein expression 
(probably through activation of the proto-oncogene c-Myc) in colorectal adenocarcinoma cells is of 
interest and further adds to the existing body of evidence implicating iron in both the amplification 
of Wnt signalling and the suppression of functioning p53 levels. 102 132 248 The fact that IRP2 
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expression was greatest in locally advanced, proximal colonic lesions and may be associated with 
perturbation of the MAPK signalling cascade (e.g. mutations in constituents such as B-raf) offers the 
potential that it may serve (either directly or indirectly) as a biomarker for Deferasirox efficacy, 
offering the potential for personalised medicine and a reduction in needless side effects. 
 
Finally, it was demonstrated that drug redeployment offers a valid area worthy of further 
investigation for the identification of potential new agents that are effective against both 
oesophageal and colorectal carcinoma. A number of drugs demonstrated significant efficacy within 
the in-vitro and in-vivo models utilised, particularly Colchicine and Mebendazole. Of note, the anti-
helminthic drug Niclosamide and the HDAC inhibitor Valproic acid were also significantly effective 
under hypoxic conditions and, in the case of Valproic acid, demonstrated evidence of synergy when 
administered with sub-therapeutic doses of Deferasirox. This adds further weight to the argument 
that iron chelators may act as chemosensitising agents. 
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7.2 Further Work 
 
7.2.1 Laboratory Studies 
 
In terms of the oesophagus, further in-vitro exploration of the drug’s effects on other pathways 
(such as mTOR) would be beneficial. The conclusive demonstration that Deferasirox’s anti-neoplastic 
efficacy is not restricted to merely iron deprivation through chelation alone and is actually achieved 
through a multi-modal mechanism of action would be extremely interesting and highly relevant to 
any future potential for clinical translation. With this in mind, the analysis of existing stored OE19 
OAC xenograft specimens for markers of Deferasirox’s effect on the NFκB signalling pathway in-vivo 
would be particularly important as it would help to conclusively determine the interaction of the 
drug with it. 
 
In terms of the colon, again in-vitro assessment of Deferasirox’s ability to act through iron 
independent channels would be interesting (particularly on Wnt signalling and downstream targets 
of it such as c-Myc). Determining the effects of Deferasirox upon intra-cellular ROS levels would also 
be relevant. Of greatest importance, however, would be the further exploration and demonstration 
of the drug’s in-vivo efficacy. Although a murine xenograft type model could easily be utilised (as in 
the oesophagus) and is likely to demonstrate a positive result (in the opinion of the author), 
transgenic models of sporadic intestinal tumourigenesis now represent the gold standard for the 
investigation of colorectal cancer development and progression. 102 201 202 As such, future 
experiments should persist with this approach and re-evaluate the drug’s effect on survival in 
models such as the ApcMin/+ mouse. In addition, the drug’s effect on Wnt targets (such as c-Myc) 
could also be evaluated through immunohistochemical and qRT-PCR based approaches.  
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The construction of a stable IRP2 ‘knockdown’ cell line (using shRNA) would permit valuable further 
investigation into the effect of IRP perturbation on colorectal adenocarcinoma cell line phenotype 
(both in-vitro and in-vivo using xenograft models). It would also allow the effect of IRP2 expression 
on Deferasirox efficacy to be formally assessed (something that has not been attempted thus far). 
Furthermore, the successful transfection of the inducible B-raf V600E construct that was created 
during this thesis into a colorectal cell line that had a normal MAPK signalling cascade (i.e. wild type 
K-ras and B-raf) would permit further analysis of the interaction with IRP2. This could then be further 
augmented through the perturbation of c-Myc thus identifying whether it is a c-Myc dependent 
phenomenon.  
 
7.2.2 Clinical Studies 
 
In terms of the oesophagus, the next step would be to design and initiate a clinical trial of 
Deferasirox therapy. The demonstration that patients presenting with oesophageal adenocarcinoma 
(both resectable and advanced) are systemically iron replete is a crucial finding en-route to the 
design of any future trial of Deferasirox in this setting. Preliminary protocols are at present being 
designed for a Phase 1 safety and tolerability study of the drug in palliative patients. If this is 
successful then further more advanced trials could be planned. 
 
In both the oesophagus and the colon, other than the obvious requirement for the demonstration 
that Deferasirox is safe and well-tolerated amongst patients with cancer, the next crucial step would 
be the demonstration of an effect of the drug at the level of the tumour. This could be achieved 
through the obtaining of a pre and post-therapy biopsy (or the surgically resected specimen), almost 
as a window study. Markers of iron metabolism, apoptosis and Wnt targets could be assessed within 
the tumour. Ultimately, if the drug was given after staging but before surgical resection, a 
pathological response to therapy scoring system could also be applied. 309 
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In conclusion, iron metabolism and iron chelation therapy represents an important novel therapeutic 
avenue for the treatment of gastrointestinal cancer that is worthy of ongoing and further 
investigation to improve outcome in this clinically important disease. 
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Pre-treatment with the oral chelating agent ICL670A may enhance chemotherapy response in 
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